

Eosinophilic myalgia syndrome
connective tissue disease and, 692
localized scleroderma and, 427

Eosinophils
age related changes and, 250
innate immunity response and,
245

EPA (Environmental Protection Agency)
asbestos regulation and, 785
environmental risk assessment, 122
hazardous exposure and, 356
National Ambient Air Quality Standards and, 122
water pollution and, 125

Ependymoma
clinical manifestations of, 1376, 1377f
gliomas overview and, 1372
incidence of, 1370
pediatric tumors and, 1400

Ephelides (juvenile freckles),
hyperpigmentation and, 451

Epinondylectomy, medial, tardy ulnar palsy and, 1611

Epidermal growth factor receptor (EGFR), pancreatic cancer pathogenesis and, 917

Epididymitis, 979

Epilepsy
childhood
absence epilepsy and, 1544
centrotemporal spikes of, 1544

Epilepsia partialis continua,
1545

severe myoclonic, 1544

clinical manifestations of, 1535, 1535f, 1535b

etiology and risk factors of,
1532-1533

etiology and risk factors
adult-onset seizure disorder and,
1532-1533, 1533b

infantile seizures, 1533

idiopathic, 1532

implications for therapist,
1545-1546

infancy and childhood and,
1543-1545

juvenile myoclonic, 1544

medical management of,
1535-1539

overview and definition of, 1532

pathogenesis of, 1534-1535

posttraumatic, 1545

seizure classification and, 1539-1534, 1540f, 1540b

traumatic brain injury and,
1492-1493

Epileptic seizure
classifications
complex partial seizure and,
1534, 1541-1542

partial seizure and, 1539-1540

partial seizure secondarily
generalized and, 1542-1543

simple partial seizure and, 1541

generalized
atonic seizures, 1543

generalized absence seizures
and, 1542

myoclonic seizures, 1543

status epilepticus and, 1543

tonic-clonic seizures, 1543

Epineurium
aging peripheral nervous system
and, 1596

peripheral nervous system
structure and, 1595

Epiphyseal fracture, 1295

Epiphysis
hyperplasticism and, 461

slipped capital femoral (SCFE),
chondrolysis and, 1250

Epiphysitis, vertebral. *See*
Scheuermann's disease

Epithelial cells, cystic fibrosis and,
790

Epithelioid sarcoma, benign soft tissue tumors and, 1225

Epithelium
cervical cancer pathogenesis and,
1000

tumor classification and, 349

Epitope
autoimmune disease and, 243f,
283

immune response and, 242, 243f,
244

EPO. *See* Recombinant human erythropoietin (rHuEpo)

Epogen. *See* Recombinant human erythropoietin (rHuEpo)

Epoprostenol (Flolan), pulmonary hypertension treatment and,
819

Epstein-Barr virus (EBV). *See also*
infectious mononucleosis
aseptic meningitis and, 1353
CNS infectious disease and, 1358

Hodgkin's lymphoma and, 701

posttransplant lymphoproliferative disease and, 1077

Equipment, personal protective (PPE), 1671-1672

Erb's palsy
clinical manifestations of, 1148

definition and overview of, 1147
etiology and risk factors of,
1147-1148

implications for therapist,
1149-1150

medical management of, 1148-1149, 1150

Erb-Duchenne palsy, brachial plexus palsy types and, 1147

ERCP (endoscopic retrograde cholangiopancreatography). *See*
Endoscopic retrograde cholangiopancreatography

Erectile dysfunction (ED)
benign prostatic hyperplasia and,
970

coronary artery disease and, 534

etiology of, 983

implications for therapist,
984-985

medical management of, 984

overview, incidence and risk
factors of, 982-983, 983b

prostate cancer treatment and, 975

Ergometry, functional electric stimulation, spinal cord therapy and, 1515

Ergonomics, 138-140

Erlangen Fitness Osteoporosis Prevention Study (EFOPS), menopausal transition and, 994

Erosions, acute lesions of the mucosa and, 842

Error theory, aging and, 24

Erysipelas, cellulitis and, 320, 320f, 404

Erythema maraginatum, rheumatic fever rash of, 604

Erythema migrans, Lyme disease and, 340, 340f, 342

Erythema, palmar, hepatic disease and, 882

Erythrocyte disorders
anemias and, 685-690

chronic bronchitis and, 765

sickle cells and, 732

Erythrocyte sedimentation rate (ESR), 429, 1651-1652

chronic inflammation and, 151, 225

polymyalgia rheumatica and, 429

primary tumor diagnosis and,
1206

prostheses and implant infection and, 1189

Erythromycin, hypertrophic pyloric stenosis and, 847

Erythropoietin (EPO)
cancer treatment and, 374

erythrocyte production and, 686

formation of blood cells and, 678

renal insufficiency and, 735, 737

thalassemia treatment and, 741

Erythropoietin, human recombinant, thalassemia treatment and, 741

Escherichia coli, urinary tract and,
306, 929

Esophageal atresia, types of, 840f

Esophageal cancer. *See also*
Neoplasm
implications for therapist, 839

Esophageal varices, 839-840

implications for therapist, 829t, 840

Esophagitis, radiation and, 167

ESRD (end-stage renal disease). *See also*
Kidney disease, chronic (CKD); Kidney transplantation
clinical manifestations of, 940-944

diabetes and, 493

exercise and, 948

hypertension and, 555

kidney transplantation and, 1066

pyelonephritis and, 931

sickle cell disease and, 735

estradiol, coronary artery disease and, 527

Estrogen. *See also* Menopause
bone density loss and, 1104

cardioprotective benefits of, 527

endometriosis and, 995

menopause and, 988

postmenopausal osteoporosis and,
1159

side effects of, 1170b

urinary incontinence treatment and, 958

Estrogen hormone replacement therapy, cancer and, 356

Estrogen receptor-negative (ER-negative), chemotherapy and, 1026

Estrogen receptor-positive (ER-positive)
breast cancer hormone exposure and, 1018, 1025

breast cancer treatment and, 1026-1027

Estrogen-dominant environment, petro chemicals and, 130

Estrogenic endocrine-disrupting chemicals (EDCs), xenobiotics and, 130

Ethical issues, gene therapy and, 15

Ethnicity
adenocarcinoma of the colon and,
864

asthma and, 768

breast cancer incidence and, 1017

breast cancer risk factor and, 1019

cancer and, 356-357, 376

coronary artery disease and, 533

cystic fibrosis and, 789

death from lung cancer and, 809

definition of, 21

diabetes mellitus type2 and, 465b, 491

ESRD and, 939-940

hypertension and, 552

malignant melanoma and, 416

nephrotic syndrome and, 949

osteoporosis risk factor and,
1159-1160

pancreatic cancer and, 916

prostate cancer and, 971

pulmonary tuberculosis and,
752-753

sarcoidosis and, 806

sickle cell disease and, 21, 730

Eugenics, gene therapy and, 15

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC-30), intervention measurement tools and, 1392

EUS (endoscopic ultrasonography). *See* Ultrasonography, endoscopic

Evaluation, neuropsychologic, traumatic brain injury diagnosis and, 1489

Evoked potential response testing, multiple sclerosis diagnosis and, 1434

Ewing's sarcoma
implications for therapist, 1221

medical management of, 1219f,
1219-1221, 1220f

overview and incidence of, 1219

Exanthema (roseola infantum), sixth disease and, 337

Excisional biopsy (lumpectomy), tissue and, 369

Excitotoxicity
Alzheimer's disease pathogenesis and, 1414

amyotrophic lateral sclerosis and, 1403

traumatic brain injury and, 1481

Exercise
aerobic. *See* Aerobic exercise

aquatic. *See* Aquatic exercise

as psychologic therapy, 51

benefits of, 14b, 15b

blood tests and, 1649

breast cancer. *See* Breast cancer exercise

chemotherapy and, 178, 387

depression and, 116

female reproductive system and,
994

gender and, 26

guidelines for, 1674

incontinence and, 962

inflammation and, 226

isometric. *See* Isometric exercise

menopause and, 992-993

nitric oxide formation and, 203

pharmacokinetics and, 155

posttransplant exercise and, 1057

prescriptive, primary tumors and,
1209

protein synthesis and, 209

pulmonary capacity and, 748-749

radiation therapy and, 173

spinal cord therapy and, 1516

steroids and, 164-165

systemic pathology and, 152

Exercise immunology, 253-255
implications for therapist,
254-255

Exercise science, 16b

Exercise tolerance, aging and, 749

Exercise training, circuit resistance, 1516

Exhaustion, general adaptation syndrome and, 47

Exocrine glands, cystic fibrosis and,
788, 789f

Exocrine pancreatic insufficiency, cystic fibrosis and, 792

Exogenous antioxidants, Vitamin C, E, beta-carotene and, 202

Exophthalmos, hyperthyroidism and, 466, 467f

Exosystem, interaction with, 18

Expanded Disability Status Scale, multiple sclerosis prognosis and, 1435

Experimental approaches
multiple sclerosis treatment and,
1435

parkinsonism treatment and,
1445

Expressivity, variable, 1602

Exterior defenses, innate immunity and, 250

External counterpulsation (EECP), heart surgery and, 572, 573f

Extracapsular silicone, fibromyalgia and, 289

Extracellular fluid (ECF)
fluid imbalances and, 182

sodium imbalances and, 185

Extracellular matrix (ECM)
breast cancer pathogenesis and,
1020

Extracorporeal Membrane Oxygenation (ECMO)
assisted gas exchange and, 1089

cardiopulmonary support and,
1089, 1089f, 1091

Extramedullary hematopoiesis, enlarged spleen and, 679

- Extraovarian primary peritoneal carcinoma (EOPPC). *See* Ovarian cancer
- Extreme Cold Weather Clothing System (ECWCS), cold injuries and, 434
- Exudate definition of, 826 inflammatory types of, 220t vascular alterations and, 213b, 219, 219f
- F**
- FAB system (French-American-British), acute myelogenous leukemia classification and, 695, 696t
- Factitious disorder, 99, 101 Munchausen syndrome and, 104
- Factor replacement therapy, hemophilia treatment and, 722
- Factor X, disseminated intravascular coagulation and, 729
- Factor XII release, disseminated intravascular coagulation and, 729
- Factor, rheumatoid (RF), 1662
- Failure of homeostasis, aging endocrine system and, 458
- Fall Prevention for Older People: Resource Screening Tools, 1304
- Falling fear of, 1303, 1304, 1305b Parkinson's disease physical therapy and, 1446 stroke consequence and, 1453 traumatic brain injury risk factors and, 1477
- Falls. *See* Bone fracture; Fracture
- False negative, 1639
- False positive, 1639
- Familial adenomatous polyposis (FAP), 864 obstructive jaundice and, 925
- Family history colorectal cancer and, 866 coronary artery disease and, 533 degenerative disk disease and, 1259 migraine headaches and, 1552 prostate cancer risk factors and, 971, 971b
- Famine, breast cancer pathogenesis and, 1020
- Fas ligands sun exposure and, 414 treatment of melanoma and, 418
- Fascicles, aging peripheral nervous system and, 1596
- Fasciculations, amyotrophic lateral sclerosis and, 1404
- Fasting blood sugar (FBS), 1641
- Fat emboli, ischemic stroke treatment and, 1461
- Fat embolism syndrome, fat thromboembolic phenomena and, 624
- Fat mass measurement of, 36 patterns of distribution and, 37
- Fatigue. *See also* Cancer related fatigue (CRF) aging musculoskeletal system and, 1106 cardiovascular disease and, 520-521, 523 left-sided heart failure and, 569 mitral valve prolapse and, 597 multiple myeloma and, 712 multiple sclerosis manifestations and, 1428 neuromuscular, multiple sclerosis manifestations and, 1428 parkinsonism clinical manifestations and, 1442 spinal cord injury and, 1505 valvular heart disease and, 599
- Fatigue prevention, HIV and, 266
- Fatty liver infiltrate, heavy drinkers and, 905
- Fc receptors, function of, 284
- FDG-PET (fluorine-18-fluorodeoxyglucose positron emission tomography), osteomyelitis diagnosis and, 1185-1186
- Fear conditioning, emotional instability and, 1337
- Fear-Avoidance Beliefs Questionnaire (FABQ), 109
- Fear-Avoidance Model of Exaggerated Pain Perception (FAMEPP)
- Fear-avoidance-behavior (FAB), screening tools for, 109
- Febrile nonhemolytic reaction, 681, 682b
- Fecal incontinence, gastrointestinal disease symptoms and, 830
- Fecaliths, trapped fecal material and, 863
- Feet ankylosing spondylitis positioning and, 1286 rheumatoid arthritis exercise and, 1275
- Felty's syndrome, RA extraarticular manifestations and, 1268-1269
- Female athlete triad, 90, 92 osteoporosis diet and, 1161
- Female genital/reproductive system aging and, 986-994 breast disease and, 1015-1036 disorders of the ovaries and, 1005-1010 exercise and, 994 menopause and, 986-994 overview of, 986, 987f pelvic floor disorders and, 1010-1015 perimenopause and, 986 sexual dysfunction and, 994-995 uterus and fallopian tube disorders and, 995-1005
- Femoral and popliteal arteries implications for therapist, 619-624 occlusive disease and, 618, 618t
- Femoral head, osteonecrosis overview and, 1310
- Ferritin, 1646
- FES. *See* Stimulation, functional electric (FES)
- Fetal alcohol syndrome (FAS), 80
- FEV₁. *See* Forced expiratory volume
- Fever causes of, 299, 300t infectious disease and, 289-290, 290f, 299, 299b older adults and, 301
- Fever of undetermined origin (FUO), osteomyelitis diagnosis and, 1186
- Feverfew, migraine headaches and, 1558
- Fiber, fast oxidative, type IIa human muscle and, 1104
- Fibers fast twitch, type II human muscle and, 1104 slow oxidative slow twitch, type I human muscle and, 1104
- Fibrillary, neuroglial fibrils and, 1372
- Fibrillation, atrial (AF) abnormal cardiac rhythms and, 589 congenital heart disease and, 587
- Fibrinogen aging skeletal system and, 1103 coronary artery disease and, 533 stroke risk factor and, 1450-1452
- Fibrinolytic systems, chemical inflammatory mediators and, 223, 223f, 223-224
- Fibroadenoma. *See also* Breast disease, benign benign neoplasm of the breast and, 1015 breast disease and, 1015-1016 etiological factors and pathogenesis of, 1015
- Fibroblasts cortisol and, 457 human, 449 tissue repair and, 209, 212, 227 type III collagen and, 211
- Fibroblast growth factor (FGF), endothelial cells and, 213
- Fibrocartilaginous union (soft callus), fracture healing and, 233f
- Fibrochondrocytes, meniscus cells and, 236
- Fibroma, fibrous tumors and, 377
- Fibromyalgia. *See also* chronic fatigue syndrome clinical manifestations, 291-292, 292f, 293t definition and overview, 288 etiologic factors of, 289, 290f exercise and, 295 hypothyroidism and, 472 implications for therapist, 294-296 Lyme disease and, 343 medical management, 291-294, 292f pathogenesis, 289-291
- Fibronectin, wound healing and, 209
- Fibrosis hindered muscle repair and, 231 pancreatitis and, 914-915 progressive lung scarring and, 780 radiation and, 170
- Fibrotic myopathy, systemic sclerosis treatment and, 430
- Fibrous lesions, 1228-1229, 1229f
- Fight or flight stress response, 44 adrenaline release and, 95 trauma and, 58
- FIGO (International Federation of Gynecology and Obstetrics). *See* International Federation of Gynecology and Obstetrics (FIGO)
- Filariasis secondary lymphedema and, 652, 656 structural impairment and, 655
- Filgrastim (neupogen). *See* Colony-stimulating factor (CSF)
- Film studies, lateral, spinal cord injury diagnosis and, 1410
- Financial exploitation, elderly and, 42
- Fine-needle aspiration (FNA), thyroid cancer diagnosis and, 474
- Fingolimod, multiple sclerosis treatment and, 1434-1435
- Fire and pyrolysis, environmental hazards of, 126
- First line defenses, external pathogen inhibition and, 306, 310
- First-use syndrome, chronic dialysis and, 947
- Fissures, annulus injury and, 238
- Fistula, perilymph definition and overview of, 1584 implications for therapist, 1584-1585
- Five-axis system, chronic pain and, 105, 106b diagnostic criteria and, 108
- Fixation, breast cancer manifestations and, 1020, 1022f
- Flaccidity, traumatic brain injury and, 1487
- Flagyl (metronidazole), anaerobic bacteria and, 314
- Flail chest blunt chest trauma and, 782, 782f treatment of, 782
- Flap. *See* Deep inferior epigastric perforator (DIEP) flap; Transverse rectus abdominis myocutaneous (TRAM) flap
- Flapping tremors. *See* Asterixis
- Flavivirus treatment of, 1360-1361 West Nile virus and, 1356-1357
- Flexion contractures, diffuse scleroderma and, 429, 429f
- Flexion, interphalangeal (IP), tardy ulnar palsy and, 1610, 1611f
- Flexor carpi ulnaris (FCU), tardy ulnar palsy and, 1611
- Flexor tenosynovitis, diabetes and, 494, 494f
- Flick sign, carpal tunnel diagnosis and, 1606
- Flight personnel, increased cancer risk and, 416
- Flocculent densities, mitochondria and, 206, 206f
- FLT3 gene mutation, acute myelogenous leukemia and, 696
- Fluid analysis, implications for therapist, 1668 cerebrospinal, appearance of, 1666-1667, 1668 intake neurogenic bladder disorders and, 956 renal stone prevention and, 938 overload peripheral vascular and, 802 pulmonary edema development and, 801 peritoneal, analysis of, 1667, 1668 pleural and pericardial, analysis of, 1667, 1668 shift, fluid imbalance and, 183, 184 synovial analysis of, 1667, 1668 classification of, 1668t volume deficit (FVD) diabetes and, 492 fluid imbalance and, 183, 185 volume, serum hormones and, 1660
- Fluid imbalances. *See also* electrolyte imbalances antibiotic-associated colitis and, 859 GI diseases and, 831 implications for therapist, 184, 191 management of, 184 manifestation of, 189b overview of, 182 types of, 183
- Fluoroquinolone. *See* Antibiotics, fluoroquinolone
- Flutter valve airway clearance technique and, 795, 796f therapy and, 796
- fMRI. *See* Functional magnetic resonance imaging (fMRI)
- Focal brain injuries, traumatic brain injury and, 1479
- Focal neurologic syndrome, neurotoxicants and, 135
- Focal segmental glomerulosclerosis (FSGS), nephrotic syndrome and, 949
- Folate cancer prevention and, 1019 red blood cell and, 1649
- Folate deficiency, sickle cell disease and, 735
- Folic acid deficiency decreased erythrocytes and, 687 neural tube defects and, 1117
- Folic acid, red blood cell and, 1649
- Follicle-stimulating hormone (FSH), 113 endometriosis treatment and, 997 hypothalamic hormones and, 453, 456f
- Follicular lymphoma, non-Hodgkin's lymphoma and, 707, 709

Fomite
HIV transmission and, 258
indirect contact transmission and, 305

Food
contaminates and, 125-126
diverticular disease and, 862
heartburn and, 830
irritable bowel syndrome and, 859
malabsorption symptoms and, 849
urinary tract infection prevention and, 930

Foodborne illnesses. See also
Botulism (Clostridium botulinum)
implications for therapist, 852
overview and incidence of, 851

Foot care, diabetes and, 509

Footballer's migraine, traumatic brain injury and, 1482

Forced expiratory volume (FEV₁)
chest wall oscillation vest and, 796
COPD diagnosis and, 760, 763
lung function measures and, 793
pulmonary function test and, 1666

Forced vital capacity (FVC)
COPD exercise and, 763
lung function measures and, 793
pulmonary function tests and, 1666

Footdrop. See Neuroma, Morton's

Forestier disease. See Diffuse idiopathic skeletal hyperostosis (DISH)

Four Square Step Test (FSST), 1304

Fowler's position
ascites treatment and, 891
congestive heart failure
positioning and, 575
cystic fibrosis and, 803
exercise-induced asthma and, 772

Fracture
classification of, 1294, 1295f
clinical manifestations of, 1297-1298, 1298b
complications of, 1298
elbow. *See Palsy, tardy ulnar*
fat embolism syndrome, 624
implications for therapist, 1301-1309
insufficiency, overview of, 1294
medical management of, 1298-1301
diagnosis of, 1298-1299
prevention and, 1298, 1299b
prognosis and, 1300-1301
treatment and, 1299-1300
overview of, 1294-1296, 1295f
pathogenesis of, 1297
pathologic. *See Pathologic fracture*
pelvic/sacral. *See Pelvic/sacral fracture*
prevention of, 1172, 1301-1307
acute care and complications of, 1308-1309
exercise and, 1305-1306
fall gait and movement characteristics and, 1303
fall testing and, 1304
functional limitations testing and, 1304-1305, 1305b
incidence of, 1301-1302
identifying history of falls and, 1303-1304
rehabilitation and, 1309
risk factors and red flags of, 1302b, 1302-1303
steps to take and, 1306b, 1306-1307
stress/reaction fracture and, 1307-1308, 1308b
therapists perspective and, 1307
visual impairment and, 1303
primary tumor manifestation and, 1204
risk factors and incidence of, 1296, 1297b
stress. *See Stress fracture*

Fracture (Continued)
traumatic, 1294, 1296
vertebral compression. *See Vertebral compression fracture (VCF)*

Fracture healing, abnormal, 1298

Framingham heart study
claudication and, 611
coronary artery disease and, 529
hypertension and, 552
mitral valve prolapse and, 596

Frank blood, traumatic brain injury and, 1481

Frank-Starling law, effects of aging and, 524

Free radical theory
aging and, 516
asthma treatment and, 772

Free radicals
airway inflammation and, 772
amyotrophic lateral sclerosis and, 1403

cell injury and, 201-202, 202f

cellular dysfunction and, 1320

collagen formation and, 211

ionizing radiation and, 167

nitric oxide (NO) and, 203

pancreatitis and, 913

Parkinson's disease pathogenesis and, 1439

traumatic brain injury and, 1481, 1491

Freezing (gait akinesia), parkinsonism clinical manifestations and, 1441

Frontal lobe
amyotrophic lateral sclerosis and, 1404
higher brain function deficits and, 1331

Frontotemporal dementia, cognitive change dementia and, 1411

Frostbite, cold injuries and, 433-434, 434f

Frozen pelvis, endometriosis powder burn implants and, 996

Frozen shoulder. See Adhesive capsulitis

Fructosamine testing, glucose monitoring and, 498t, 498-499

Fuhrman nuclear grade, renal cell carcinoma staging and, 933

Fukutin-related proteins (FKRPs), Walker-Warburg syndrome, 1134

Fumes, environmental diseases and, 786-787

Function, autonomic, diabetic neuropathy and, 1619

Functional Activities Questionnaire, Alzheimer's disease diagnosis and, 1416

Functional Assessment of Cancer Therapy—Brain (FACT) tool, intervention measurement tools and, 1392

Functional Assessment of Chronic Illness Therapy (FACIT) Scale, intervention measurement tools and, 1392

Functional disturbances, multiple sclerosis diagnosis and, 1431

Functional impairment, obesity and, 35

Functional Independence Measure (FIM), changes in function measurement tools and, 1392

Functional limitations, disablement model and, 4

Functional Living Index—Cancer (FLIC), intervention measurement tools and, 1392

Functional magnetic resonance imaging (fMRI)
CNS disorder diagnosis and, 1345
spinal cord injury diagnosis and, 1507

Functional Mobility Assessment (FMA), postoperative rehabilitation and, 1216

Functional residual capacity (FRC)
pulmonary function and, 1665t, 1665-1666

Functional somatic syndrome, somatization disorder and, 98, 99

Fungal infections (dermatophytoses)
athlete's foot (*tinea pedis*), 407
implications for therapist, 407-408
ringworm (*tinea corporis*), 407, 407f

Fungal spores, hypersensitivity pneumonitis and, 786

Fungi, infectious diseases and, 303

G

γ -aminobutyric acid. See GABA (γ -aminobutyric acid)

GABA (γ -aminobutyric acid)
amino acids and, 1324-1325
ammonia and, 889
complex regional pain syndrome and, 1635
epilepsy pathogenesis and, 1534
migrain headache pathogenesis and, 1553

GAGs. See Glycosaminoglycans

Gait analysis, amyotrophic lateral sclerosis and, 1409

Gait pattern, parkinsonism clinical manifestations and, 1441

Galeazzi test (Allis' sign), hip dislocation and, 1127f, 1128

Galeazzi's fracture, fracture types and definitions of, 1295b

Gallbladder
distention of, 923
functions of, 881
hypomotility, cholesterol gallstone formation and, 920

Gallbladder cancer, 924-925

Gallium scan
Hodgkin's lymphomas and, 708
nuclear medicine and, 705

Gallstone disease. See Cholelithiasis (gallstone disease)

Gallstones
folate deficiency and, 735
types of, 919

Ganglia
basal
amyotrophic lateral sclerosis and, 1403

CNS disorder recovery of function and, 1350

Parkinson's disease pathogenesis and, 1438-1439, 1439-1440, 1440f

benign soft tissue tumors and, 1223

Gangliocytomas, 1383

Gangliogiomas, 1383

Ganglion
cells, achalasia and, 830
dorsal root, sciatica and, 1608

Gangrene, definition of, 323

Gardasil, cervical cancer vaccine and, 1002

GAS. See General adaptation syndrome (GAS)

Gas gangrene (clostridial myonecrosis), 323
implications for therapist, 323

Gastric cancer, primary gastric lymphoma, 845

Gastric mucosa, stomach lining and, 841

Gastritis
acute
mucosal defense mechanism and, 842
NSAIDs and, 841

chronic, 841
phases of, 842
types of, 841

definition and incidence of, 841

implications for therapist, 842

medical management of, 842

stress-induced, acute erosive gastritis and, 841

Gastroesophageal reflux disorder (GERD)
causes of, 835t
definition of, 834

exercise and, 837

implications for therapist, 837

medical management of, 835-837, 836t

Shaker head-lifting exercise and, 832f

Gastroesophageal varices, portal hypertension and, 887

Gastrointestinal (GI) system
aging and, 832-833
appendix and, 875-878

bleeding
eruptive gastritis and, 831
gastrointestinal disease symptoms and, 830

chemotherapy toxicity and, 175

cutaneous burn pathogenesis and, 437

esophagus and, 833-841

ESRD manifestation and, 941

excessive blood loss and, 686

exercise and, 832, 832f

intestines and, 848-875

motor activity and, 859

NSAIDs and, 156

parathyroid glands and, 454

peritoneum and, 878-879

rectum and, 879-880

rosacea and, 402

serotonin and, 861

signs and symptoms of disease and, 828-832

steroids and, 162

stomach and, 841-848
systemic toxicity of, 134t

Gastrointestinal disease, 828-831
clinical manifestations of, 829

Gastrointestinal tract, overview of, 828, 829f

Gastroplication, GERD treatment and, 836

GBS. See Guillain-Barré syndrome

GBV-C virus, HIV treatment and, 269

GCS. See Glasgow Coma Scale (GCS)

Geerstmann-Straussler-Scheinker syndrome, prion disease transmission and, 1362

Gel phenomenon, osteoarthritis morning stiffness and, 1252

Gender
alcohol-related liver disease and, 904

antiretroviral drugs and, 269

breast cancer risk factor and, 1018, 1018b

cardiovascular system and, 525-528

carpal tunnel syndrome and, 140

chronic pain and, 106, 107

colorectal cancer and, 864

cor pulmonale and, 820

coronary artery disease and, 533

depressive disorders and, 112

eating disorders and, 87

ergonomic differences of, 139

health and, 25-26

hemophilia and, 718

HIV and, 258

hyperthyroidism and, 466

hypothyroidism and, 470

osteoporosis pathogenesis and, 1162-1163

polymyalgia rheumatica and, 1241

sarcoidosis and, 180

spontaneous pneumothorax and, 822

Gene doping, 15

Gene mutation theory, aging and, 24

Gene profiling
breast cancer subtypes and, 1016-1017

breast cancer treatment and, 1027

cancer treatment and, 371

Gene therapy
approaches to, 15

- Gene therapy (*Continued*)
 cardiovascular disease and, 543
 CNS damage control and, 1348
 cystic fibrosis and, 794
 fracture treatment and, 1300
 hemophilia treatment and, 723
 human genetic engineering and,
 14-15
 potential uses of, 12b, 13
 retrovirus vector and, 14f
- General adaptation syndrome (GAS),
 8, 46, 47f
 resistance/adaptation, 47
- Generalized adaptation response, 44
- Generalized lymphadenopathy,
 lymphatic system inflammation
 and, 650
- Genes
 DNA and, 13, 13f
 migraine headaches and, 1552
 obesity and, 34
 regeneration associated (RAGs),
 spinal cord repair and, 1512
 testicular cancer and, 980
- Genetic and developmental disorders
 arthrogryposis multiplex congenita
 and, 1154-1156
 congenital dysplasia of the hip
 and, 1226-1130
 congenital myopathy and,
 1140-1141
 congenital neural tube defects and,
 1116-1226
 Down syndrome and, 1107-1111
 Erb's palsy and, 1147-1150
 kyphoscoliosis and, 1116
 neuromuscular disorders and,
 1130-1140
 osteogenesis imperfecta and,
 1150-1154
 scoliosis and, 1111-1115
 spinal muscular atrophy and,
 1141-1144
 torticollis and, 1145-1147
- Genetic cardiomyopathies
 primary cardiomyopathies and,
 579, 580t
- Genetic control theory, aging and,
 24
- Genetic counseling, cystic fibrosis
 and, 792
- Genetic disease, inherited, cystic
 fibrosis and, 789
- Genetic factors
 alcohol-related liver disease and,
 904
 cell injury and, 200
 degenerative disk disease and,
 1259
 Huntington's disease and, 1424
 lung cancer and, 811
 multiple sclerosis etiology and,
 1425-1426
 neural tube defects and, 1117
 osteoporosis risk and, 1159
 Parkinson's disease etiology and,
 1438
 rheumatoid arthritis pathogenesis
 and, 1265
 Genetic signature, breast cancer gene
 profiling and, 1027
- Genetic testing, 15
 breast cancer detection and,
 1023-1024
 cystic fibrosis and, 792
- Genital herpes (HPV), sexually
 transmitted infection and, 344f
- Genital ulcers, herpes virus and,
 330
- Genital warts (HPV), 329t. *See also*
 Human papillomavirus (HPV)
- Genitofemoral neuralgia, inguinal
 hernia and, 872
- Genomics, 12
- Gentamicin, intratympanic, hydrops
 treatment and, 1583
- Geographic pathology, 20
- GERD. *See* Gastroesophageal reflux
 disorder (GERD)
- Geriatric Depression Scale, 118
- Geriatric therapy practice, pulmonary
 complications and, 748
- Germ theory, 7
- Germ theory part II, mental illness
 and, 7
- Germ-line gene therapy, 15
- Gerontology, 24
- Gestational diabetes mellitus, 489
- GFR. *See* Glomerular filtration rate
- GH. *See* Growth hormone
- GH deficiency, hypopituitarism and,
 463
- GI. *See* Gastrointestinal (GI) system
- Giant cell arteritis (GCA). *See*
 Arteritis
- Giant cell tumor, 1221-1222, 1222f
- Gibbus. *See* Rotational deformity
- Gigantism, anterior pituitary gland
 and, 461
- Gilbert's syndrome, bilirubin and,
 884-885
- Gland's salivary, Sjögren's syndrome
 manifestation and, 1287
- Glasgow Coma Scale (GCS)
 concussion and, 1481
 intracerebral hemorrhage
 treatment and, 1467
 traumatic brain injury
 measurement and, 1488,
 1489b, 1490, 1492
- Glatiramer acetate, multiple sclerosis
 manifestations and, 1430
- Gleason score, prostate cancer grading
 and, 972, 972f, 973b, 974
- Glia cells, gliomas overview and,
 1370-1371
 central nervous system and, 1320-
 1321, 1321f
 immune system and, 290f, 291.
See also Astrocyte
- Glia scars, CNS necrotic area and,
 229
- Gliding contusions, traumatic brain
 injury and, 1479
- Glioblastoma multiforme (GMB)
 high-grade astrocytoma and, 1373,
 1375f
 primary brain tumor
 manifestation and, 1368
- Gliomas
 benign (low-grade), 1370
 brainstem, pediatric tumors and,
 1400
 ependymoma and, 1376
 etiologic and risk factors of, 1372
 high-grade astrocytoma—grades III
 and IV and, 1373-1376
 low-grade astrocytoma—grades I
 and II and, 1372-1373
 malignant, 1370
 medulloblastoma and, 1376
 oligodendrogloma and, 1376
 overview and incidence of, 1366,
 1370-1372, 1371t
- Gliosis
 CVA and, 151
 spinal cord injury and, 1501
- Global inhibition, musculoskeletal
 dysfunction and, 232
- Global Initiative for Chronic
 Obstructive Lung Disease
 (GOLD), COPD guidelines of,
 759
- Global Stroke Initiative, stroke
 resources and, 1453
- Glomerular basement membrane
 (GBM), 949
- Glomerular diseases
 implications for the therapist, 950
 medical management of, 950
 overview of, 949
- Glomerular filtration rate (GFR)
 cardiovascular disease and, 941
 kidney function and, 940
 NSAIDs and, 940
- Glomeruli, kidney filtering units
 and, 949
- Glomerulonephritis
 crescentic, 950
 ESRD and, 949
- Glucagon, endocrine pancreas and,
 454
- Glucocorticoid (cortisol)
 acute stress response and, 1339
 adverse effects of, 160-162
 antiinsulin diabetogenic hormones
 and, 457
 bone mineral density and, 48,
 774
 corticosteroids and, 160-164
 immunosuppressive agent and,
 158
- Glucosamine. *See also*
 Supplementation,
 glucosamine-chondroitin
 osteoarthritis treatment and, 1255
- Glucosamine/Chondroitin Arthritis
 Intervention Trial (GAIT), 1255
- Glucose
 Achilles tendon and, 495
 blood
 basic metabolic panel and,
 1641-1643, 1642t
 insulin, glucose levels, exercise
 and, 1643-1644
 cerebral spinal fluid and, 1667
 metabolism, coronary artery
 disease and, 530
 monitoring, 498-499
 oral tolerance test (OGTT),
 1641-1642
 urinalysis and, 1663
- Glucosuria, diabetes and, 492
- GlucoWatch G2 Biographer (GW2B),
 glucose monitoring and, 498
- Glutamate
 amino acids and, 1324
 ammonia and, 889
 amyotrophic lateral sclerosis and,
 1403
 secondary neuronal damage and,
 1455
- Glutamyltransferase (GGT), liver
 function panel and, 1644
- Glutathione, cystic fibrosis lung
 disease and, 790
- Gluten, malabsorption syndrome
 and, 849
- Glycated (glycosylated) HbA1c,
 glucose monitoring and, 498,
 498t
- Glycemic states, clinical symptoms
 of, 514t
- Glycocalyx, prostheses and implant
 infection and, 1189
- Glycogenolysis, islets of Langerhans
 and, 487
- Glycogenesis, catecholamine and, 457
- Glycolysis abnormalities,
 carbohydrate metabolism and,
 472
- Glycoproteins, neural groove closure
 and, 1118
- Glycosaminoglycans (GAGs)
 cartilage and, 240
 knee cartilage and, 1253
 synovial membrane and, 237
 tendon repair and, 234
- Glycosylation, congenital muscular
 dystrophy and, 1134
- Gn-RH. *See* Gonadotropin-releasing
 hormone (Gn-RH)
- Goiter
 Graves' disease and, 466
 iodine and, 473, 473f
 thyroid gland hyperplasia and,
 454
- Golgi complex, glycosylation and,
 1134
- Gonadotropin-releasing hormone
 (Gn-RH)
 endometriosis treatment and, 997
 hypoestrogenism and, 994
- Gonorrhea
 incidence of, 343
 sexually transmitted infections
 and, 329t, 344f
- Gout (hyperuricemia). *See also*
 Hyperuricemia; Pseudogout
 clinical manifestations of, 1292,
 1293f
- heart transplantation
 complications and, 1077
 implications for therapist, 1293
 medical management of, 1292
 overview of, 1291
 polycythemia vera and, 716
 risk factors and etiologic factors
 of, 1291-1292
- Gout, intercritical period, 1292
- Gower's sign, Duchenne's muscular
 dystrophy and, 1135, 1135f
- Grading
 primary tumor medical
 management and, 1206
- Graft dysfunction, transplantation
 complications and, 1067
- Graft failure
 acute
 heart transplantation
 complication and, 1077
 infection and, 1090
 lung transplantation and, 1089
- Graft rejection. *See also* Ventricular
 assistive device (VAD)
 kidney transplantation
 complications and, 1067
- T-cell mediated, 1076
- transplants and, 297
 types of, 1052-1054
- Graft-versus-host disease (GVHD)
 chimerism and, 1048
 localized scleroderma and, 427
 symptoms of, 1054b, 1066
 transplantation prognosis and,
 1064
- Grafting, bone, fracture treatment
 and, 1300
- Grafts
 cable, neurotmesis and, 1617
 interfascicular, neurotmesis and,
 1617
- Gram stain
 bacterial classification and, 302,
 303f
 microbiologic studies and, 1663
- Gram-negative enterobacteria,
 prostatitis pathogens and, 966
- Grand mal (tonic-clonic seizure),
 1543
- Granulation tissue
 fracture healing and, 233f
 tissue healing and, 227, 229
- Granulocyte colony-stimulating
 factors (G-CSFs). *See* Colony-
 stimulating factor (CSF)
- Granulocyte-macrophage colony-
 stimulating factor (GM-CSF),
 prostate cancer vaccine and, 976
- Granulocytes
 definition of, 690
 leukocyte type of, 244
- Granulocytosis. *See* Neutrophilia
- Granuloma, inflammation and, 200
- Graves' disease
 hyperthyroidism and, 466-468
- Gravity, specific, kidney test and,
 1662-1663
- Green tea polyphenols (GTPs),
 Sjögren's syndrome treatment
 and, 1287
- Grey matter, 1500
- Gross Motor Function Classification
 System (GMFCS), cerebral palsy
 classification and, 1517, 1519b
- Group A streptococci
 rheumatic fever, 605
streptococcus pyogenes and, 319,
 319b
- Group B streptococci, *S. agalactiae*
 and, 321-322
- Growth hormone (GH), 457. *See*
 also Human growth hormone
 (HGH)
 aging and, 459
 hyperpituitarism and, 461
- Growth, steroids and, 162

- Guanine, molecular language and, 13
- Guillain-Barré syndrome (GBS). *See also* Atelectasis clinical manifestations of, 1622 implications for therapist, exercise and, 1624 lateral-costal breathing and, 744t, 745 medical management of, 1622-1623 overview and definition of, 1621 pathogenesis of, 1621-1622, 1622t Gulf War syndrome (GWS), 149 Gut immune system, GI tract and, 828 Gut microflora, intestinal microbes and, 35
- H**
- H & H, hemoglobin tests and, 1648 *H. pylori* (*Helicobacter pylori*) esophageal cancer and, 838 gastric adenocarcinoma and, 846 germ theory and, 7 ischemic heart disease and, 533 non-Hodgkin's lymphoma and, 707 peptic ulcer risk factor and, 843 HAART (Highly active antiviral therapy) exercise and, 273 HIV and, 708 HIV treatment and, 268-269 Hodgkin's lymphomas and, 704, 708 rheumatic disorders in HIV and, 265 *Haemophilus influenzae*, type B (Hib), meningitis etiology and, 1352 Hageman factor fibrin clot and, 224f plasma protein and, 223f, 223-224 Hair cell, ototoxicity and, 1585 Hammer toes, Charcot-Marie-Tooth disease and, 1603, 1603f Hand cream (lotion) HIV protection and, 267b hypersensitivity disorders and, 280 petrochemicals and, 130 petroleum based, 4 radiation therapy and, 172 skin care and, 395 Hand stiffness endocrine disease and, 460 osteoarthritis manifestation and, 1252-1253, 1253f psoriatic arthritis manifestation and, 1288 Hand-and-foot syndrome (Dactylitis) dactylitis and, 735, 735f sickle cell disease and, 735, 735f Handicap, 18 Handwashing disease prevention and, 310-311 home health care and, 314 microbe transmission and, 307, 307b new guidelines for, 307b, 311 personal protection and, 1672, 1673 pneumonia precautions and, 751 Hashimoto's disease autoimmune disease and, 280 lymphocytic thyroiditis and, 474 Hattler catheter. *See also* A-lung artificial lung and, 1091, 1091f Haversian system, fracture healing and, 232 Hayflick limit, cell division and, 354 Hb. *See* Hemoglobin, oxygen carrying (Hb) Hb A, sickle cell trait genes and, 730, 739 Hb F, fetal Hb and, 730 Hb H, thalassemias and, 740 Hb S, sickle cell trait genes and, 730, 739 HBV. *See* Hepatitis B virus (HBV)
- HCC. *See* Carcinoma, primary hepatocellular (HCC)
- HCHL. *See* Mixed-cellularity Hodgkin's lymphoma
- HCV. *See* Hepatitis C virus (HCV)
- HDL. *See* High-density lipoprotein (HDL)
- Headache cervicogenic implications for therapist, 1562 medical management of, 1561-1562 overview of, 1561 chronic subdural hematoma, 1471 cluster (CH) clinical manifestations of, 1560f, 1560-1561 implications for therapist, 1561 overview and definition of, 1559 pathogenesis of, 1559-1560 traumatic brain injury and, 1482 in elderly, 1564 medication overuse and, 1564 menstrual migraine, 1554 migraine. *See* Migraine headache overview of, 1547-1548, 1549f, 1549f postdural puncture, 1565 posttraumatic syndrome and clinical manifestations of, 1562-1563, 1563b implications for therapist, 1563-1564 medical management of, 1563 overview, definition, and risk factors of, 1547, 1562 primary cluster and, 1559-1561 migraine and, 1551-1559 tension-type of, 1548-1551 secondary cervicogenic and, 1561-1562 in the elderly and, 1564 medication overuse and, 1564 overview of, 1547 postdural puncture and, 1565 posttraumatic headache syndrome and, 1562-1564 sinus and, 1564-1565 temporal arteritis and, 1564 sinus, 1564-1565 temporal arteritis and, 1564, 1564b tension-type. *See* Tension-type headache venous malformations and, 1470 Headache Impact Test, headache impact measurement tools and, 1547
- Healing hemostasis and degeneration phase of, 215 inflammation phase of, 215-225 proliferation and migration phase of, 226 remodeling and maturation phase of, 227, 233f systemic factors and, 151
- Health children and, 25 definition of, 1 gender and, 25 geographic variations and, 20 lifestyle and, 26-28 promotion of, 10 race/ethnicity and, 21 social issues and, 17 Health and Illness, theories of, 7-9, 8f
- Health behavior change, therapist and, 50-51
- Health Belief Model (HBM), 49
- Health care biomedical model of, 17 disparities elimination of, 23b factors of, 23, 53
- Health care (Continued) racial/ethnic factors and, 22 social factors and, 21, 52 environmental barriers to, 52, 53 implications for therapist, 57 psychologic considerations in, 54 spiritual development in, 71-72
- Health care worker (HCW) barrier precautions for, 1671-1672 cultured *S. aureus* and, 319 guidelines for HIV infected, 272 guidelines for infected, 1671 potential exposure sources for, 1671
- pulmonary tuberculosis exposure and, 757-758 spread of microrganisms and, 306-307, 319
- transmission of CDAD and, 315 transmission prevention guidelines and, 307b, 310-311 with infectious disease, 312-313t
- Health promotion, special implications for therapist, 10b
- Health status, demographics of, 18 *Healthy People 2000*, blood pressure control and, 553
- Healthy People 2010* adolescents and, 25 adverse childhood experience and, 28 AIDS case reduction and, 266 asthma management and, 771 breast cancer death reduction and, 1021 cancer cases and, 368 goals for children and, 1164 health disparities, 23b health targets of, 10 heart disease goals and, 536 high blood pressure and, 553 kidney failure reduction and, 944 lung cancer mortality reduction and, 812 obesity prevention and, 38b occupational injury and outdoor air pollution and, 124 pneumonia objectives and, 751 pressure ulcer reduction and, 444 quality of life and, 19 substance abuse and, 81 tobacco use and, 77
- Hearing dysfunction, traumatic brain injury and, 1487
- Heart rate (pulse rate), 1676b, 1676-1677 rhythm, 1678
- Heart and Estrogen/Progestin Replacement Study (HERS), cardioprotection and, 527
- Heart attack exercise and, 567 myocardial infarction symptom of, 562, 563f occurrence of, 559
- Heart block, abnormal cardiac rhythms and, 589-590
- Heart disease, 7, 573-574 air pollution and, 124 classification of, 574b gender and, 26 migraine headache and, 1552 radiation and, 168
- Heart failure atrial fibrillation and, 589 clinical manifestations of, 569t pulmonary edema and, 800 ventricular assist devices and, 1085
- Heart healing, scar tissue and, 230
- Heart murmur, valvular leak and, 597
- Heart muscle diseases angina pectoris and, 548-552 congenital heart disease and, 584-588 congestive heart failure and, 567-576
- Heart muscle diseases (Continued) hypertensive cardiovascular and, 552-559 ischemic heart disease and, 528-548 myocardial infarction and, 559-567 myocardial disease and, 578-583 myocardial neoplasms and, 583-584 orthostatic hypotension and, 576-578 trauma and, 583
- Heart rate abnormal response of, 1677-1678 acute respiratory distress syndrome and, 805 aging and, 1677 heartbeats per minute and, 523 parkinsonism clinical manifestations and, 1442 types of, 589
- Heart rate variability (HRV), postoperative exercise and, 547
- Heart rhythm, types of, 589-590
- Heart transplantation candidates for, 1074-1075, 1075b complications of, 1076-1077 future trends of, 1078 implications for therapist, 1078-1082 mechanical circulatory support and, 1082-1086 overview of, 1074 procedures for, 1075-1076 prognosis of, 1077-1078 transplantation candidates for, 1074-1075 exercise and, 1080 therapist's role acute care phase and, 1079-1080 denervation effects and, 1080-1082, 1081b exercise and, 1080 pretransplant and, 1078-1079
- Heart valve deformities, classification of, 594, 595f
- Heart valve diseases aortic regurgitation, 598-599 aortic stenosis, 597-598 implications for therapist, 599-600, 602, 605 infective endocarditis, 600-602 mitral regurgitation, 595-596 mitral stenosis, 594-595 mitral valve prolapse, 596-597 rheumatic fever and, 603-605 tricuspid stenosis and regurgitation, 599
- Heartburn, gastrointestinal disease symptoms and, 830
- HeartMate XVE, ventricular assistive device and, 1083, 1083f
- Heat illness, 132t
- Heat shock, stress response of, 133
- Heat stress, 131-132, 136
- Heat, multiple sclerosis manifestations and, 1429
- Heavy metals amyotrophic lateral sclerosis and, 1403 occupational hazards of, 127-130
- Heerfordt's syndrome, sarcoidosis symptoms and, 807b
- Helicobacter pylori* (*H. pylori*). *See also* *H. pylori* (*Helicobacter pylori*) Heliox therapy, bronchiolitis treatment and, 777
- Helmet, bicycle, traumatic brain injury risk factor and, 1477
- Helminths (parasitic worms) inflammatory bowel disease and, 853, 856
- Helper T cells HIV/AIDS, 260, 260f sarcoidosis and, 806 T cell subpopulation of, 247, 249f
- Hemachromatosis, primary hepatocellular carcinoma and, 909

Hemangioblastoma, 1383
von Hippel-Lindau disease and, 1372

Hemangiopericytoma, vascular neoplasms and, 636

Hemarthrosis, joint spaces bleeding and, 719

Hematocrit (HCT), red blood count and, 1646, 1648, 1649

Hematologic disorders exercise and, 680 implications for therapist, 680-681 signs and symptoms of, 678-680, 679b

Hematologic system. *See also* Immune system; Lymphatic system definition of, 616f, 678 disorders of, 678-681 formation of blood cells and, 678

Hematology, definition and overview of, 678

Hematoma, epidural, 1471, 1473f traumatic brain injury and, 1482

Hematopoiesis, blood formation and, 1648

Hematopoietic growth factors. *See* Colony-stimulating factor (CSF)

Hematopoietic malignancies, cancer and, 350

Hematopoietic system. *See also* Aging, immune system aging and, 681 ESRD manifestations of, 941, 942t

Heme, thalassemia protein and, 739

Hemianesthesia, middle cerebral artery syndrome and, 1455

Hemiballismus, posterior cerebral artery syndrome and, 1457

Hemineglect, right hemisphere syndrome and, 1332

Hemiparesis, stroke consequence and, 1453

Hemiplegia middle cerebral artery syndrome and, 1455 traumatic brain injury and, 1494

Hemodialysis dialysis form of, 945 HBV/HCV risk and, 896 kidney transplantation and, 1066

Hemodynamic measurements, exercise guidelines and, 1086

Hemoglobin (Hgb) glycosylated (HbA_{1c}), 1642-1643 oxygen carrying, fetal sickle cell disease and, 737 red blood cells and, 1646 red blood tests and, 1648, 1649

Hemoglobin concentration, mean corpuscular (MCHC), 1648

Hemoglobin levels, CRT exercise and, 387

Hemoglobin, oxygen carrying (Hb) anemia and, 689 molecular structure of, 732 sickle cell disease and, 730 thalassemias and, 740

Hemoglobinopathies Sickle cell disease, 730-739 Sickle cell trait, 739-741

Hemolysis, erythrocyte destruction and, 686

Hemopericardium, pericardial fluid analysis and, 1667

Hemophilia, 41 activities by risk and, 724-725, 725t and gene therapy, 14 antibody inhibitors and, 721 exercise and, 724, 726 HIV and, 258, 259, 274 implications for therapist, 724-727 medical management and, 722-723 muscle hemorrhages and, 721 overview, 718 transmissible disease and, 722 women and, 719

Hemophilia A, clotting factor VIII and, 718

Hemophilia B clotting factor IX and, 718 mild hemophilia treatment and, 723 treatment of, 723

Hemophilia Joint Health Score, joint evaluation scale and, 721

Hemophilic arthropathy classification of, 720t, 720-721, 721f stages of, 720, 720b, 720t, 720f

Hemopneumothorax chest trauma and, 822 fractured rib and, 782

Hemoptysis bronchiectasis and, 774 coughing and, 743

Hemorrhage intracerebral. *See* Intracerebral hemorrhage (ICH) intraparenchymal. *See* Intracerebral hemorrhage (ICH) subarachnoid. *See* Subarachnoid hemorrhage (SAH)

Hemorrhage interventricular (IVH), cerebral palsy pathogenesis and, 1518, 1521f intracerebral clinical manifestations of, 1465-1466 etiologic and risk factors of, 1464-1465 incidence of, 1464 medical management of, 1466-1468 overview and definition of, 1463-1464 pathogenesis of, 1465 subdural. *See* Subdural hemorrhage

Hemorrhagic transformation intracerebral hemorrhage pathogenesis and, 1465

Hemorrhoids, 879-880 external, 880 internal, 880

Hemostasis coagulation inhibitions and, 1653-1654 coagulation tests and, 1653 definition of, 716 implications for therapist, 1654 tendon repair and, 234 tests of, 1652-1653, 1653, 1653t tissue repair and, 228, 231

Hemostasis disorders aspirin and, 729 disseminated intravascular coagulation, 729-730 hemoglobinopathies and, 730-741 hemophilia and, 716-728 thrombocytopenia and, 728 von Willebrand's disease and, 716-718

Hemothorax, pleural effusion and, 825f, 826

Hennebert's sign, perilymph fistula manifestations and, 1584

HEPA. *See* High efficiency particulate air (HEPA) mask

Heparin angina attacks and, 550 low-molecular-weight (LMWH), 1653

Hepatectomy, HCC treatment and, 910

Hepatic arterial infusion (HAI) therapy, metastatic malignant liver tumors and, 911

Hepatic disease, signs and symptoms of, 881-883, 882b

Hepatic encephalopathy implications for therapist, 889 liver disease and, 883 overview of, 888 stages of, 889

Hepatic failure, liver impairment and, 881

Hepatic neoplasms. *See* Neoplasms, liver

Hepatic system, healing of, 883-884

Hepatic toxicity chemotherapy and, 176 liver injury and, 912

Hepaticojejunostomy, biliary bypass and, 925

Hepatitis alcoholic, progressive liver damage and, 904 autoimmune implications for therapist, 904 overview and incidence of, 902 chronic, 892 fulminant, 892-893 viral implications for therapist, 899-900 medical management of, 896-899 risk factors for, 893-896, 895t types of, 892, 893, 894t

Hepatitis A virus (HAV) (infectious hepatitis) CNS infectious disease and, 1358 overview of, 893, 894t preventive measures and, 897 prognosis of, 899 risk factors of, 893-894, 895t treatment of, 898

Hepatitis B virus (HBV) health care workers and, 311t, 326-327 hemophilia and, 722 infection transmission and, 1671 liver transplantation and, 1070, 1070t nondisclosing MSM and, 259 overview of, 893, 894t prevention of, 897 primary hepatocellular carcinoma and, 909 prognosis of, 899 risk factors of, 895, 895t sexually transmitted infections and, 329t treatment of, 898 vaccine and, 369

Hepatitis B virus immunoglobulin (HBIG), Hepatitis B virus vaccine and, 326-327

Hepatitis C virus (HCV) cirrhosis and, 885 health care workers and, 326, 327 Hepatitis B virus DNA and, 897 overview of, 893, 894t prevention of, 897 primary hepatocellular carcinoma and, 909 prognosis of, 899 risk factors of, 895t, 896 treatment of, 898

Hepatitis D virus (HDV) (delta virus) overview of, 893, 894t, 895t prognosis of, 899

Hepatitis E virus (HEV) overview of, 893, 894t prevention of, 897 prognosis of, 899 risk factors of, 895t

Hepatitis G virus (HGV), overview of, 893

Hepatocellular liver disease, drug-induced hepatitis and, 901

Hepatocyte transplantation hepatic system healing and, 884 liver transplantation future trends and, 1073

Hepatocytes, lipoproteins and, 205

Hepatoiminodiacetic acid (HIDA) scan, biliary scintigraphy and, 923

Hepatojugular reflex, pulmonary edema diagnosis and, 802

Hepatomegaly alcohol hepatitis and, 905 cavernous hemangioma and, 909

Hepatorenal syndrome, 891-892

Hepatosplenomegaly, inflammatory arthritis and, 1277

Hepatotoxicity, drug-related causes of, 900, 901b implications for therapist, 902 overview and incidence of, 900

Hepcidin, hereditary hemochromatosis and, 684

HER2/neu, defective growth-promoting oncogene and, 1029

Herberden's nodes osteoarthritis diagnosis and, 1254 osteoarthritis of the hands and, 1252-1253

Hereditary disorders idiopathic epilepsy and, 1532 polycystic kidney disease and, 936

Hereditary hemochromatosis implications for therapist, 685 medical management of, 684-685

Heredity breast cancer risk factor and, 1019 cancers and, 352 genetic and chromosomal mutations, 133 osteoporosis risk factor and, 1159 stress and, 48

Hernia acquired, 833 athletic. *See* Hernia, sports clinical manifestations of, 872 congenital, 833 definition and incidence of, 870, 871f direct, overview of, 871f, 871-872 femoral, overview of, 871f, 872 hiatal definition and incidence of, 833, 833f etiology and risk factors of, 833, 834b implications for therapist, 834 medical management of, 834 Shaker head-lifting exercise and, 832f implications for therapist, 873-874 incisional, 871f, 872 inguinal clinical manifestation of, 872 treatment of, 873 medical management of, 872-873 risk factors of, 870, 872t sports clinical manifestation of, 872 overview of, 870-871, 871f postoperative rehabilitation of, 874 umbilical, overview of, 871f, 872

Hernial sac, manipulations of, 872

Herniation, disk injury and, 238

Herniorrhaphy, hernia surgical repair and, 872

Heroin, drug infection and, 346

Herpes encephalitis, HSV and, 331

Herpes simplex virus (HSV) types 1 and 2 aseptic meningitis and, 1353 Bell's palsy and, 1609 clinical manifestations of, 328-331 encephalitis and, 1358 implications for therapist, 332 incidence, etiology, risk factors of, 328, 329t medical management of, 331

Herpes simplex virus-1, 328, 330

Herpes simplex virus-2, 329t, 330-331

Herpes zoster (HZ), 1626. *See also* Varicella zoster virus (VZV) clinical manifestation of, 404, 405f herpes virus type 3 and, 332 implications for therapist, 405-406 medical management of, 405

Herpesvirus cytomegalovirus (herpesvirus type 5), 336-337

Herpesvirus (Continued)
herpes simplex viruses types 1 and 2, 328b, 328-331
herpesviruses types 6,7,8, 337
infectious mononucleosis (herpesvirus type 4), 335-336
Kaposi's sarcoma and, 419
multiple sclerosis and, 7
overview and definition, 328, 328b
types of, 337
varicella zoster virus (herpes virus type 3), 332-334
Herpetic keratitis, HSV and, 331
Herpetic whitlow
health care workers and, 317t, 332
HSV-1 and, 328, 330, 331f
Herring classification, Legg-Calvé-Perthes disease diagnosis and, 1314
Heterosexual intercourse, AIDS transmission and, 259
Heterotypic ossification
bone morphogenetic protein (BMP) and, 1238
clinical manifestations of, 1238-1239
implications for therapist, 1239-1240
medical management of, 1239
overview and definition of, 1237-1238, 1238b
risk factors of, 1238
Heterozygous hemoglobin sickle cell, single sickle cell gene and, 730
HHV-6, B-cell lymphotropic virus and, 337
HHV-7, T-cell lymphotropic virus and, 337
HHV-8, Kaposi's sarcoma and, 337, 419-420
Hiatal hernia
rolling, 833f
sliding, 833f
High blood pressure. See Hypertension
High efficiency particulate air (HEPA) mask
airborne infection isolation and, 1671
pulmonary tuberculosis monitoring and, 756
white blood cell count and, 1649
High-altitude
cerebral edema, 133
environmental hazards of, 132-133, 137
pulmonary edema, 133
High-density lipoprotein (HDL). See also Atherosclerotic cardiovascular disease (CVD)
cholesterol in women and, 527
coronary artery disease and, 530
hormones and, 527
physical activity and, 31
High-sensitivity C-reactive protein (hsCRP), coronary artery disease and, 533
Higher brain function deficits, CNS disorder manifestation and, 1331f, 1331-1333, 1332f
Highly active antiviral therapy (HAART). See HAART
Hilar adenopathy, bilateral, arthritis in sarcoidosis and, 808
Hip dislocation, cerebral palsy manifestation and, 1521, 1523f
Hip replacement, sickle cell disease and, 739
Hip-knee-ankle-foot orthosis (HKAFO), 1126, 1152
Hippocampus, epilepsy pathogenesis and, 1534-1535
Hippocratic philosophy, 10
Hispanic NHANES (HNANES). See NHANES (National Health and Nutrition Examination Survey)

Histamine
cluster headache pathogenesis and, 1559
hydrops treatment and, 1583
Histocompatibility complex, major, idiopathic inflammatory myopathies and, 1244
Histocompatibility, posttransplant complications and, 1052
Histoplasmosis, fungal pneumonia and, 750
HIV (human immunodeficiency virus). See also AIDS
addiction and, 76
asymptomatic early stage of, 260, 262, 273
CD4 T cells and, 260-262
cervical intraepithelial lesions and, 1000
diagnosis of, 267-269
gender and, 26
health care workers and, 327
hemophilia and, 722, 727
immune system and, 241
manifestations of, 263t
meningitis etiology and, 1352
non-Hodgkin's lymphoma and, 707-708
osteonecrosis risk factors and, 1310
parkinsonisms and, 1447
prevention of, 266-268
rehabilitative therapy and, 272-273
transmissible disease and, 722
transmission of, 270-271, 271b
treatment of, 268-269
universal precautions and, 1669
HIV advanced disease
AIDS and, 262
exercise and, 273
HIV associated dementia (HAD). See HIV/AIDS encephalopathy
HIV pain syndromes, groups of, 263
HIV PEP (Postexposure prophylaxis). See Postexposure prophylaxis
HIV-I antibody enzyme immunoassay test, 267
HIV-1 (type I retrovirus)
illness spectrum of, 258
infectious process of, 261
pathogenesis of, 260f
screening of, 267-268
HIV-associated myopathy, muscle weakness and, 265
HIV/AIDS
exercise and, 273-274
peripheral nerve system inflammations and, 1627
HIV/AIDS encephalopathy, advanced disease and, 262, 263t
HL. See Hodgkin's lymphoma (HL)
HLA (human leukocytic antigen). See Human leukocyte antigen (HLA)
hNT2.17, spinal cord repair and, 1512
Hodgkin's lymphoma (HL)
cancer staging and, 350
classic Hodgkin's lymphoma and, 702-703, 703f, 704f
definition and overview of, 701, 701f
implications for therapist, 706
medical management of, 704-706, 705f
pregnancy and, 703-704
risk factors of, 701, 702t
Hoehn and Yahr Classification of Disability, parkinsonism clinical manifestations and, 1442, 1443t
Hoffmann's signs, amyotrophic lateral sclerosis and, 1405
Holiday heart syndrome, etiology of arrhythmias, 588
Holistic health, 17
Holter monitor, arrhythmia monitoring and, 590, 591f, 593
Homans' sign, pulmonary embolism and, 817
Home health care, infectious disease and, 314-315
Homeless, healthcare needs of, 27, 28b
Homeostasis theory, 8-9, 232
Homocysteine (Hcy)
atherosclerotic disease tests and, 1654
cardiac markers and, 564
coronary artery disease and, 533, 537
metabolism and NTDs, 1118
stroke risk factor and, 1452
thromboangiitis obliterans and, 614
Homozygous Hb S, sickle cell genes and, 730
HORIZON Pivotal Fracture trials, osteoporosis treatment and, 1168
Hormonal changes, migraine headache and, 1552
Hormonal dysfunction
depression and, 113
hypothalamic-pituitary-adrenal (HPA) axis and, 34
lipedema and, 677
medical management of, 673-675, 675f
Hormonal therapy
breast cancer treatment and, 1028-1029
primary brain tumor treatment and, 1387
side effects of, 1032
Hormone replacement therapy (HRT)
advantages/disadvantages of, 988, 989t
bisphosphonates and, 1168
menopause and, 988-989
postmenopausal women and, 527
rectocele treatment and, 1014
strength training and, 1105
thalassemia treatment and, 741
Hormone replacement therapy, continuous combined (cCHRT), 988
Hormone therapy
cancer treatment and, 375
prostate cancer stage D treatment and, 975
side effects of, 978
Hormone, adrenocorticotropin. See ACTH (adrenocorticotropin hormone)
Hormones
antiinsulin diabetogenic, 457
cancer and, 353, 355, 865
coronary artery disease and, 527-528
corticotropin-releasing (CRH), infantile and childhood epilepsy and, 1541544
ectopic
hyponatremia and, 189
production of, 456
endocrine system and, 453, 455t
epilepsy and, 1533
osteoporosis risk factor and, 1159
pituitary, epilepsy treatment abnormalities and, 1538-1539
serum, 1660, 1660t
implications for therapist, 1660-1661
thyroid, 1660
Horner's syndrome
anterior inferior cerebellar artery syndrome and, 1458
cervical sympathetic plexus invasion and, 815
cluster headache manifestation and, 1560
syringomyelia and, 1501
Hospice care, physical therapists and, 385, 419
Hospital acquired pneumonia (HAP), mortality rate and, 751
Hot flashes, menopause symptoms and, 987, 987b
HPV. See Human papillomavirus (HPV)
HRT. See Hormone replacement therapy (HRT)
HRV (heart rate variability). See Heart rate variability
HSCT. See Transplantation, hematopoietic cell (HSCT)
HSV (herpes simplex virus). See herpes simplex virus
Huang scores, modified, cystic fibrosis scoring system and, 793
Hubbard tank, Guillain-Barré syndrome and, 1624
Human aggregates, ecologic model and, 18
Human genetic engineering. See gene therapy
Human genome, 13, 13f
Human Genome Project, 12, 13f, 15b
Human growth hormone (HGH), prolactin and, 453
Human immunodeficiency virus (HIV). See HIV
Human leukocyte antigen (HLA)
antinuclear antibodies and, 1662, 1662t
autoimmune hepatitis type 1 and, 902
bone marrow transplantation and, 374
celiac disease and, 849
cell markers and, 243
inclusion body myositis and, 1195
multiple sclerosis genetic determinants and, 1426
pneumonitis and, 786
polymyalgia rheumatica and, 1241
psoriasis and, 421
transplant matching and, 297
transplant sibling match and, 1060, 1061
Human papillomavirus (HPV)
cervical cancer risk and, 1000
incidence of, 343
screening for, 1002t
unprotected sexual intercourse and, 1000
vaccination and, 1002
vaccine and, 369
warts and, 406
Humanitarian Use Device, cardiac transplantation future trends and, 1078
Humoral immunity
acquired immunity and, 245-246, 247f
age related decline of, 250
bronchiectasis and, 774
Huntington's disease (HD)
clinical manifestations of, 1423-1424
implications for therapist, 1425
medical management of, 1424f, 1424-1425
overview and definition of, 1422
pathogenesis of, 1422-1423, 1423f
Huntington's disease, clinical manifestations
movement disorders and, 1423
neuropsychologic and psychiatric disorders and, 1423-1424
Hydration, urine and, 1662-1663
Hydrocephalus
cerebral palsy manifestations of, 1521
choroid plexus papilloma and, 1380-1381
shunting and, 1124-1125, 1125b
signs and symptoms of, 1118b
Hydrochloric acid, gastroesophageal reflux disorder and, 834
Hydrocortisone. See Cortisol
Hydrolysis, gating mechanisms and, 789

- Hydrops, endolymphatic
 clinical manifestations of, 1582
 definition and overview of, 1581, 1582f
 implications for therapist, 1583-1584
 medical management of, 1582-1583
 pathogenesis of, 1581-1582
- Hydrostatic pressure, lung fluid movement and, 801
- Hydrotherapy pool
 burn treatment and, 441
- infectious disease protocol and, 314
 pressure ulcers and, 441f, 449
- Hydroureter, ureteral wall and, 968
- Hydroxyurea
 hypersensitivity pneumonitis and, 786
 sickle cell disease of, 737
- Hypgiene hypothesis, asthma risk factors and, 768
- Hypgiene physical therapy. *See* Airway clearance techniques
- Hyaline cartilage (soft callus), fracture healing and, 232
- Hyperalgesia, 1635t
- Hyperalimentation, intravenous feeding and, 850
- Hyperbaric oxygen therapy (HOT), 170, 448
- Hypercalcemia
 bone metastases and, 362
 calcium movement and, 185, 186t
 hyperparathyroidism and, 476
 metastatic tumors and, 1231
 multiple myeloma and, 710, 713
- Hypercapnia
 aging and, 747
 cystic fibrosis exercise and, 794
- Hypercortisolism, 48
 Cushing's syndrome and, 482
- Hyperglycemia. *See also* Neuropathy
 classifications of, 489
 cystic fibrosis and, 790
 diabetic complications and, 492, 513
 steroids and, 162
- Hyperhemolysis, sickle cell disease and, 735
- Hyperhemolytic, sickle cell manifestation and, 733, 733b
- Hyperinsulinemia, spinal cord injury and, 1506
- Hyperkalemia
 acidosis and, 192
 older adults and, 188
 potassium and, 189
- Hypermobility syndrome
 osteoarthritis risk factors and, 1251
- Hypernatremia
 Conn's syndrome and, 484
 fluid imbalances and, 183, 191t
 infantile seizures and, 1533
- Hyperosmolar hyperglycemic state (HHS), diabetes complication and, 514t, 514b, 515
- Hyperostosis, diffuse idiopathic skeletal. *See* Diffuse idiopathic skeletal hyperostosis (DISH)
- Hyperparathyroidism
 calcium levels and, 454
 definition and incidence, 475
 implications for therapist, 477
 medical management of, 476
 systemic manifestations of, 476t
- Hyperpathia, 1635t
- Hyperpigmentation, increased melanin and, 450-451
- Hyperpituitarism
 implications for therapist, 462-463
 medical management of, 462
 overview of, 461
- Hyperplasia
 adrenal cortex and, 456
 atypical ductal, breast carcinoma and, 1020
- Hyperplasia (*Continued*)
 benign prostatic (BPH)
 aging male and, 964
 clinical manifestations of, 967-968, 968f
 implications for therapist, 970
 medical management of, 968-970
 prostatic nodules and, 967, 968f
 prostatitis and, 965
 cell increase and, 205
 definition of, 348
 immunocompetent cells and, 221
 primary lymphedema and, 651-652, 652f
- Hyperprolactinemia, radionecrosis and, 171
- Hypersensitivity angiitis, PVD and, 613
- Hypersensitivity disorders
 clinical manifestations of, 277, 278t
 implications for the therapist, 280
- Hypersensitivity pneumonitis, 786
 occupational pulmonary disease, 144
 organic dust and, 783
- Hypersensitivity reactions
 Type II, 278, 281f
 Type III, 278
 Type IV, 279, 283f
- Hypertension
 intracranial, traumatic brain injury compressive damage and, 1481
 portal
 implications for therapist, 888
 liver disease and, 883, 886-888, 888f
 liver transplantation procedure and, 1071
 pulmonary
 high blood pressure and, 746
 scleroderma and, 781
 pulmonary hypertension, 746
 systolic, Alzheimer's disease etiology and, 1413
- Hypertension (hypertensive vascular disease)
 chronic kidney disease and, 940-941
 coronary artery disease and, 530
 definition and overview of, 552
 etiology and risk factors of, 552-554, 553t
 implications for therapist, 557-559
 intracerebral hemorrhage and, 1464
 medical management of, 555-557
 obesity and, 37
 pathogenesis of, 554-555
 stroke risk factor and, 1450
 traumatic brain injury and, 1491
 women and, 528
- Hypertensive cardiovascular disease, types of, 552
- Hypertensive heart disease, 559
- Hyperthermia, cell injury and, 201
- Hyperthyroidism
 aging endocrine system and, 459
 definition and overview, 466
 exercise and, 469
 implications for therapist, 468-469
 medical management of, 468
 neuromuscular manifestations of, 467
 systemic manifestations of, 467t
 thyroid hormone hypersecretion and, 454
- Hypertrichosis, Cushing's syndrome and, 484f
- Hypertriglyceremic waist. *See* Metabolic syndrome
- Hypertrophic cardiomyopathy, 581f, 581-582
 genetic cardiomyopathies and, 579, 580t
- Hypertrophy
 adenotonsillar, 777
 benign prostatic. *See* Hyperplasia, benign prostatic (BPH)
 cell size and, 205
 effects of aging and, 524
 pyloric stenosis, sphincter and, 847
- Hyperuricemia
 primary, gout and, 1291
 secondary, gout risk factors and etiology of, 1291
- Hyperventilation, traumatic brain injury and, 1483
- Hypervolemia, Conn's syndrome and, 484
- Hypocalcemia
 infantile seizures and, 1533
 pseudohypoparathyroidism and, 478
 tetany and, 190, 190f
- Hypocondriases, somatoform disorder and, 98, 99, 101
- Hypoglycemia
 exercise and, 507
 hyperpituitarism and, 462
 infantile seizures and, 1533
 insulin therapy complications and, 503, 503t
- Hypoinsulinemia, diabetes mellitus type 1 and, 490
- Hypokalemia
 Conn's disease and, 484
 manifestations of, 191
 potassium and, 1641
- Hypomania, 110
- Hyponatremia
 cystic fibrosis athlete and, 798
 older adults and, 927
 SAIDH and, 189, 190, 191t, 465
- Hypoparathyroidism. *See also* Hyperparathyroidism
 definition, 477, 478b
 implications for therapist, 479
 medical management of, 478
 systemic manifestations of, 478t
- Hypopigmentation, decreased melanin and, 450
- Hypopituitarism
 (panhypopituitarism)
 (dwarfism)
 causes of, 463
 clinical manifestations of, 463b
 implications for therapist, 463-464
- Hypopnea
 partial pharyngeal closure and, 778
 reduction of breathing and, 777
- Hypoproteinemia, spinal cord injury and, 1506
- Hypotension
 infections and, 300
 orthostatic
 parkinsonism treatment and, 1445
 spinal cord injury therapy and, 1513
 ventricular assistive device and, 1086
- Hypothalamic control
 cluster headache pathogenesis and, 1559
 posterior pituitary and, 453-454, 456f
- Hypothalamic dysfunction, female athlete and, 994
- Hypothalamic growth hormone (GH) axis, somatic changes and, 990
- Hypothalamic-pituitary-adrenal (HPA) axis, 47-48
 depression and, 113
 fibromyalgia regulatory systems and, 289-290, 290f
 hormonal dysfunction and, 34
 neuro-endocrine-enteric axis and, 9
 steroid therapy and, 453
 stress and overactivity of, 1339
- Hypothalamus, autonomic nervous system and, 1340
- Hypothermia
 cold injuries and, 433-434
 near drowning and, 787
- Hypothyroidism
 definition and etiology of, 470
 exercise and, 473
 hypopituitarism and, 463
 implications for therapist, 472-473
 medical management of, 471-472
 serum hormones and, 1660
 thyroid hormone deficiency and, 454
 type I/primary, 470
 type II/secondary, 470, 470t
- Hypotonicity, coordinated movement disorders and, 1330
- Hypovolemia
 burns and, 189, 437
 dehydration and, 183, 185
 orthostatic hypotension and, 191
- Hypovolemic shock
 Addison's disease and, 480
 sickle cell disease and, 736
- Hypoxemia
 causes of, 743t
 restrictive lung disease and, 779, 780
 signs and symptoms of, 743t
- Hypoxia. *See also* Ischemia
 bronchiectasis and, 198
 definition of, 742
 near drowning and, 787
 secondary neuronal damage and, 1455
 traumatic brain injury and, 1481, 1490
- Hypoxia-reperfusion injury, free radicals and, 781
- Hysterectomy. *See also* Menopause, surgical
 endometriosis treatment and, 997, 999
 total abdominal (TAH), ovarian cancer treatment and, 1009
- Hysteria, 1623
- Hysterical neurosis, somatoform disorder and, 98
- Hysteroscopy, uterine fibroid treatment and, 998
- I**
- iatrogenic hypoparathyroidism, 477
 iatrogenic immunodeficiency, 255-256
- IBC. *See* Inflammatory breast cancer
- IBS. *See* Irritable bowel syndrome (IBS)
- Ibuprofen, high dose, lung inflammation reduction and, 793
- ICH (intracerebral hemorrhage). *See* Intracerebral hemorrhage (ICH)
- Icterus. *See* Jaundice
- Idiopathic environmental intolerance (IEI), 134
- Idiopathic facial paralysis. *See* Bell's palsy
- Idiopathic hypertension. *See* Hypertension
- Idiopathic hypoparathyroidism, 478
- Idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis and, 780
- IDU. *See* Injection drug user (IDU)
- IF. *See* Intrinsic factor
- IFA. *See* Immunofluorescent assay
- Ig-Ag complex, 226
- IgA, mucus membrane surfaces and, 246
- IgD, B lymphocytes and, 246
- IgE
 asthma pathogenesis and, 768
 atopic dermatitis and, 398
 basophilia and, 691
 hypersensitivity response and, 277-278
 parasitic infections and, 246

IgM, initial immune response of, 246
IGF-IR (insulin-like growth factor receptor I), Ewing's sarcoma treatment and, 1220
IL-1. *See* Interleukin-1
Ileus, adynamic or paralytic functional intestinal obstruction and, 869t, 874
 implications for therapist, 875
Ilioinguinal nerve, inguinal hernia and, 872
Ilioinguinal neuritis, nerve entrapment and, 872
Iliopsoas hemorrhage, muscle bleeding and, 721
Iliopsoas muscle test
 appendicitis and, 878
 Crohn's disease and, 857, 857f
 diverticular disease, 857f, 858f, 863
 hernia screening and, 873
Iliopsoas palpitation, appendicitis and, 858f, 878
Illness
 acute, stages of dependency and, 2
 definition of, 8
 psychologic aspects of, 3
 stage of dependency and, 2
 stress and, 46
Illness (subacute), 2
Imaging
 diffusion tensor (DTI), spinal cord injury diagnosis and, 1507
 primary tumor diagnosis and, 1205-1206
 superparamagnetic iron oxide, multiple sclerosis diagnosis and, 1433
Immediate hypersensitivity reactions, allergen exposure and, 277
Immobilization
 clinical problems of, 239-240
 fracture, osteogenesis imperfecta treatment and, 1152, 1153f
 musculoskeletal response and, 1099-1100
 osteoarthritis pathogenesis and, 1252
Immotile cilia syndromes, bronchiectasis and, 774
Immune complexes, type III hypersensitivity of, 278
Immune function, acute phase response, 254
Immune response, 243t
 acquired, 245-248
 acquired immunity and, 245-248
 age related changes in, 250-251
 antigens and, 242-243
 innate immune response and, 249, 251f
 innate immunity and, 243-245
 major histocompatibility complex of, 243
 sarcoidosis and, 806
 summary of, 248-250
Immune system
 aging endocrine system and, 458
 cell injury and, 199-200
 cutaneous burn pathogenesis and, 437
 dysfunction of, 250
 fibromyalgia and, 291
 gut and, 230
 HIV treatment and, 269
 psoriasis and, 422
 spinal cord injury and, 1498
 stress and, 46
 toxicity of, 134t
Immune-based therapy. *See* biotherapy
Immune-modulating agents, multiple sclerosis manifestations and, 1430
Immunity
 factors affecting, 251-252, 252b
 types of, 241

Immunization
 health care workers and, 310, 311t
 host susceptibility and, 242t, 309
 viral hepatitis and, 896t
Immunoablation, immunosuppression and, 284
Immunodeficiency diseases
 acquired immune deficiency syndrome, 257-274
 chronic fatigue/immune dysfunction syndrome, 275-277
 iatrogenic immunodeficiency, 255
 infection control and, 257, 257f
Immunodeficiency, consequences of, 151, 256-257
Immunofluorescent assay (IFA)
 influenza and, 338
 Lyme disease and, 342
 rapid viral cultures and, 331
Immunoglobulin (Ig)
 Hepatitis B virus and, 326
 types of, 246, 246b
Immunoglobulin E (IgE), COPD and, 761
Immunoglobulin G (IgG), infectious arthritis pathogenesis and, 1193
Immunoglobulin M (IgM), West Nile virus diagnosis and, 1359
Immunohistochemical (IHC), breast cancer staging and, 1025
Immunology
 antinuclear antibodies and, 1662
 definition of, 241
 diagnostic of, 1661
 polymerase chain reaction, 1661
 rheumatoid factor and, 1662
 tumor-associated antigens, 1661-1662
Immunomodulation therapy
 chronic lymphocytic leukemia treatment and, 700
 malignant melanoma and, 418
Immunosuppression
 agents of, 158-160
 adverse effects of, 159t
 classes of, 158
 implications for therapist, 160
 avascular necrosis and, 1055
 cancer and, 1055
 effects of, 154t, 1054-1055. *See also* Hypothyroidism
 rheumatoid arthritis
 pharmacotherapy and, 1270-1271
Immunotherapy. *See also* Biotherapy
 primary brain tumor treatment and, 1387
 prostate cancer treatment and, 975-976
Immunotics, disease prevention and, 10
Impaired fasting glucose (IFG), hyperglycemia and, 489
Impaired glucose tolerance (IGT), hyperglycemia and, 489
Impairments
 cognitive and behavioral, traumatic brain injury and, 1483b, 1483-1485, 1485t
 disablement model and, 4, 18
Impetigo
 definition and overview of, 402
 medical management of, 403
 skin lesions and, 320
Implant, filter, pulmonary embolism treatment and, 818
Implantation, breast. *See* Breast implant, silicone (SBI)
Implants
 breast
 breast-conserving therapy and, 1025-1026
 side effects of, 1032-1033
 endometrial cell migration and, 996
Impotence. *See also* Erectile dysfunction
 risk factors for, 983b
In situ squamous cell carcinoma, tumors of, 413
In utero gene therapy (IUGT), 14
Inching, modified NCV technique and, 1606
Incidence, rate of pressure ulcers and, 444
Incontinence
 cystic fibrosis and, 799
 functional
 definition of, 957
 pathogenesis of, 958
 treatment of, 960
 Huntington's disease and, 1423
 mixed, definition of, 957
 myelomeningocele and, 1120
 overflow
 definition of, 957
 pathogenesis of, 958
 treatment of, 961
 postsurgical, definition of, 957
 pressure ulcers and, 450
 stress
 cystocele and, 1013
 definition of, 957
 pathogenesis of, 958
 pelvic floor exercise and, 962
 treatment of, 960-961
Increased intracranial pressure (ICP), 1365, 1368
 cerebral edema and, 207
Incubation period, infectious disease and, 302
Indoles (vegetable phytochemicals), breast cancer risk reduction and, 1020
Induction-latency period, occupational cancer and, 145
Infants
 atelectasis treatment and, 800
 botulism and, 1663
 hypertrophic pyloric stenosis and, 847
 secondhand smoke exposure and, 787
 tracheoesophageal fistula and, 841
Infarction
 cerebellar, 1591
 definition of, 678
Infection
 acute unilateral vestibulopathy
 incidence and etiology of, 1580
 medical management of, 1580-1581
 treatment of, 1581
 bone and joint, *Pseudomonas* and, 325
 burn wounds and, 439
 central nervous system, *pseudomonas* and, 324
 coronary artery disease and, 533
 diabetes mellitus and, 494
 dormant microorganisms and, 302
 exercise and, 254
 health care-associated (HAI), 1669
 heart transplantation and, 1076-1077
 heart transplantation complication and, 1076-1077
 leukemia and, 693
 lymphedema and, 663-664
 multiple myeloma manifestations and, 710
 neonatal, 321-322
 nosocomial, 1669
 respiratory tract
 IV drug users and, 346
pseudomonas and, 324
 signs of, 300
Infection exposure, Parkinson's disease risk factors and, 1438
Infection in drug users, 346-347
 implications for therapist, 346
Infection/Inflammation
 Guillain-Barré syndrome and, 1621-1624
 herpes zoster/post-herpetic neuralgia and, 1626
 HIV/AIDS and, 1627
 post-polio syndrome/muscular atrophy and, 1624-1626
 trigeminal neuralgia/tic dououreux and, 1626-1627
 vasculitis and, 1627-1628
Infections, urological system
 pyelonephritis and, 931-932
 urinary tract infection and, 928-931
Infectious agents
 cell injury and, 198-199
 pneumonia and, 749
Infectious disease
 aging and, 301
 chain of transmission, 303-315
 control of transmission, 306-315
 definition and overview, 301-302
 diagnosis of, 315
 musculoskeletal system
 diskitis and, 1191-1192
 extrapulmonary tuberculosis and, 1197-1200
 implications for therapist
 summary of, 1200
 infectious (inflammatory) muscle diseases and, 1195-1197
 infectious (septic) arthritis and, 1192-1195
 osteomyelitis and, 1182-1187
 overview of, 1182
 prostheses, implants and, 1187-1191
 organism types of, 302-303
 preliminary discussion of, 298
 signs and symptoms of, 299b, 299-301
Infectious Diseases Society of America (IDSA), 1355
Infectious hepatitis. *See* Hepatitis A virus (HAV)
Infectious mononucleosis (herpesvirus type 4)
 implications for therapist, 336
 medical management of, 335-336
Infective endocarditis
 clinical manifestations of, 601t, 601-602
 endocardium infection and, 600
 implications for therapist, 602
Inflammation
 acute
 responses of, 216-217
 systemic effects of, 150
 adipose tissue and, 487
 bronchial wall and, 754
 carcinogenesis and, 358
 chemical mediators of, 221-225
 arachidonic acid derivatives of, 221
 blood coagulation system and, 223, 223f
 complement system and, 223
 cytokines and, 222, 222b
 fibrinolytic system and, 223
 histamine and, 221
 phagocytosis and, 224
 platelet-activating factors of, 221
 chronic
 pressure ulcers and, 447
 RA neurologic manifestations and, 1268
 responses of, 217-218
 subcutaneous nodules of, 226
 systemic effects of, 150
 chronic bronchitis and, 764
 components of, 218-225
 cystic fibrosis lung damage and, 789
 exercise and, 226
 glucocorticoids and, 160
 granulomatous, sarcoidosis and, 808

- Inflammation (Continued)**
 implications for therapist, 225-226
 osteoarthritis pathogenesis and, 1251
 overview and definition of, 215-216
 trauma response and, 1100-1101
- Inflammatory bowel disease (IBD).** *See also Crohn's disease; Ulcerative colitis*
 clinical manifestations of, 854-855
 enteropathic arthritis and, 1280
 etiology and pathogenesis of, 852-854
 implications for therapist, 857-858
 medical management of, 855-857
 musculoskeletal system disease and, 1107
 overview and definition of, 852
- Inflammatory breast cancer (IBC)**
 breast cancer subtype and, 1017
 clinical manifestation of, 1020
- Inflammatory disease**
 acute bronchitis, 759
 lung abscess, 758
 peripheral vascular disease and, 610
Pneumocystis carinii pneumonia and, 751-752
 pneumonia and, 749-751
 pneumonitis, 758
 pulmonary tuberculosis and, 752-758
- Inflammatory disorders**
 arteritis nodosa and, 612
 hypersensitivity angitis and, 613
 implications for therapist, 615
 Kawasaki disease and, 613-614
 polyarteritis nodosa and, 611
 thromboangiitis obliterans and, 614-615
 vasculitis and, 611
- Inflammatory mediators**
 asthma pathogenesis and, 769
 free radicals and, 781
 leukotrienes and, 221, 222f
 systemic sclerosis and, 781
- Inflammatory phase**
 fracture healing and, 232
 tendon healing and, 234
- Influenza**
 avian influenza A virus and, 337
 medical management of, 338
- Information molecules**, 9
- Information processing**, 5
- Inhaled insulin, diabetes mellitus type 1 treatment and**, 500
- Inheritance patterns, hemophilia and**, 718, 719f
- Initial lymphatics, lymphatic vessel system and**, 643, 643f, 644f, 649f
- Injection**
 cervical epidural steroid, cervicogenic headache treatment and, 1561-1562
 steroid
 carpal tunnel and, 1607
 sciatica and, 1607
- Injection drug user (IDU)**, 86
 AIDS and, 258
- Injections, subcutaneous, multiple sclerosis manifestations and**, 1430
- Injury**
 abducens nerve, traumatic brain injury and, 1487
 cerebral, voiding dysfunction and, 955
 closed head, traumatic brain injury etiology and, 1478
 definition of, 8
 diffuse axonal (DAI), traumatic brain injury diagnosis and, 1488
 hypoxic-ischemic cerebral palsy pathogenesis and, 1520-1521
- Injury (Continued)**
 cerebral edema and, 207
 infantile seizures and, 1533
 musculoskeletal, sports related and, 1099
 open head, traumatic brain injury and, 1478
 peripheral nervous system response and, 1597
 sports-related, spinal cord injury and, 1496
 trigeminal nerve, traumatic brain injury and, 1487
- Injury prevention**, 1237, 1496-1497
- Innate immunity**
 acquired immunity and, 249, 251f
 aging and, 250
 types of, 241, 242f, 243-245
- INR.** *See Ratio, international normalized*
- Intrauterine contraceptive device (IUD)**, ectopic pregnancy and, 1004
- Inspissated meconium, cystic fibrosis and**, 791
- Institute of Medicine (IOM), breast implants and**, 1026
- Institutional factors, social ecology and**, 18
- Insufficiency (regurgitation), heart valve impairment and**, 594
- Insulin neuritis syndrome, sensory neuropathy and**, 496
- Insulin pump**
 diabetic insulin dosage and, 499-500, 500f
 exercise and, 508-509
- Insulin reaction.** *See also Insulin therapy*
 metabolic risk factor and, 534
- Insulin resistance syndrome (IRS).** *See also Metabolic syndrome*
 diabetes mellitus and, 512-513
 implications for therapist, 513
 metabolic risk factor and, 534
 prediabetes and, 489
 spinal cord injury and, 1506
- Insulin therapy, complications of**, 503-509
- Insulin, corticosteroids and**, 165
- Insulin-cancer hypothesis, cancer and**, 356
- Insulin-dependent diabetes mellitus (IDDM). See Diabetes mellitus (type 1) (DM)**
- Insulin-like growth factor I (IGF-I), hyperpituitarism and**, 462
- Insulin-resistance-associated hepatic iron overload syndrome (IRHIO)**, 1648
- Insulinoma, endocrine pancreas and**, 454
- Integrins, transmembrane receptors and**, 1020
- Integumentary disorders**
 blistering diseases, 451-452
 cutaneous sarcoidosis, 452
 integumentary ulcers, 442
 pigmentary disorders, 450-451
 pressure ulcers, 442-449
 ulcers, 442
- Integumentary system**
 aging and, 396-397
 implications for therapist, 397-398
 toxicity and, 134t
- Intelligence quotient (IQ)**
 lead poisoning and, 128
- Intensity modulated radiation therapy (IMRT), cancer treatment and**, 372
- Intensive care unit acquired paresis (ICUAP)**, 164
- Interdigital perineural fibroma (IPF).** *See Neuroma, Morton's*
- Interdigitating dendritic cell, innate immunity and**, 243-244
- Interferon**
 biotherapy and, 374, 413
 soluble mediators and, 245
 viral hepatitis treatment and, 900
- Interleukin-1**
 cancer-related fatigue and, 366
 cytokines and, 222, 222b, 244
 Down syndrome and, 1109
 idiopathic inflammatory myopathies, 1244
 infectious arthritis pathogenesis and, 1193
 Reed-Sternberg cells and, 702
- Interleukin-2, advanced RCC treatment and**, 934
- Internal capsule, intracerebral hemorrhage syndromes and**, 1466
- Internal carotid artery syndrome, ischemic stroke syndromes and**, 1456
- Internal counterpulsation, heart surgery and**, 572, 573f
- Internal mammary arter (IMA) graft, bypass surgery in women and**, 527
- Internal normalization ratio (INR), ventricular assistive device and**, 1086
- International Assoc for the Study of Pain**, 105
- International Autoimmune Hepatitis Group, classification and**, 902
- International Classification of Functioning, Disability, and Health (ICF)**
 disablement model and, 6
 enablement language, 5
 health and, 4
 World Health Organization and, 4
- International Federation of Gynecology and Obstetrics (FIGO)**
 cervical cancer staging and, 350, 1003b
 uterine cancer staging and, 999, 999b
- International Headache Society (IHS), headache classification and**, 1547, 1548b
- International League Against Epilepsy, seizure classification and**, 1539, 1540b
- International normalized ratio (INR), arrhythmia assessment and**, 593
- International Society of Heart and Lung Transplantation**, 1077
- International Union Against Cancer (UIICC), cancer staging and**, 350, 351b
- Interpersonal factors, social ecology and**, 18
- Interpersonal processes, social ecology and**, 18
- Interstitial lung disease.** *See Pulmonary fibrosis*
- Interstitial pancreatitis**, 912
- Interstitial tissues, pulmonary edema and**, 801
- Intervention**
 physical activity and, 31
 surgical, primary tumor treatment and, 1206
 therapeutic, 104
- Intestinal angina, atherosclerotic plaque-induced eschemia**, 851
- Intestinal ischemia, acute**, 851
 implications for therapist, 851
- Intestine transplantation**, 1096
- Intestines**
 antibiotic-associated colitis and, 859
 bacterial infections, 851-852
 diverticular disease and, 861-863
 foodborne illnesses (botulism), 851-852
 inflammatory bowel disease and, 852-858
 irritable bowel syndrome and, 859-861
 malabsorption syndrome, 848-851
 neoplasms and, 863-868
 obstructive disease and, 868-875
- Intestines (Continued)**
 sensory function of, 828
 vascular diseases, 851
- Intimate partner violence (IPV)**
 definition of, 42
 reporting of, 43b
- Intitute of Medicine (IOM), 18. See also IOM**
 study of racial/ethnic differences in health care and, 22-23
- Intraaortic balloon pump (IABP), heart surgery and**, 572, 573f
- Intraarticular injections, corticosteroids and**, 164
- Intraarticular ligaments, ligament repair and**, 234
- Intracellular fluid (ICF), fluid imbalance and**, 183
- Intracerebral hemorrhage**
 drug-related, 1465
 supratentorial, 1464
- Intracerebral hemorrhage (ICH)**
 clinical manifestations of, 1465-1466
 etiologic and risk factors of, 1464-1465
 incidence of, 1464
 intracerebral hemorrhage pathogenesis and, 1465
 medical management of, 1466-1468
 overview and definition of, 1463-1464
 pathogenesis of, 1465
- Intracranial**
 hematomas, cerebral edema and, 207
 hemorrhages (ICH), hemophilia and, 721
 pressure (ICP)
 traumatic brain injury and, 1479, 1490, 1494
 vertebral and posterior inferior cerebellar artery syndromes and, 1457
- Intradiskal biacuplasty, degenerative disk treatment and**, 1262
- Intradiskal electrothermal therapy (DET), degenerative disk treatment and**, 1262
- Intrahepatic cholestasis of pregnancy**, 908
- Intrapersonal factors, social ecology and**, 18
- Intrapersonal, influence on behavior**, 18
- Intrathecal baclofen**
 cerebral palsy treatment and, 1524
 complex regional pain syndrome and, 1635
 oral spasticity and, 1436
 spinal cord injury and, 1510
- Intravenous (IV) heparin therapy**, 541t-542t, 564
- Intrinsic factor (IF)**
 aging GI system and, 833
 cobalamin deficiency and, 686-687
 gastritis and, 842
 malabsorption syndrome and, 849
- Intussusception, bowel obstruction and**, 863, 863f, 870
- Invasive ductal carcinoma (IDC), breast cancer subtype and**, 1017, 1020
- Invasive squamous cell carcinoma, tumors of**, 413
- Involucrum, new bone sheath and**, 1184, 1184f
- Iodine-131 therapy, hyperthyroidism and**, 468
- Ion channelopathies, genetic cardiomyopathies and**, 579, 580t
- channels, central nervous system and**, 1322, 1323f
- transport, cystic fibrosis and**, 788

Ionizing radiation, 130, 167
cancer and, 356, 372
delayed effects of, 168t
Ions, electrolytes and, 185
Iontophoresis
 acetic acid, 469
 PT modalities and, 239
IPF. *See* Idiopathic pulmonary fibrosis
Iraq War, PTSD and, 149
Iron absorption disorders
 hereditary hemochromatosis, 684-685
Iron storage disease. *See* Spondyloarthropathy
Irradiation
 cell injury and, 201
 chest, pulmonary fibrosis and, 780
 total nodal, 256
Irreversible cell injury, 205-207
Irritable bowel syndrome (IBS)
 definition and incidence of, 859
 implications for therapist, 861
 medical management of, 860
Ischemia
 angina and, 549, 549f
 cancer pain and, 364
 cell injury and, 198
 electrolyte imbalance and, 185
 heart disease and, 526, 526t
 myocardial, causes of, 549, 549t
 pathologic atrophy and, 205
 pressure ulcers and, 445, 447f
Ischemic heart disease. *See also*
 coronary artery disease;
 coronary heart disease
arteriosclerosis, 529
atherosclerosis, 529b, 529-548
exercise monitoring and, 547
heart transplantation indications
 and, 1074
medical management of, 536-543
Ischemic pain, gastrointestinal
 disease symptoms and, 830
Ischemic penumbra, secondary
 neuronal damage and, 1454
Ischemic reperfusion injury,
 posttransplant complications
 and, 1051-1052
Ischemic stroke
 clinical manifestations of,
 1455-1458
 medical management of, 1458-
 1459f, 1460f
 pathogenesis
 occlusion of major arteries, 1453
 secondary neuronal damage,
 1454-1455
 secondary vascular response,
 1453-1454
 pathogenesis of, 1453-1455
Islets of Langerhans. *See* Pancreas
Isoimmune disease, organ and tissue
 transplant and, 296-297
Isolated systolic hypertension
 causes of, 553
 hypertensive vascular disease types
 of, 552
Isolation and barriers, disease
 transmission and, 307
Isolation, airborne infection,
 1670-1671
Isometric exercise
 heart transplantation and, 1082
 metastatic tumors and, 1233
IV drug users
 infections and, 346
 osteomyelitis and, 346
IV immune globulins (IVIGs)
 immunosuppressive agent and,
 158
 Kawasaki disease and, 614

J

Jackson-Pratt suction drain,
 intracranial surgery
 complications and, 1389
Janus kinase 2 (JAK2)
 essential thrombocythemia and, 715
 polycythemia vera and, 716

Janz syndrome, juvenile myoclonic
 epilepsy and, 1544
Jaundice (icterus)
 classifications of, 884b
 hepatitis disease and, 883
 implications for therapist, 885
 liver impairment and, 881
 sickle cell disease and, 735
Join, effusion
 infectious diseases and, 301
 sickle cell disease pain and, 739
Joint
 apophyseal, cervicogenic headache
 and, 1561
 carpometacarpal, osteoarthritis
 manifestation and, 1253
 distal interphalangeal
 Herberden's nodes and, 1253
 rheumatoid arthritis joint
 manifestations and, 1267,
 1267f
 fluid of, synovial fluid analysis
 and, 1667
 protection, osteoarthritis
 implications and, 1256-1257
 proximal interphalangeal,
 Bouchard's nodes and, 1253,
 1253f
 restrictions, cerebral palsy
 manifestation and, 1521-
 1522, 1523f
Joint Commission Office "Do Not
Use List," 1638, 1638t
Joint disorder
 chondrolysis and, 1250
 degenerative intervertebral disk
 disease and, 1258-1263
 implications for therapist,
 1249-1250
 neuroarthropathy and, 1294
 osteoarthritis and, 1250-1258
 rheumatic diseases and,
 1263-1294
Joint syndrome, hypermobility. *See*
 Hypermobility syndrome
Jones
 criteria, diagnosis of rheumatic
 fever, 604, 605t
 fracture, fracture types and
 definitions of, 1295b
Joy, development of, 65
Jugular venous distention (JVD)
 peripheral edema and, 521, 571f
 right ventricular failure and, 571
Juvenile idiopathic arthritis (JIA)
 enthesis-related, 1277-1278
 exercise and, 1280
 etiology, risk factors and
 pathogenesis of, 1278
 implications for therapist,
 1279-1280
 medical management of,
 1278-1279
 overview and incidence of,
 1276-1278, 1277b, 1277f,
 1277b
 pauciarticular (PjIA), 1276-1277
 polyarticular (Polla), 1277
 psoriatic, 1277
 systemic-onset (SoJIA), 1277,
 1278f
 treatment and prognosis of,
 1279
Juvenile onset diabetes mellitus.
 See Diabetes mellitus
 (type 1) (DM)
Juvenile rheumatoid arthritis (JRA).
 See Juvenile idiopathic arthritis
 (JIA)

K

K-ras mutation, pancreatic cancer
 pathogenesis and, 917
Kaposi's sarcoma
 definition and overview, 419
 HHV-8 and, 337, 419-420
 HIV and, 263, 264f
 implications for therapist, 421
 medical management of, 420
 vascular neoplasms and, 636

Karnofsky Index
 renal cell carcinoma prognosis
 and, 934
 terminally ill patient and, 384
Karnofsky Performance Status Scale,
 functional performance
 measurement tools and, 1390,
 1391t, 1392
Kaposi's sarcoma, types of, 419-420,
 420f
Karyolysis, cell nucleus damage and,
 206
Karyorrhexis, cell nucleus damage
 and, 206
Katz hand diagram, carpal tunnel
 syndrome assessment and, 1605
Kawasaki disease
 overview and etiology of, 613
 phases of, 614
Kegel pelvic muscle contraction,
 urinary incontinence and,
 959-960
Kehr's sign, referred pain patterns
 and, 832
Kellgren and Lawrence Grading
 System, osteoarthritis
 classification and, 1254, 1254f
Keloids, collagen formation and,
 229, 229f
Keratinization, epidermal cell
 maturation and, 412
Keratinocytes
 malignancy of, 413
 psoriasis and, 421
 skin transplantation and, 1097
Kernig's sign, meningitis
 manifestations of, 1354, 1354f
Ketoacidosis
 causes of, 514b
 definition and overview of, 513
 implications for therapist, 515
 insulin therapy complications and,
 503-504, 504t
 medical management of, 514-515
 metabolic acidosis and, 195
 symptoms of, 514t
Ketone
 fat metabolism and, 492
 urinalysis and, 1663
Ketone esters, amyotrophic lateral
 sclerosis and, 1408
Ketonuria, acetone secretion and,
 492
Kidney
 bioartificial, future trends and,
 1068-1069
 filtration and storage functions of,
 927
Kidney damage,
 hyperparathyroidism and, 476
Kidney disease
 chronic (CKD)
 clinical manifestations of,
 940-944
 etiology and risk factors of, 940
 exercise and, 947-948
 implications for therapist,
 945-948
 medical management of,
 944-945
 overview of, 939
polycystic (PKD)
 autosomal dominant (ADPKD),
 935-936
 autosomal recessive (ARPKD),
 935-936
 ESRD and, 935
Kidney failure, systemic
 manifestations of, 942t
Kidney transplantation
 complications of, 1067-1068
 exercise and, 1069
 future trends of, 1068-1069
 implications for therapist, 1069
 overview of, 1038t, 1066-1067
 procedures for, 1067, 1068f
 prognosis of, 1068
Kindling, 56
 definition of, 78
 emotional instability and, 1335

Kindling (*Continued*)
 epileptic seizure pathogenesis and,
 1535
Kinin enzymatic system
 fibrinolytic system and and, 224
 Hageman factor and, 223
Klebsiella, carbapenem-resistant
 bacteria and, 298
Klinefelter's syndrome, testicular
 cancer risk and, 980
Klippel-Trénaunay-Weber syndrome
 (KTWS), primary lymphedema
 and, 651
Klumpke's palsy, brachial plexus
 palsy types and, 1147, 1148,
 1148f
Knee-ankle-foot-orthoses (KAFOs),
 type II spinal muscular atrophy
 and, 1143, 1143f
Koebner phenomenon, psoriasis
 lesions and, 422
Kohn's pores, deep breathing and,
 800
Koilonychia, mild anemia and, 687,
 687f
Koo-Menter Psoriasis Instrument
 (KMPI), systemic psoriasis
 therapy and, 422
Krebs cycle, ketones and, 1663
Kronos Early Estrogen Prevention
 Study (KEEP), 988
KS. *See* Kaposi's sarcoma
KSHV. *See* Kaposi's sarcoma-associated herpesvirus
Kugelberg-Welander disease, type III
 spinal muscular atrophy and,
 1141, 1142t
Kurtzke Expanded Disability Scale,
 1437
Kuru, prion disease and, 1362
Kussmauls respirations, respiratory
 alkalosis and, 195
Kwashiorkor, cell injury and, 200
Kyphoplasty, acute vertebral fracture
 treatment and, 1299
Kyphoscoliosis, 1116
 adult round back and, 1116
 implications for therapist, 1116
Kyphosis, juvenile. *See*
 Scheuermann's disease

L

Labile (unstable) diabetes. *See* Brittle
 diabetes
Labile cells, division of, 227
Labile hypertension, 552
Laboratory tests
 abbreviations of, 1638, 1638t,
 1638b
 limitations of, 1639
 purpose of, 1639
Labyrinthitis, intracerebral
 hemorrhage diagnosis and,
 1467
Laceration, spinal cord injury and,
 1497
Lactate dehydrogenase (LDH),
 non-Hodgkin's lymphoma
 and, 708
Lactic acidosis
 AIDS treatment of, 268
 metabolic acidosis and, 195
Lactic dehydrogenase (LDH),
 primary tumor diagnosis and,
 1206
Lactobacillus acidophilus
 irritable bowel syndrome and,
 861
 urinary tract infection prevention
 and, 930
Lactoferrin, neutrophils and, 220
Lactulose, hepatic encephalopathy
 therapy and, 889-890
Lacunar syndrome, ischemic stroke
 syndromes and, 1458, 1459f,
 1460f
Lambert-Eaton myasthenic syndrome
 (LEMS), neuromuscular
 paraneoplastic syndrome and,
 368

- Laminectomy
disk surgery and, 1262, 1263
spinal metastasis treatment and, 1398-1399
- Landau-Kleffner syndrome, infant and childhood epilepsy and, 1544
- Landouzy-Dejerine
facioscapulohumeral dystrophy (FSHD), 1134
- Langerhans cells, aging skin and, 397
- Laparoscopy
ectopic pregnancy diagnosis and, 1005
pancreatic cancer diagnosis and, 917
peritoneal cavity inspection and, 832
- Lapatinib (Tykerb), breast cancer treatment and, 1029
- Lapides Classification, neurogenic bladder disorders and, 954
- Laplace's law, compression bandaging and, 667
- Large antibody-antigen (Ig-Ag) complex. *See Ig-Ag complex*
- Lasègue's sign, Morton's neuroma and, 1616
- Laser therapy, low-level, cancer treatment and, 383, 813
- Late phase hypersensitivity reaction, allergen exposure and, 277
- Late-state lupus, systemic lupus erythematosus and, 284
- Latent lupus, 284, 284b
- Lateral-costal breathing, altered breathing patterns and, 744t, 745
- Latex allergy dermatitis, 146f, 280.
See also Rubber latex allergy (LA)
- Latex, sources of, 148t
- Lavage, pulsatile with suction (PLWS), 1672b, 1673
- LB.P (lower back pain), 56
psychosocial factors and, 109
- LDL. *See Low-density lipoprotein (LDL)*
- LDS. *See lipodystrophic syndrome*
- LE (lupus erythematosus). *See Lupus erythematosus*
- Lead poisoning, 128, 136
- Learning disability, 6
- Learning, CNS disorder recovery of function and, 1350
- Left ventricular assist device. *See Ventricular, left assist device (LVAD)*
- Left ventricular assistive device. *See Ventricular left assistive device (LVAD)*
- Left ventricular failure, pulmonary edema and, 570f, 800
- Left ventricular noncompaction cardiomyopathy, genetic cardiomyopathies and, 579, 580t
- Left-sided heart failure, 569, 569t
clinical manifestations of, 569t
congestive heart failure and, 567, 569-571
pathophysiologic mechanism of, 570f
- Leg-Calvé-Perthes disease
clinical manifestations of, 1313
definition and overview of, 1312
implications for therapist, 1315
medical management of, 1313-1315, 1314f
osteonecrosis pathogenesis and, 1311
pathogenesis of, 1312-1313, 1313f, 1313t
- Legionella, infectious disease and, 298
- Leiomyomas, intestinal smooth muscle tumors and, 863
- Lenalidomide, multiple myeloma therapy and, 711
- Length of stay (LOS), acute care, 11b
- Lennox-Gastaut syndrome, infant and childhood epilepsy and, 1544
- Lentigines (liver spots), hyperpigmentation and, 451
- Lentigo maligna melanoma (LMM), type of melanoma, 415, 415f
- Leptin
inflammation and, 487
obesity and, 485
- Leptomeningeal carcinomatosis, 1365
- LES. *See Lower esophageal sphincter*
- Achalasia and, 830
- Lesion
chronic focal epileptogenic, epilepsy pathogenesis and, 1535
- skin, woundculture and, 1664
- spinal cord
etiology of, 1497-1498
multiple sclerosis manifestations and, 1428
- Lesions
brain, signs of, 1371t
- cervical intraepithelial, cervical cancer precursor and, 1000
- complete, spinal cord injury and, 1502, 1503b
- fibrous. *See Fibrous lesions*
- hemorrhagic. *See Gliding contusions*
- incomplete, spinal cord injury and, 1502, 1503b
- osteolytic, metastatic tumor prognosis and, 1233
- T2 hyperintense, multiple sclerosis diagnosis and, 1430, 1433f
- Lesions in the region of the micturition center to S2, voiding dysfunction and, 955
- Letrozole (Femara), breast cancer recurrence and, 1030
- Leukapheresis, procedures for transplantation and, 1062
- Leukemia
acute
definition of, 693
forms of, 695
- acute lymphoblastic, 697
- acute lymphocytic, 697
- acute myelogenous. *See Acute myelogenous leukemia (AML)*
- chronic
definition of, 693
major groups of, 698
- chronic myeloid, 698, 699
- implications for therapist, 700
- overview of, 693, 693t
- stroke risk factor and, 1452
- Leukemia cutis, acute myelogenous leukemia and, 695, 696f
- Leukocyte accumulations, vascular alterations and, 219-221
- Leukocyte disorders
basophilia and, 691
- eosinophilia and, 691-692
- leukocytosis and, 690-691
- leukopenia and, 691
- lymphocytosis/lymphocytopenia and, 692
- monocytosis and, 692
- neutropenia and, 692
- neutrophilia and, 692
- Leukocyte reactive oxygen species (ROS), exhaustion of, 203
- Leukocyte, polymorphonuclear (PMN), synovial fluid analysis and, 1667
- Leukocytes
groups of, 690
- meningitis etiology and, 1353
- types of, 244
- Leukocytopenia, 1651
- Leukocytosis
definition and etiology of, 690, 690b
- handwashing and, 691
- Leukocytosis (Continued)
implications for therapist, 691
- medical management of, 690-691
- white blood cell test and, 1651
- Leukomalacia, periventricular (PVL), cerebral palsy pathogenesis and, 1518, 1521f
- Leukopenia, definition and etiology, 691
- Leukotriene
bronchospasm and, 769
- inflammation mediator and, 221-222, 222f
- Leukotriene-receptor antagonists, cystic fibrosis treatment and, 793
- Levodopa (L-dopa), Parkinson's disease treatment and, 1444
- Lhermitte's sign
multiple sclerosis manifestations and, 1430
- rheumatoid arthritis spine manifestations and, 1267, 1268
- Li-Fraumeni syndrome, gliomas risk factors and, 1372
- Lichenification, chronic dermatitis and, 401
- Life expectancy, 24
- Lifestyle
colorectal cancer treatment and, 865
- Down syndrome and, 1110
- GERD treatment and, 836
- health and, 26-28
- implications for therapists, 28b
- peptic ulcer risk factor and, 843
- Ligament
anterior cruciate (ACL). *See Anterior cruciate ligament (ACL)*
- anterior longitudinal. *See Anterior longitudinal ligament (ALL)*
- Ligament injury, tissue repair and, 234-235
- Ligamentum flavum, cartilage and, 233, 235
- Light therapy, seasonal affective disorder (SAD) and, 114
- Like-glycosyltransferase (LARGE), muscle-eye-brain disease and, 1134
- Limb-sparing procedures
osteosarcoma treatment and, 1214, 1214f
- phases of, 1207
- prescriptive exercise and, 1209
- Limbic system, 63
- CNS disorder recovery of function and, 1350
- Limited cutaneous systemic sclerosis, 426. *See also CREST syndrome*
- Lines of defense, infectious disease susceptibility and, 306
- Linezolid, gram positive bacteria and, 310
- Lipase, pancreatitis diagnosis and, 913
- Lipedema
implications for therapist, 677
- medical management of, 676-677
- overview and stages of, 675f, 675-676, 676f
- Lipid-lowering agents, ischemic stroke prophylaxis and, 1462-1463
- Lipids. *See also Atherosclerotic disease*
atherosclerotic disease tests and, 1654, 1655t
- liver damage and, 205
- primary biliary cirrhosis and, 907
- Lipodystrophic syndrome (LDS)
exercise and, 273
- HIV fat metabolism and, 265, 265f
- Lipodystrophy. *See Lipodystrophic syndrome (LDS)*
- Lipofuscin, cellular aging and, 197
- Lipogenic effect, insulin therapy complications and, 503-504
- Lipoma
benign fatty tumors and, 377, 863
- benign soft tissue tumors and, 1223
- Lipopolysaccharide, disseminated intravascular coagulation and, 729
- Lipoprotein (a), coronary artery disease and, 533
- Lipoprotein lipase (LPL) theory, obesity and, 35
- Liposarcoma, benign soft tissue tumors and, 1225
- Liposuction, obesity treatment and, 497
- Lipoxygenase pathway, leukotrienes and, 222
- Liquid carbon dioxide detergents (LCD), psoriasis treatment and, 422
- Liquid-based cytology, sexually transmitted disease diagnosis and, 345
- Livedo reticularis, essential thrombocythemia and, 715, 715f
- Liver
abscess of, 911-912
- alcohol-related liver disease and, 904-905
- autoimmune hepatitis and, 902-904
- C-reactive protein and, 1656
- cirrhosis, decreased serum and albumin of, 801
- cystic fibrosis and, 792, 803
- disease complications and, 884-892
- drug-related hepatotoxicity and, 900-902
- functions of, 881
- hepatic system healing and, 884
- hepatitis and, 892-900
- injuries of, 912
- intrahepatic cholestasis of pregnancy and, 908
- neoplasms of, 908-911
- primary biliary cirrhosis and, 905-908
- sarcoidosis symptoms and, 807b
- transplantation and, 794
- vascular disease of, 908
- Liver biopsy, chronic hepatitis diagnosis and, 892
- Liver disease
alcohol-related. *See also Hepatitis, viral*
- implications for therapist, 905
- medical management of, 905
- overview, incidence, and risk factors of, 904-905
- ascites and, 890-891
- cirrhosis and, 885-886
- hepatic encephalopathy and, 888-890
- hepatorenal syndrome and, 891-892
- jaundice (icterus) and, 884-885
- portal hypertension and, 886-888
- primary biliary cirrhosis and, 905
- Liver flap. *See Asterixis*
- Liver flukes, liver abscess and, 911
- Liver injury
healing of, 884
- implications for therapist, 912
- toxic, 912
- treatment and prognosis of, 902
- Liver palms. *See Palmar erythema*
- Liver transplantation
complications of, 1072
- exercise and, 1074
- future trends of, 1073
- implications for therapist, 1073-1074
- live donor, 1071, 1071f
- overview of, 1070, 1070t
- procedure for, 1070-1072, 1071f
- risk factors for, 1071

Liver tumors, metastatic malignant, 911. *See also* Carcinoma, primary hepatocellular (HCC); Neoplasms, liver (hepatic)

Liver, cirrhosis of, liver injury and, 884

LMN (lower motor involvement). *See* Neuron, lower motor (LMN) involvement

LMWH (low-molecular-weight heparin). *See* Low-molecular-weight heparin

Lobar hematoma

- intracerebral hemorrhage syndromes and, 1466 treatment of, 1468

Lobar pneumonia, pulmonary inflammation and, 749

Localized scleroderma, 426, 427b

Locked-in syndrome, altered states of consciousness, 1333

Löfgren's syndrome, sarcoidosis symptoms and, 807b, 808

Long arms, glial cells and, 1370

Long-stretch compression bandages, lymphedema and, 666-667

Long-term oxygen treatment (LTOT), COPD treatment and, 762

Loop electrosurgical excision procedure (LEEP), cervical cancer treatment and, 1001

Looser's zones

- hepatitis disease symptoms and, 882
- osteomalacia diagnosis and, 1175
- osteomalacia pathogenesis and, 1174, 1175f

Lotion. *See* Hand cream (lotion)

Lou Gehrig's disease, Gulf War and, 149

Low-density lipoprotein (LDL). *See also* Atherosclerotic disease

- cardioprotection and, 527
- cholesterol and, 528
- chromosome 1 mutations and, 534-535

Low-dose spiral CT (LDCT), lung cancer diagnosis and, 813

Low-molecular-weight heparin (LMWH)

- deep venous thrombosis management and, 628
- pulmonary embolism and, 816-817

Lower back pain (LBP), 56. *See also* LBP

Lower lobe infection, pneumonia and, 751

Lumbar degenerative disk disease, 1259

Lumbar plexopathy, radiation and, 172

Lumbar puncture

- fluid analysis and, 1666, 1666b
- herpes simplex encephalitis diagnosis and, 1359
- meningitis diagnosis and, 1354

Lumbar spine, muscular dystrophy and, 141

Lumpectomy (excisional biopsy)

- breast cancer treatment and, 1025, 1026f
- considerations of, 1032
- tissue and, 369

Lund-Browder method, burn size determination and, 435, 437f, 438f

Lung abscess

- definition of, 758
- medical management of, 758

Lung Allocation System (LAS)

- lung transplantation and, 1043b, 1087
- wait time and, 1087-1088

Lung cancer

- black women and, 356
- characteristics of, 809t
- clinical manifestations of, 811-812
- implications for therapist, 814-816

Lung cancer (*Continued*)

- lung transplantation
 - contraindication and, 1087
 - medical management of, 812-814
 - metastasis of, 812, 1229
 - non-small cell. *See* NSCLC (non-small cell lung cancer)
 - overview of, 809
 - pneumoconiosis, 784
 - risk factors of, 810-811
 - small cell. *See* SCLC (small cell lung cancer)
- Lung disease
 - lung cancer and, 810
 - radiation and, 168
 - restrictive. *See* Restrictive lung disease
- transplantation categories of, 1087
- transplantation cluster categories of, 1087

Lung function

- pulmonary function tests and, 793
- sarcoidosis manifestation and, 808
- ventilation/respiration and, 742
- weight loss and, 749

Lung imaging fluorescence endoscope (LIFE), lung cancer diagnosis and, 813

Lung injury. *See also* Blunt chest trauma

- acute respiratory distress syndrome and, 803
- near drowning and, 787
- transfusion-related acute, 681-682
- transplantation and, 1087

Lung parenchyma

- peripheral conditioning and, 749
- sarcoidosis and, 808

Lung transplant, exercise and, 797

Lung transplantation

- candidates for, 1087-1088, 1088b
- complications
 - bone density loss and, 1089
 - graft failure and, 1089-1090
 - infection and, 1090
 - pulmonary problems and, 1090
 - rejection and, 1090
- complications of, 1089-1090
- COPD treatment and, 762, 1087
- exercise and, 1094
- future trends of, 1091
- implications for therapist, 1091-1094
- overview of, 1087
- prognosis of, 1090-1091
- sarcoidosis and, 808
- systemic sclerosis and, 781
- therapist's role
 - acute care phase, 1092
 - outpatient phase and, 1093-1094

- Lung volume, expanded, COPD monitoring and, 764
- Lung, capacity, total (TLC). *See* Tests, pulmonary function
- Lung-volume reduction surgery (LVRS), COPD treatment and, 762
- Lupus carditis, myocardial disease and, 578
- Lupus Erythematosus (LE). *See* Systemic lupus erythematosus (SLE)

- autoimmune disease and, 180
- cutaneous lupus erythematosus, 424-425

- Lupus erythematosus, discoid. *See* Discoid lupus erythematosus (DLE)
- Lupus, drug-induced, 284
- Luteinizing hormone (LH), 113

- endometriosis treatment and, 997
- hypothalamic hormones and, 453, 456f

- Lux, light therapy and, 114
- Lyme disease, 339-343

- clinical manifestations of, 340-341
- definition and overview of, 339-340

Lyme disease (*Continued*)

- implications for therapist, 342-343
- medical management of, 341-342, 342b

Lymph drainage, manual, lymphedema therapy and, 666

Lymph nodes, 647

- esophageal cancer manifestation and, 839
- infectious diseases and, 300-301
- lung cancer metastasis and, 812
- lymphatic vessel system and, 646, 647
- primary tumor physical exam and, 1205

Lymph pump deterioration, chronic lymphedema and, 654

Lymph transport capacity, lymphedema pathogenesis and, 653, 654f

Lymph trunks, lymphatic vessel system and, 644, 646

Lymph vessels, afferent, lymph nodes and, 646

Lymphadenectomy, ovarian cancer treatment and, 1009

Lymphadenitis, enlarged lymph nodes and, 673

Lymphadenopathy

- breast cancer manifestations and, 1020
- inflammatory arthritis and, 1277
- lymph node enlargement and, 647, 679
- non-Hodgkin's lymphoma and, 707

Lymphangiectasia, lymphatic hyperplasia, 652

Lymphangiodyplasias, primary lymphedema and, 651, 651f

Lymphangion, lymphatic vessel system and, 644, 646f

Lymphangiosclerosis, lymph vessel scarring and, 654

Lymphangitis, 221

- definition of, 673
- erysipelas and, 320, 320f
- implications for therapist, 675
- infection and, 300, 654
- medical management of, 673-675, 675f

Lymphatic cording, 1033, 1033. *See also* Axillary web syndrome (AWS)

Lymphatic obstruction, pulmonary edema and, 802

Lymphatic system. *See also* Lymphedema

- anatomy and physiology of, 642-647
- breast cancer metastases and, 1021f
- implications for therapist, 647
- inflammation and infection
 - lipedema, 675-677
 - lymphadenitis, 673
 - lymphangitis, 647, 673-675
 - lymphedema, 650-673
- inflammation and infection of, 647-677
- metastasis and, 363

Lymphatic system watersheds, drainage territories and, 646, 649f

Lymphatic transport system

- functional impairment and, 655-656
- structural impairment and, 654-655, 655f, 656f

Lymphatic vessels, 636-637. *See also* Lymphatic system

- lymphatic capillaries and, 643
- lymphatic system and, 642
- network of, 642

Lymphatics, edema and, 221

Lymphedema

- abdominal hernia and, 660
- breast cancer treatment side effects and, 1034

Lymphedema (Continued)

- breast cancer-related (BCRLE), lymphedema exercise and, 667
- classification of, 650, 650b
- clinical manifestation of, 656-658
- complications of, 657-658
- etiology of, 651-653
- exercise and, 389
- hematolymphatic disorders and, 679
- implications for therapist, 660-673, 662t
- medical management of, 658-660
- orthopedic, postsurgical joint replacement and, 664
- pathogenesis of, 653-656, 654f
- radiation and, 170, 363
- soft tissue fluid and, 647
- therapy
 - components of, 649f, 666-668
 - education and home program of, 668-669, 669f, 671f
 - exercise and, 667-668

Lymphedema comprehensive management

- physical therapy intervention and, 665

Lymphedema praecox. *See* Primary lymphedema

Lymphedema tarda. *See* Primary lymphedema

Lymphocyte-predominant Hodgkins lymphoma (LPHL), 703

Lymphocytes

- differentiation of, 247, 248f, 690
- helper, inducer, T4, or CD4, 244
- rheumatoid factor and, 226
- white blood cell test and, 1652, 1652t

Lymphocytosis/Lymphocytopenia, 692

Lymphodynamic insufficiency, lymphedema treatment and, 661

Lymphoid tissue, cancer of, 350

Lymphokines

- protein mediators and, 248, 374
- T-cell lymphocytes and, 374

Lymphoma

- AIDS-related (ARL), 265
- Diffuse large B-cell (DLBCL). *See* Diffuse large B-cell lymphoma (DLBCL)
- extranodal. *See* Lymphoma, primary CNS (PCNSL)
- groups of, 701
- hepatic, liver transplantation and, 1070
- lymph tissue cancer and, 350, 350b
- primary CNS (PCNSL), 1383
- primary intestinal, 868
- risk factors of, 702t
- sarcoidosis symptoms and, 807b

Lymphoscintigram

- lipedema diagnosis of, 676
- lymphedema diagnosis of, 659

Lymphotomes, lymphatic system drainage and, 646-647, 649f

M

Macrosopic quantum coherence, 9

Macrocytic, larger than normal RBCs and, 688

Macroglia, CNS cell type and, 1320-1321

Macrolides, inflammatory mediator suppression and, 793

Macrophage colony-stimulating factor (M-CSF), alphavbeta3 integrin and, 1162

Macrophages

- bone fracture pathogenesis and, 1297
- exercise and, 253
- lymphatic system and, 642, 654
- muscle regeneration and, 231
- phagocytosis and, 226, 226f, 244

- Macrophages (*Continued*)
 spinal cord injury, 1499
 tumor cell defense and, 244
- Maculopapular eruptions, skin lesions, 300
- Mad cow disease. *See* Bovine spongiform encephalopathy
- Mad Hatter syndrome, 129
- Magnesium basic metabolic panel and, 1640t, 1641
 cerebral spinal fluid and, 1666
 electrolyte imbalance and, 185, 187t, 188t
 migraine headache treatment and, 1558
- Magnetic resonance angiography (MRA), 564
 coronary disease assessment and, 537
- Magnetic resonance imaging. *See* MRI (magnetic resonance imaging)
- Magnetic resonance spectroscopy (MRS), primary brain tumor diagnosis and, 1384
- Maisonneuve fracture, fracture types and definitions of, 1295b
- Major depressive disorder, 110
- Major histocompatibility complex, immune response and, 243
- Mal de débarquement syndrome (MDDS)
 overview and definition of, 1586
 pathogenesis, clinical manifestation, and treatment of, 1586-1587
- Malabsorption syndrome clinical manifestations of, 849, 849f
 definition and overview of, 848
 implications for therapist, 850-851
 medical management of, 850
 symptoms associated with, 849t
- Malaris, sickle cell disease and, 730
- Maldigestion, malabsorption disorder and, 848
- Male genital/reproductive system aging and, 964
 overview of, 964, 965f
 prostate disorders and, 964-978
 testes disorders and, 978-985
- Male stereotype, health and, 26
- Malignant hypertension, hypertensive vascular disease types of, 552
- Malignant lymphomas Hodgkin's lymphoma, 701-706
 multiple myeloma, 709-713
 non-Hodgkin's lymphoma, 706-709
 risk factors of, 702t
- Malignant melanoma, 418. *See also* Squamous cell carcinoma definition and overview, 414
 etiology and risk factors of, 416, 416b, 417f
 implications for the therapist, 419
 medical management of, 416-418
 prognosis of, 418
 types of, 415f
- Malingering, 99-101, 104
 conscious symptom magnification and, 108
- Mallory-Weiss syndrome gastroesophageal mucosal tear and, 828, 837
- Malnutrition alcohol-related liver disease and, 905
 malabsorption syndrome and, 850
- Malunion, abnormal fracture healing and, 1298
- Mammary dysplasia. *See* Breast disease, benign
- Mammography breast cancer detection and, 1023, 1023b
- Mammography (*Continued*) digital, breast cancer diagnosis and, 1024
 screening, no breast cancer lump and, 1023
- Manic depressive disorder. *See* Bipolar disorder
- Mantle cell lymphoma, non-Hodgkin's lymphoma and, 707
- Manual lymphatic drainage (MLD), lymphedema complications and, 658, 666
- Manual tender point survey, fibromyalgia diagnosis and, 294
- Marasmus, cell injury and, 200
- Marfan's syndrome aneurysms and, 608
 aortic regurgitation and, 600
- Margination, white cell migration and, 1101
- Marie-Strümpell disease. *See* Ankylosing spondylitis (AS)
- Marijuana, lung cancer risk factor and, 810
- Marjolin's ulcer, squamous cell carcinoma and, 414, 414f
- Mass, primary tumor manifestation and, 1204
- Massage, cancer pain control and, 365
- Mast cells age related change and, 250
 histamine and, 245
 urticaria and, 392
- Mastectomy surgery breast cancer treatment and, 1025
 mastectomy reconstruction and, 660, 1025-1026
 side effects of, 1032
- Maternal myasthenia gravis (MG), arthrogryposis multiplex congenita and, 1155
- Matrix metalloproteinases (MMPs), ligament healing and, 235
- Mattis Dementia Rating Scale, Alzheimer's disease diagnosis and, 1416
- Maturation phase, tendon healing and, 234
- Mature-onset diabetes of the young (MODY), hybrid diabetes mellitus type 2 and, 488-489
- Maximal VO_2 (VO_{max}), oxygen delivery and, 749
- Maze procedure, heart surgery and, 591
- MC1R, malignant melanoma and, 416
- McBurney point appendicitis and, 858f, 876f, 877, 877f, 878
 diverticular disease and, 863, 876f
 hernia screening and, 873
- McGill Quality of Life Questionnaire (MQOL), as ALS assessment tool, 1408
- MD. *See* Muscular dystrophies (MDs)
- MDI. *See* Metered-dose inhaler
- Mechanical circulatory support alternate cardiac disease treatment and, 1082
 overview of, 1082
 types of, 1082-1085
- Mechanical Embolus Removal in Cerebral Ischemia (MERCI), intercranial clot retrieval and, 1461
- Mechanical insufficiency, lymph vascular insufficiency, 637
- Mechanical loading, skeletal shape and, 232
- Mechanism, pincer, neurapraxia syndrome and, 1501
- Mechanism-based classification model, chronic pain and, 105-106
- Meckel's diverticulum, 875
- Meconium ileus, cystic fibrosis and, 791
- Medical errors, mortality and, 18
- Medical model, physical therapists and, 17
- Medical Therapy of Prostatic Symptoms (MTOPS), benign prostatic hyperplasia medications and, 969
- Medicare, hospice criteria and, 384
- Medications antipsychotic, side effects of, 117b
 depression and
 digitalis toxicity from, 541t-542t, 576
 exercise guidelines for, 1674, 1675t
 immunity and, 252
 immunosuppressive, heart transplantation complications and, 1077
- Intracerebral hemorrhage risk factors and, 1465
- Osteoarthritis implications and, 1256
- Osteoporosis and, risk factor of, 1158b, 1160
- Osteoporosis treatment and, 1167-1169
 reduction and withdrawal of, 1048
 transplantation and, 104f, 1046-1048, 1047f
- Medicine bloodless, techniques of, 683
 discriminatory, 531-532
 regenerative, tissue engineering and, 1046
- Medulloblastoma, 1376
 gliomas overview and, 1372
 pediatric tumors and, 1400
- Meige's syndrome, primary lymphadema and, 651
- Melanin skin pigmentation and, 450
- Melanocyte-stimulating hormone (MSH), chronic adrenal insufficiency and, 480
- Melanocytes, vitiligo and, 451
- Melanoma, acral lentiginous (ALM), 415, 415f
- Melasma (pregnancy mask) hyperpigmentation and, 451
 skin changes and, 396
- Melatonin, seasonal affective disorder (SAD) and, 112, 115
- Memantine, amyotrophic lateral sclerosis and, 1408
- Membrane attack complex (MAC), complement system and, 224, 224f
- Memories of pain, 56
- Memory declarative, memory problems and, 1337
 deficits of, 5
 loss, multiple sclerosis manifestations and, 1429
- Nitric oxide and, 203
- Posterior cerebral artery syndrome and, 1457
- problems CNS disorder manifestations and, 1337-1339, 1338t, 1338f
 types of, 1337
- Memory B cells, B lymphocytes and, 246
- Men acalculous cholecystitis and, 923
 breast cancer and, 1018
 breast cancer recurrence and, 1030
 chronic pancreatitis and, 915
 headache without aura and, 1555
 musculoskeletal injury and, 1100
 prostate cancer and, 964, 970-971
 testicular cancer and, 980
 traumatic brain injury risk factor and, 1477, 1496
- Men who have sex with men (MSM) AIDS and, 258-259
 prevention strategies and, 266, 267b
- Menière's syndrome. *See also* Hydrops, endolymphatic clinical manifestations of, 1582, 1583b
 implications for therapist, 1583-1584
 incidence, etiology, and risk factors of, 1581
 pathogenesis of, 1582
 prognosis of, 1583
- Meninges, brain and spinal cord inflammation and, 1352
- Meningioma acoustic neuroma and, 1587
 overview of, 1376-1377
 pathogenesis of, 1377, 1378f, 1379f
- Meningitis anthrax, diagnosis of, 1355
 aseptic (viral), 1353
 bacterial, 1353-1354
 clinical manifestations of, 1354, 1354f
 intracranial surgery complications and, 1390
 medical management of, 1354f, 1354-1355
 neoplastic. *See also* Leptomeningeal carcinomatosis diagnosis of, 1355
 pathogenesis of, 1352-1354
Pseudomonas and, 324
s. pneumoniae and, 322
 tuberculous, 1353, 1354f. *See also* *Mycobacterium tuberculosis*
- Meningocele, 1116. *See also* Spina bifida aperta definition of, 1116, 1117f
- Menisci (knee) cartilage healing and, 236, 236f types of tears and, 236, 237f
- Menopause bone density loss and, 1104
 common symptoms of, 987, 987b
 diabetes and, 511
 endocrine theory of aging and, 458
 hormonal changes and, 459
 hormone replacement therapy and, 988-989
- Musculoskeletal system and, 989
 overview of, 986-988
 surgical, lower back pain and, 991
- Menses, endometriosis and, 995
- Menstruation, retrograde, endometriosis causal theory and, 996
- Mental disorders, 75b
- Mental illness, germ theory part II and, 7
- Mercury, 128-130
 sources of, 129
- Merosin-negative congenital muscular dystrophy, without brain involvement and, 1134
- Mesosystem, and interaction, 18
- Mesothelioma asbestos and, 785
 pneumoconiosis and, 784
- MET (metabolic equivalent of the task) system, monitoring vital signs and, 566
- Metabolic acidosis, 193t, 195
- Metabolic alkalosis, 194t, 195
- Metabolic disorders osteomalacia and, 1173-1176
 osteoporosis and, 1157-1173
 overview of, 1157
- Page's disease and, 1176-1181
 vestibular consequences of, 1592
- Metabolic equivalent of the task (MET) definition of, 32b
- Metabolic neuronal diseases phenylketonuria and, 517
 porphyrias and, 518
 Wilson's disease and, 517

- Metabolic syndrome** coronary artery disease and, 534 insulin resistance and, 512 obesity and, 34 prediabetes and, 489 risk factors of, 534, 534b **Metabolic system**, 515-518 acid-base balance and, 516 aging and, 516-517 fluid and electrolyte balance and, 515-516 **Metacarpophalangeal (MCP)** extension, tardy ulnar palsy and, 1610 **Metal fume fever**, occupational diseases and, 786-787 **Metaplasia** cell function and, 205 definition of, 348 **Metaplasia-dysplasia-carcinoma sequence**, esophageal adenocarcinoma and, 838 **Metastases** bone breast cancer and, 1020-1021, 1031 cancer pain and, 364, 811 exercise and, 1233 pathogenesis of, 1230 treatment of, 1231 types of, 362 central nervous system, 362-363 hepatic system (liver), 362 implications for therapist, 867-868 lymphatic system, 363 primary tumor manifestation and, 1204 pulmonary system (lungs), 361-362, 815, 867 rectal tumors and, 867-868 skeletal system, 362, 1230, 1231, 1233 spinal, 1232 **Metastasis** brain clinical manifestations of, 1397, 1398 medical management of, 1397-1398 cancer recurrence of, 363 clinical manifestations of, 361-363 diagnosis of, 363 incidence of, 359 liver, 868 mechanisms of, 359-361, 360t, 361f seed versus soil theory of, 359 spinal clinical manifestations of, 1398 medical management of, 1398f, 1398-1399 **Metastatic cascade**, tumor-host interactions and, 360 **Metered-dose inhaler (MDI)** asthma medication, exercise and, 765b, 773 COPD medications and, 764, 765b **Methacholine challenge test**, asthma diagnosis and, 771 **Methamphetamine (meth)**, abuse of, 80 **Methionine and S-adenosylmethionine (SAM)**, abnormal metabolism of, 904 **Methotrexate**, psoriasis treatment and, 423 **Methylprednisolone**, spinal cord injury and, 1510 **MI**. See *Myocardial infarction* **Microadenomas**, pituitary gland lesions and, 1378 **Microbial theory**, of obesity, 35 **Microbiology**, studies of gram stain, 1663-1664 implications for therapist, 1664 **Microcephalus**, cerebral palsy manifestations of, 1521 **Microcytic**, smaller than normal RBCs and, 688 **Microfibrinous adhesions**, muscle stiffness and, 231 **Microglial antagonism**, pathogen replication and, 306 **Microglia**, CNS cell type and, 1320-1321 **Micrographia**, parkinsonism clinical manifestations and, 1441 **Microsystem**, and interaction, 18 **Microtubule-associated protein 2 (MAP2)**, neuronal differentiation marker, 418 **Middle cerebral artery syndrome**, ischemic stroke syndromes and, 1455-1456, 1456f **Migraine Disability Assessment (MIDAS)**, headache impact measurement tools and, 1547 **Migraine headache** clinical manifestations of, 1554-1557 etiologic and risk factors of, 1551-1552 implications for therapist, 1558-1559 manifestations of basilar-type and, 1555-1556 chronic migraine and, 1557 migraine aura status and, 1557 ophthalmoplegic and, 1556 retinal and, 1556 sporadic and familial hemiplegic and, 1555 status migrainosus and, 1556-1557 typical aura without headache and, 1555 vestibular and, 1556, 1556b with aura and, 1555, 1555f without aura and, 1554-1555 medical management of, 1557-1558, 1558b **Mohs' micrographic surgery**, basal cell carcinoma and, 412 **Mold**, hypersensitivity pneumonitis and, 786 **Molecular epidemiology**, 121 **Molecular language and DNA**, 13f **Molecular techniques**, PCP diagnosis and, 752 **Molecule**, neural cell adhesion (NCAM), 1617 **Monamine Inhibitors (MAO)**, antidepressants and, 114t **Mongolian spots** congenital dermal melanocytosis and, 41, 42f lumbosacral area and, 392, 394f **Monochromatic near-infrared photo energy (MIRE)**, diabetic ulcer healing and, 501 **Monoclonal antibody (mAbs) technique** biotherapy and, 374-375 colorectal cancer treatment and, 867 development of, 11, 371 **Monoclonal gammopathy of undetermined significance (MGUS)**, multiple myeloma and, 710-711 **Monocytes** innate immunity and, 244 leukocyte class of, 690 **Monocytosis**, leukocyte disorder and, 692 **Monokines** macrophage secretion and, 244 mononuclear phagocytes and, 374 **Mononeuritis multiplex** inflammatory disorders and, 615 vasculitic neuropathy and, 1628 **Mononeuropathy**, 1619 neuropathy classification and, 1599 **Monteggia's fracture**, fracture types and definitions of, 1295b **Mood disorders**, 75b, 109-117 exercise and, 994 implications for therapists, 115-117 **Mitochondrial deoxyribonucleic acid (DNA)**. *see DNA*
- Mitochondrial theory of aging**, metabolic system and, 516 **Mitoxantrone**, multiple sclerosis treatment and, 1434 **Mitral regurgitation** etiology and pathogenesis of, 595-596 medical management of, 596 **Mitral stenosis** medical management of, 595 rheumatic fever and, 594 **Mitral valve prolapse (MVP)**. *See also Mitral regurgitation* exercise and, 600 female hearts and, 525 incidence and etiology of, 596 medical management of, 597 starvation and, 89 **Mitral valve prolapse syndrome (MVPS)**, exercise and, 600 **Mixed cardiomyopathies** primary cardiomyopathies and, 579, 580t **Mixed sleep apnea**, sleep-disordered breathing and, 777 **Mixed-cellularity Hodgkin's lymphoma (HCHL)**, 704 **Mixed-cellularity Hodgkin's lymphoma**, AIDS and, 704 **MLD** *See Manual lymph drainage and MM*. *See Multiple myeloma* **MMPs**. *See Matrix metalloproteinases* **Mobility**, spinal cord injury therapy and, 1513 **Moderate exercise**, definition of, 32b **Modified Fatigue Index**, 1436 **MODS**. *See Multiple organ dysfunction syndrome (MODS)* **Mohs' micrographic surgery**, basal cell carcinoma and, 412 **Mold**, hypersensitivity pneumonitis and, 786 **Molecular epidemiology**, 121 **Molecular language and DNA**, 13f **Molecular techniques**, PCP diagnosis and, 752 **Molecule**, neural cell adhesion (NCAM), 1617 **Monamine Inhibitors (MAO)**, antidepressants and, 114t **Mongolian spots** congenital dermal melanocytosis and, 41, 42f lumbosacral area and, 392, 394f **Monochromatic near-infrared photo energy (MIRE)**, diabetic ulcer healing and, 501 **Monoclonal antibody (mAbs) technique** biotherapy and, 374-375 colorectal cancer treatment and, 867 development of, 11, 371 **Monoclonal gammopathy of undetermined significance (MGUS)**, multiple myeloma and, 710-711 **Monocytes** innate immunity and, 244 leukocyte class of, 690 **Monocytosis**, leukocyte disorder and, 692 **Monokines** macrophage secretion and, 244 mononuclear phagocytes and, 374 **Mononeuritis multiplex** inflammatory disorders and, 615 vasculitic neuropathy and, 1628 **Mononeuropathy**, 1619 neuropathy classification and, 1599 **Monteggia's fracture**, fracture types and definitions of, 1295b **Mood disorders**, 75b, 109-117 exercise and, 994 implications for therapists, 115-117 **Morbid obesity**, 33 **Morbidity**. *See also Mortality* physical activity and, 29-30 **Morphea**, localized scleroderma and, 426 **Morphine**, pulmonary edema treatment and, 802 **Mortality** acute respiratory distress syndrome and, 805 common causes of, 18 COPD and, 762 obesity and, 18, 33, 35 *P. carinii pneumonia* and, 752 physical activity and, 29 pneumonia and, 749 primary pulmonary hypertension and, 819 pulmonary tuberculosis and, 756 race and, 21 sickle cell disease and, 738 stroke prognosis and, 1453 **Mosaic warts**, plantar warts and, 406 **Mosquitoes (*Culex*)**, West Nile virus and, 1357 **Motor action potential**, distal compound (CMAP), 1623 **Motor control** amyotrophic lateral sclerosis and, 1404 musculoskeletal dysfunction and, 232 **Motor deficits**, traumatic brain injury and, 1487 **Motor endplate disorders**, myasthenia gravis, 1631-1633 **Motor learning theory**, silver collar workers and, 142 **Motor learning**, stages of, 1351 **Motor neuron syndrome**, myelopathy and, 171 **Motor synkinesis (crocodile tears)**, Bell's palsy and, 1610 **Movement disorders**. *See also Extrapyramidal effects* clinical implications and, 1363 **CNS disorder** manifestations and, 1328, 1330f coordinated, CNS disorder manifestations and, 1328-1331 **parkinsonism** clinical manifestations and, 1441, 1446, 1446b the therapist and, 1436 traumatic brain injury and, 1487, 1494 **MRI (magnetic resonance imaging)** benign prostatic hyperplasia assessment and, 969 breast cancer diagnosis and, 1024 cavernous malformation diagnosis and, 1471 **CNS disorder** diagnosis and, 1344-1345 endometriosis diagnosis and, 996 hemophilic arthropathy and, 721, 721f Huntington's disease diagnosis of, 1424, 1424f intracerebral hemorrhage diagnosis and, 1467 ischemic stroke diagnosis and, 1459 multiple sclerosis diagnosis and, 1430 myocardial infarction diagnosis and, 564 osteoarthritis diagnosis and, 1254 pregnancy and Hodgkin's lymphoma diagnosis, 703 primary brain tumor diagnosis and, 1384 **primary tumor** radiographic exam and, 1203f, 1205, 1206f prostate cancer staging and, 974 spinal cord injury diagnosis and, 1507, 1508f, 1509f traumatic brain injury diagnosis and, 1489

- MRI (magnetic resonance imaging) (*Continued*)
vascular disorder diagnosis and, 1576
- MRI, diffusion weighted (DWI), ischemic stroke diagnosis and, 1459
- mRNA (messenger RNA), affected DMD/BMD gene and, 1131-1132
- MRSA (*Staphylococcus aureus*, methicillin-resistant bacteria). *See Staphylococcus aureus*
- MS (multiple sclerosis). *See Multiple sclerosis (MS)*
- MSD. *See Musculoskeletal disorder*
- Mucin clot test, 1667
- Mucin glycoproteins, cholesterol gallstone formation and, 920
- Mucolysis
cystic fibrosis therapy and, 793
Recombinant human deoxyribonuclease I, 793
- Mucositis, graft-versus-host disease and, 1054
- Mulder's sign, Morton's neuroma and, 1616
- Multicausal theory, 8, 8f
- Multiple myeloma (MM), 1222-1223
definition and overview, 709
diagnosis of, 710, 711t
implications for therapist, 712-713
musculoskeletal manifestations of, 710
prognosis of, 712
renal impairment and, 710
treatment of, 711
- Multiple myeloma, exercise and, 712
- Multiple organ dysfunction syndrome (MODS), 181, 1644
acute respiratory distress syndrome and, 803
implications for therapist, 182
- Multiple organ failure syndrome (MOFS), 1644
- Multiple sclerosis (MS)
clinical manifestations of, 1428-1430
etiological and risk factors of, 1425-1426
implications for therapist, 1436-1437, 1437b
incidence of, 1425, 1426f
Lyme disease and, 343
medical management of, 1430-1436, 1432f, 1433f
overview and definition of, 1425
pathogenesis of, 1426-1428
- Multiple systems conditions affecting, 151b
disorders affecting, 150-152, 179-181
- Munchausen by Internet, 99
- Munchausen syndrome, 99
- Mural thrombus, definition and resolution of, 625-626
- Murphy's sign, costovertebral angle tenderness and, 931
- Muscle
dysmorphia of, 87
fiber, type I and II, 1102
saropenia and, 1102
flap procedures, breast implants and, 1026
function, musculoskeletal system and, 1105
inhibition of, 232
injured, soft tissue injuries and, 1236
mass
exercise and, 994
menopause and, 992
- paraspinal
exercise and, 1115
scoliosis curvature and, 1112-1113
- strain of, 239
- tone, cerebral palsy manifestation and, 1522, 1523t
- Muscle (*Continued*)
transection of, 231
wasting, tumor necrosis factor-alpha and, 767
- Muscle disease, infectious (inflammatory)
bursae and tendon infections and, 1196-1197
myositis, 1195-1196
- Muscular atrophy, progressive spinal, amyotrophic lateral sclerosis and, 1405f, 1406
- Muscular dystrophies (MDs)
clinical manifestations of, 1132t, 1134-1137
definition and overview of, 1130
implications for therapist, 1139-1140
medical management of, 1137-1139
pathogenesis of, 1130-1134, 1132f
- Muscular dystrophy Becker's (BMD)
clinical manifestations of, 1136
overview of, 1130, 1131f
- congenital (MDC)
clinical manifestations of, 1136
diagnosis of, 1138
overview of, 1130, 1131f
pathogenesis of, 1132t, 1134
- Duchenne's (DMD)
clinical manifestations of, 1134-1136, 1135f
overview of, 1130, 1131f
pathogenesis of, 1131-1133, 1132t
treatment of, 1138-1139
- Duchenne's and Becker's (DMD/BMD). *See also Muscular dystrophies*
diagnosis of, 1137
pathogenesis of, 1131-1133, 1132t
treatment of, 1138
- Fukuyama, fukutin gene mutation and, 1134
- limb-girdle (LGMD)
clinical manifestations of, 1136
diagnosis of, 1137-1138
pathogenesis of, 1132t, 1133-1134
- Muscular dystrophy congenita. *See Muscular dystrophy, congenital*
- Muscular torticollis, congenital. *See Torticollis*
- Musculoskeletal disorder (MSD)
common disorders of, 1100b
occupational injuries and, 140-141
women in the workplace and, 992
- Musculoskeletal disorder, drug induced, 1100
- Musculoskeletal locations of pain, hepatic disease symptoms and, 882
- Musculoskeletal pain syndromes, AIDS and, 264
- Musculoskeletal problems, cerebral palsy manifestation and, 1521-1522, 1523f
- Musculoskeletal system
advances in biotechnology and, 1100
aging and
bone remodeling and, 1104
joint and connective tissue flexibility loss and, 1103-1104
muscle mass loss and, 1101-1103
biologic response to trauma and, 1100-1101
common disorders of, 1100b
disease
cancer and, 1106-1107
infection and, 1107
exercise
bone and, 1105-1106
joints and, 1105
- Musculoskeletal system (*Continued*)
muscle and, 1104-1105
specific exercises and, 1106
menopause and, 989-991
overview of, 1099-1100
- Mutations, acquired, 13
- Mutism, akinetic, anterior cerebral artery syndrome and, 1456
- MVP (mitral valve prolapse). *See Mitral valve prolapse*
- MVPS (mitral valve prolapse syndrome). *See Mitral valve prolapse syndrome*
- Myalgia, statin medication and, 548
- Myasthenia gravis (MG)
hyperthyroidism and, 468
implications for therapist, 1632-1633
medical management of, 1631-1632
overview and definition of, 1631
- Myasthenia Gravis Foundation, 1633
- Mycobacterium tuberculosis*
AIDS and, 167
drug resistant bacteria and, 298
inhalation of, 754
pulmonary tuberculosis and, 180
tuberculosis infection and, 752
tuberculous meningitis and, 1353
- Mycobacterium, pneumonitis and, 786
- Mycophenolate mofetil (CellCept), transplantation medications and, 1047, 1047f
- Mycoplasma
self-replicating bacteria and, 302
systemic sclerosis and, 427
- Mycrodysgenesis, infantile seizures and, 1533
- Myelin
loss, multiple sclerosis
pathogenesis and, 1427
peripheral nervous system structure and, 1595, 1596t, 1598f
sheath, glial cell types and, 1321
- Myelinopathy, nerve injury
classification and, 1597-1598, 1598f
- Myeloma, multiple, 1222-1223, 1223f
- Myelomeningocele. *See also Spina bifida aperta*
bladder transplantation and, 1069
clinical manifestations of, 1118, 1119f, 1120b, 1120t, 1121t
definition of, 1116, 1117f
latex allergy and, 147
management program controversies and, 1125-1126
pathogenesis of, 1118
- Myelopathy
rheumatoid arthritis prognosis and, 1272
spinal cord radiation and, 171
- Myeloproliferative disorders
essential thrombocythemia and, 715-716
polycythemia vera and, 713-715
- Myelosuppression, chemotherapy and, 175, 177
- Myenteric plexus, esophageal muscular layers and, 830
- Myocardial diseases
cardiomyopathy and, 579-583
myocarditis and, 578-579
- Myocardial infarction
aerobic fitness and, 230
cell injury and, 206
definition and incidence of, 559
implications for therapist, 565-567
ischemia and, 198, 208
medical management of, 562-565
- Myocardial infarction (MI)
(*Continued*)
myocardial infarction of, 560-562
surgery and, 539f, 572
- Myocardial ischemia/reperfusion injury, myocardial infarction and, 561
- Myocardial neoplasm, 583-584
- Myocarditis, 578-579
acquired cardiomyopathy and, 579, 580t
collagen vascular disease and, 639
implications for therapist, 579
- Myocardium, 560, 560f, 561t
heart transplantation denervation of, 1080-1082, 1081b
myocarditis and, 578
- Myofascial compartment syndromes, soft tissue injuries and, 1236
- Myofascial pain syndrome (MPS)
clinical manifestations of, 1247
fibromyalgia and, 289, 295
implications for therapist, 1249-1250
medical management of, 1247-1249
overview of, 1246
pathogenesis of, 1246-1247
- Myofibroblasts, myocytes and, 227
- Myoglobin, 1657. *See also Creatine kinase*
- Myomectomy, uterine fibroid treatment and, 998
- Myopathy
acquired, paraneoplastic syndrome and, 1244
clinical manifestations of, 1244
critical illness (CIM), intensive care units and, 1244, 1245
definition and overview of, 1243, 1244b
etiologic factors and pathogenesis of, 1243-1244
exercise and, 1245
implications for therapist, 1245-1246
medical management of, 1244-1245
muscle atrophy and, 467
myotubular (centronuclear), congenital myopathy and, 1140
nemaline, congenital myopathy and, 1140
neuropathy classification and, 1599
proximal weakness and, 1600-1601
steroid, liver transplantation outpatient care and, 1074
- Myopericarditis, cardiac dysfunction and, 606
- Myositis
etiology and pathogenesis of, 1195-1196
gas gangrene and, 323
implications for therapist, 1196
inclusion body (IBM)
clinical manifestations of, 1196
type of myositis and, 1195, 1195b
- medical management of, 1196
overview and incidence of, 1195, 1243
systemic sclerosis and, 429, 430
- Myositis ossificans (MO). *See Heterotopic ossification*
- Myotendinous junction, muscle strain and, 231
- Myotomal pattern, peripheral dysfunction symptoms and, 1599-1601
- Myotrophin, amyotrophic lateral sclerosis and, 1408
- Myxedema, hypothyroidism and, 470
- Myxedematous hypothyroidism, synovium change and, 472
- Myxomas. *See Myocardial neoplasm*

N

N-nitrosamines. *See* Nicotine
 Nagi disablement model, 3
 Narcissistic personality disorder, 100
 Narcotics
 atelectasis and, 800
 sickle cell disease and, 739
 Natalizumab, multiple sclerosis treatment and, 1434
 National and International Transplant Games, posttransplant exercise and, 1057
 National Arthritis Action Plan, 1253
 National Cancer Institute Surveillance, Epidemiology and End Results (SEER), 1367, 1401
 National Cancer Institute's Study of Tamoxifen and Raloxifene (STAR). *See* STAR (National Cancer Institute's Study of Tamoxifen and Raloxifene)
 National Cancer Institute, objectives for cancer rehabilitation and, 1393
 National Cholesterol Education Program Adult Treatment Panel III guidelines, statin therapy and, 1462
 National Emphysema Treatment Trial, COPD management study and, 762
 National Institute of Mental Health, bone loss in menopausal women and, 1160
 National Institute of Neurologic and Communicative Disorders and Stroke (NINCDS)
 Guillain-Barré syndrome diagnosis and, 1622, 1623b
 ischemic stroke treatment study and, 1461
 National Institute of Neurological Disorders and Stroke study
 Alzheimer's disease assessment and, 1416
 National Organ Transplant Act (NOTA), 1039
 National Osteoporosis Foundation (NOF)
 calcium intake of young girls and, 1164
 osteoporosis exercise and, 1169
 osteoporosis in men and, 1159
 osteoporosis screening and, 1166
 National Patient Safety Goal (NPSG), 1638
 National Wilms Tumor Study Group (NWTSG), Wilms' tumor staging and, 935
 Natural killer cells (NK)
 helper T cells and, 248, 249f
 innate immunity and, 243-245, 246f
 age related changes of, 250
 exercise and, 253
 Nausea, gastrointestinal disease symptoms and, 829
 NCCN Breast Cancer Treatment Guidelines, 1025
 NCV (nerve conduction velocity). *See Velocity, nerve conduction*
 Near drowning
 definition of, 787
 implications for therapist, 788
 medical management of, 788
 Necrosis
 aseptic. *See* Osteonecrosis
 avascular, 1055. *See also* Osteonecrosis
 developmental hip dysplasia prognosis and, 1129
 Legg-Calvé-Perthes disease and, 1312
 multiple sclerosis pathogenesis and, 1427
 muscle cells and, 231
 pressure ulcers and, 445, 447

Necrosis (Continued)

 skeletal muscle and, 1243
 types of, 206, 207, 208
 Necrotizing pancreatitis, 912
 Needle biopsy, cancer diagnosis and, 369
 Negativistic personality disorder. *See* passive-aggressive personality disorder
 Neglect, 40
 type A trauma and, 59
Neisseria gonorrhoeae, infectious arthritis and, 1193
 Neoadjuvant therapy, bladder cancer and, 954
 Neoplasia, overview of, 1587, 1588f
 Neoplasm
 benign, 1201
 central nervous system
 classifications of, 1365-1367, 1366f, 1367b
 introduction of, 1365
 metastatic tumors and, 1369-1399
 paraneoplastic syndromes and, 1399-1400
 pediatric tumors and, 1400-1401
 primary brain tumors and, 1367-1369
 primary intraspinal tumors and, 1393-1369
 specific primary brain tumors and, 1369-1393
 classifications of, 349t, 349-350
 grading systems of, 351
 staging systems of, 350-351
 definition of, 1201
 disseminated intravascular coagulation etiology and, 223f, 729
 gallbladder and biliary tract, 924-925
 implications for therapist, 925
 gastrointestinal system
 adenocarcinoma and, 864-868
 benign tumors, 863
 intestinal polyps, 863
 malignant tumors, 863-864
 implications for therapist, 730
 kidney, metastasis of, 1229
 liver (hepatic)
 benign, 909
 classification of, 908, 909f
 malignant, 909-910
 malignant, 151, 1201
 musculoskeletal
 metastatic tumors and, 1229-1234
 multiple myeloma and, 1222-1223
 primary benign bone tumors and, 1209-1212
 primary malignant bone tumors and, 1212-1222
 primary soft tissue tumors and, 1223-1229
 primary tumors and, 1201-1209
 occupational diseases and, 785
 overview and incidence, 838
 systemic effects of, 151-152
 treatment of, 839
 Neoplasms, liver, 908-911
 Neoplasms, metastatic, acoustic neuroma and, 1587
 Neoplastic blood and lymph system disease
 acute leukemia and, 695-698
 bone marrow transplantation and, 693
 chronic leukemia and, 698-701
 leukemia and, 693-695
 malignant lymphomas and, 701-713
 myeloproliferative disorders and, 713-716
 Neoplastic meloid cells, acute
 myelogenous leukemia and, 695
 Neovascularization (angiogenesis), blood vessels and, 227

Nephrectomy, radical, renal cell carcinoma treatment and, 933
 Nephritic syndrome, hematuria and, 949
 Nephrolithiasis. *See* Renal calculi
 Nephron
 kidney function and, 940, 940f
 urine waste and, 927, 940f
 Nephropathy, analgesic, renal damage and, 940
 Nephrotic syndrome, kidney-filtering system damage and, 949
 Nephrotoxicity, transplantation and, 1067
 Neriomas, acoustic, Bell's palsy and, 1609
 Nerve
 facial, Bell's palsy and, 1609
 peripheral, spinal cord repair and, 1512
 spinal, sciatica and, 1608
 vestibular, loss of tonic firing and, 1569
 Nerve growth factor (NGF), diabetic neuropathy and, 1618
 Nerve growth, ischemic stroke prophylaxis and, 1463
 Nerves, peripheral
 abnormal responses of causalgia, 1634-1636
 reflex sympathetic dystrophy, 1634-1636
 complex regional pain syndrome (CRPS), 1634-1636
 Nervous dysfunction, autonomic, orthostatic hypotension and, 576
 Nervous system
 chemotherapeutic agents and, 176-177
 hyperkalemia and, 190
 peripheral (PNS)
 abnormal response of, 1634-1636
 botulism and, 1633-1634
 cancer-induced neuropathies of, 1628-1629
 changes with aging and, 1595-1597
 dysfunction pathogenesis and diagnosis of, 1601-1604
 infections/inflammations of, 1621-1628
 injury response and, 1597
 mechanical injuries of, 1604-1617
 metabolic neuropathies and, 1617-1621
 motor endplate disorders of, 1631-1633
 nerve injury classification and, 1597-1598, 1598f, 1599t
 neuropathy classification and, 1599
 overview of, 1595, 1596f
 peripheral dysfunction symptoms and, 1599-1601, 1600f, 1601t, 1601f, 1602t
 structure of, 1595, 1596f, 1597t
 toxins of, 1629-1630
 radiation effects of, 171
 Neural function, 1500-1501
 Neural groove, pathogenesis of NTD and, 1118
 Neural tube defects, congenital (NTDs), 1116
 clinical manifestations of, 1118-1121, 1119f, 1120t, 1121t
 definition of, 1116, 1117f
 implications for therapist, 1124-1126
 incidence and etiologic factors of, 1116-1118
 medical management of, 1121-1124
 motor function prognosis and, 1123-1124
 pathogenesis of, 1118

Neuralgia

 post-herpetic, 1626
 trigeminal (TN)
 incidence and etiology of, 1626
 medical management of, 1627
 Neuromodulated hypotension (NMH), chronic fatigue syndrome and, 275
 Neuropaxia
 nerve injury classification and, 1597-1598, 1598f
 trigeminal ulnar palsy and, 1610
 Neuropaxia syndrome, spinal cord injury and, 1501
 Neurinoma, neuroma, 1379-1380, 1380. *See also* Schwann cells
 Neurinomas, acoustic
 clinical manifestations of, 1380, 1382f
 neurinoma overview and, 1379, 1380
 Neuritis, vestibular. *See* Infection, acute unilateral vestibulopathy
 Neuro-endocrine-enteric axis, 9
 Neuroarthropathy, 1294. *See also* Charcot's disease
 Neuroblastoma, childhood cancers and, 390
 Neurocardiogenic syncope, hypotension and, 523
 Neurocytokines, CNS activation of, 253
 Neuroendocrine dysfunction, chronic fatigue syndrome and, 275
 obesity and, 34
 Neuroendocrine stress response, disease resistance and, 456-458
 Neuroendocrine theory of aging, 24
 Neurofibrillary tangles
 aging central nervous system and, 1342
 Alzheimer's disease pathogenesis and, 1413, 1415f
 Neurofibromas, benign soft tissue tumors and, 1223
 Neurofibromatosis. *See* von Recklinghausen's disease
 Neurogastroenterology, clinical gastroenterology and, 828
 Neurogenesis, neuron regeneration of, 227
 Neurogenic bladder disorders
 classification of, 954
 implications for therapist, 957
 medical management of, 956
 overview of, 954
 pathogenesis of, 955-956
 Neurogenic hypotension, fibromyalgia and, 295
 Neurogenic sarcoma, malignant schwannomas and, 1223
 Neurohormonal axis, 46
 Neurohypophysis. *See* Posterior pituitary lobes
 Neuroimmunology, study of, 252
 Neuroinflammation, Parkinson's disease pathogenesis and, 1439
 Neurologic symptoms
 hepatic disease signs and, 882
 toxic exposure and, 135
 Neuroma
 acoustic, Schwann cell tumor and, 1587
 Morton's
 definition and etiology of, 1616
 interdigital perineural fibroma (IPF), 1616
 medical management of, 1616-1617
 pathogenesis of, 1616, 1616f
 Neuromuscular disorders
 congenital myopathy and, 1140-1144
 muscular dystrophies and, 1130-1140
 Neuromuscular irritability, electrolyte imbalances and, 190
 Neuromuscular symptoms, hypothyroidism and, 470

- Neuromusculoskeletal diseases, AIDS and, 263
 Neuromusculoskeletal disorder, diffuse scleroderma disease atrophy and, 429
 Neuron, lower motor (LMN) involvement, Bell's palsy and, 1610
 Neurons autonomic nervous system and, 1340-1341
 central nervous system and, 1319-1321, 1322
 damage from submersion and, 787
 glial cells and, 1370
 midbrain dopamine, Parkinson's disease and, 1437
 motor, amyotrophic lateral sclerosis and, 1403, 1404
 preganglionic sympathetic, autonomic nervous system and, 1340
 Neuropathic arthropathy. *See also* Charcot's disease; Neuroarthropathy foot deformity, 496
 Neuropathic ulcer, 443, 445, 510-511
 Neuropathies, metabolic alcoholic neuropathy and, 1620-1621
 anemia and, 1621
 chronic renal failure and, 1621
 diabetic neuropathy and, 1617-1620
 Neuropathy acute motor axonal (AMAN), 1622
 acute sensory, 1618-1619
 aging, factors of, 1597
 alcoholic, 1620-1621
 autonomic, 1619, 1619b
 chemotherapeutic agents and, 176, 178
 chronic sensorimotor, 1619
 classification of, 1599, 1599t
 diabetic (DN). *See also* Diabetes mellitus clinical manifestations of, 1618b, 1618-1620 definition of, 1617 incidence of, 1618
 diabetic bladder, voiding dysfunction and, 956
 diabetic neuropathy and, 1618
 dystal motor symptoms and, 1601
 focal, mononeuropathy, 1619
 generalized symmetric acute sensory neuropathy, 1618-1619
 autonomic neuropathy, 1619
 chronic sensorimotor neuropathy, 1619
 hereditary, 1601-1604
 hereditary motor and sensory, Charcot-Marie-Tooth disease and, 1602
 hyperglycemic, 1618
 lead, 1629-1630, 1630t
 paraneoplastic cancer-induced, 1628, 1629t
 rapidly reversible, hyperglycemic neuropathy, 1618
 systemic sclerosis and, 429
 vasculitic, symptomatic presentation of, 1628
 Neuropeptides, 9
 CNS amines and, 1325
 systemic sclerosis skin and, 429
 Neuroprotection, ischemic stroke prophylaxis and, 1463
 Neuropsychiatric manifestations, 574, 574b
 Neuropsychologic dysfunction, traumatic brain injury and, 1493
 Neurosarcoma, malignant schwannomas and, 1124, 1223
 Neurotmesis, 1598f, 1617 nerve injury classification and, 1597-1598, 1598f
 Neurotoxicity, environmental hazards and, 134-135, 137
 Neurotransmission, CNS pathogenesis and, 1323f, 1323-1324, 1324f
 Neurotransmitter 5-hydroxytryptamine (5-HT). *See* Serotonin
 Neurotransmitters, 9 depression and, 112 gaseous, nitric oxide, carbon monoxide and, 1325-1326 serotonin and, 118
 Neurotrophic factor, brain-derived (BDNF), epilepsy pathogenesis and, 1535
 Neurotubules, basement membrane and, 230
 Neutralceutical complementary or alternative therapy and, 1255 osteoarthritis implications and, 1256
 Neutropenia, 692, 737 absolute neutrophil count and, 177 white blood cell test and, 1651
 Neutrophilia, 692, 1651
 Neutrophils. *See also* Phagocytosis; Polymorphonuclear leukocyte exercise and, 253 interleukin-1 and, 223 leukocyte accumulation and, 220, 220f, 690 phagocytosis and, 225, 225f, 226f polymorphonuclear cells (PMNs) and, 244, 1651
 Nevi (moles), benign tumors and, 410
New England Journal of Medicine (Edmonton protocol), pancreas transplantation and, 1094
 New-onset angina anginal pain and, 548, 548b
 NHANES (National Health and Nutrition Examination Survey) obesity and, 33 race/ethnicity and, 21
 NHL. *See* Non-Hodgkin's lymphoma
 Nicotine addiction and, 80, 809 coronary artery disease and, 530 delayed bone healing and, 1301
 Nicotine (*N*-nitrosamines), causal agent of lung cancer and, 810
 Nidus arteriovenous malformations and, 636 osteoid tissue nest, 1210, 1210f
 Night sweats, menopause symptoms and, 987
 Nightstick fracture, fracture types and definitions of, 1295b
 Nighttime eating disorder (NED), 91
 NIH (National Institutes of Health) chemotherapy exercise guidelines and, 386 chest syndrome and, 733 ELITE estradiol study and, 988 obesity and, 32 PROMIS and, 23b prostatitis classification and, 964 pulmonary hypertension diagnosis and, 818
 NIOSH (National Institute for Occupational Safety and Health) latex alert and, 148 regulation of health care and, 121
 Nitric oxide (NO) blood vessel lining and, 535 cellular dysfunction and, 1320 cystic fibrosis and, 790 osteoarthritis pathogenesis and, 1252
 portal hypertension and, 887 sickle cell disease and, 734-735
 Nitrogen dioxide, air pollution and, 124
 Nitroglycerin, angina treatment and, 550, 551-552
 Nitrosamines, tobacco carcinogen and, 838
 Nitrous oxide (N₂O) pulmonary hypertension treatment and, 819 sickle cell disease and, 737
 NK (natural killer cells). *See* natural kill cells
 NMDA (N-methyl-D-aspartate receptor) Alzheimer's disease pathogenesis and, 1414
 CNS amino acids and, 1325 epilepsy pathogenesis and, 1534
 No Evidence of Disease (NED), cancer treatment and, 376
 Nociceptive information transmission and. *See also* Substance P soft tissue techniques and, 295 substance P, 295
 Nocturia BPH manifestation and, 967 fatigue and, 571
 Nocturnal angina, anginal pain and, 548, 548b
 Nodular melanoma, type of melanoma, 415, 415f
 Nodular sclerosing Hodgkin's lymphoma, clinical manifestations of, 702
 Nodule, rheumatoid, 1267-1268, 1268f. *See also* Rheumatoid arthritis (RA)
 Nodules, subcutaneous chronic inflammation and, 226
 Non-Hodgkin's lymphoma (NHL) etiology and risk factors of, 707 hematopoietic cell transplantation and, 1061 implications for therapist, 706, 709 medical management of, 708-709 mustine and, 173 overview and incidence of, 706-707
 Non-insulin dependent diabetes mellitus (NIDDM). *See* Diabetes mellitus, type 2
 Non-small cell lung cancer (NSCLC). *See also* Lung cancer characteristics of, 809t manifestation of, 812 squamous cell carcinoma and, 811 staging of, 813 treatment of, 814
 Nonionizing radiation, 131
 Nonmotor symptoms, parkinsonism clinical manifestations and, 1442
 Nonneural dysfunction, treatment of, 1348
 Nonsteroidal antiinflammatory drugs (NSAIDs). *See* NSAIDs
 Norepinephrine depression and, 112 hypothalamus neurotransmitter and, 1325 memory problems and, 1338
 Normocytic, normal RBCs, 688
 Normovolemic hemodilution bloodless medicine and, 683 cell salvage techniques and, 683
 Norton Scale, ulcer risk and, 447, 447t
 Nosocomial infections *C. difficile* and hospitalization and, 303-304 precautions and guidelines for, 299b, 311, 314b staphylococci bacteria and, 316 transmission of, 306, 312t VZV transmission and, 335
 Novacor, pulsatile support ventricular assistive device and, 1084, 1084f
 Noxious gases, environmental diseases and, 786-787
 NPM gene mutation, acute myelogenous leukemia and, 696
 NSAIDs (Nonsteroidal antiinflammatory drugs), 156t, 156-158 acute gastritis and, 841 blood pressure and, 554, 557 cancer prevention and, 369 congestive heart failure and, 576 endometriosis treatment and, 997 implications for therapist, 158 migraine treatment and, 1557 platelet function and, 729 renal syndromes and, 946 rheumatoid arthritis pharmacotherapy and, 1270-1271 side effects of, 157t
 systemic lupus erythematosus and, 287
 systemic sclerosis treatment and, 430
 NSCLC. *See* Non-small cell lung cancer
 NTD (neural tube defect). *See* Neural tube defects, congenital (NTDs)
 Nuclei, vestibular, vestibular system and, 1570
 Nucleic acids DNA and, 13, 13f HIV pathogenesis and, 260
 Nucleus pulposus, degenerative intervertebral disk etiology and, 1259
 Nurses' Health Study, hormone therapy and, 988
 Nutraceuticals, 155
 Nutrition. *See also* Diet breast cancer pathogenesis and, 1020 cancer and, 355, 811 chronic disease and, 32 cystic fibrosis and, 796 osteoporosis risk factor and, 1160-1161 pressure sores and, 445 pulmonary tuberculosis and, 757
 Nutritional status, immune function and, 251
 Nystagmography, video (VNG), vestibular disorder diagnosis and, 1573-1574
 Nystagmus Dix-Hallpike maneuver and, 1578, 1579 gaze-evoked anterior inferior cerebellar artery syndrome and, 1458 coordinated movement disorders and, 1330 multiple sclerosis manifestations and, 1429 optokinetic, vestibular disorder diagnosis and, 1574 vestibular dysfunction and, 1572, 1575f
 O
 O₂, arterial blood gas and, 1658-1659
 OA (Osteoarthritis), 35, 38b
 Obesity abdominal, metabolic risk factor and, 534 adipose cells and, 485 asthma and, 769 breast cancer incidence, risk factor and, 1018-1019 cancer and, 485 complications of, 35, 35b, 39b coronary artery disease and, 530 diabetes mellitus type 2 and, 490 endometrial cancer and, 999 esophageal adenocarcinoma, 838 exercise and, 36, 38b, 39, 39b female reproductive system and, 994 gallstone disease and, 919

Obesity (Continued)
 hypertension and, 556
 implications for therapist, 37-39
 inflammation and, 487
 life expectancy and, 25
 lipedema and, 676
 lymphedema risk factor and, 661
 medical management of, 35-37
 prevalence of, 33t
 risk factors for, 34b
 sleep-disordered breathing and, 777
 stroke risk factor and, 1452
Obliterative arteriosclerosis. *See* Arteriosclerosis obliterans
Observation, primary tumor treatment and, 1206
Obsessive-Compulsive Disorder (OCD), 96
 emotional instability and, 1337
Obstruction
 congenital conditions
 Meckel's diverticulum and, 875
 stenosis, atresia and, 875
 functional intestinal
 adynamic or paralytic ileus and, 874
 Ogilvie's syndrome and, 874-875
 mechanical
 adhesion and, 869
 hernia and, 870-874
 intussusception and, 870
 organic obstructive disease and, 869
 volvulus and, 870
 urinary, renal calculi and, 937, 937f
Obstructive disease (gastrointestinal)
 causes of, 868, 869t
 functional obstruction, 874-875
 mechanical obstruction, 869-874
Obstructive disease, organic,
 implications for therapist, 869
Obstructive diseases (pulmonary)
 asthma, 768-774
 bronchiectasis, 774-776
 bronchiolitis, 776-777
 chest wall trauma (lung injury), 782-783
 chronic bronchitis, 764-765
 chronic obstructive pulmonary disease (COPD), 759-764
 emphysema, 765-768
 pulmonary fibrosis, 780-781
 restrictive lung disease, 779-780
 sleep disorder breathing, 777-779
 systemic sclerosis lung disease, 781
Obstructive sleep apnea (OSA)
 continuous positive airway pressure and, 778
 sleep-disordered breathing and, 777
Obstructive sleep apnea-hypopnea syndrome (OSAHS), spinal cord injury sleep disorder and, 1409
Obturator muscle test
 appendicitis and, 878
 Crohn's disease and, 857f
 hernia screening and, 873
Occlusion, embolic, ischemic stroke and, 1453
Occlusive disease, cerebrovascular, arterial occlusive disease and, 616
Occlusive thrombus
 definition of, 625-626
 healing of, 626
Occupational
 burns, 143
 infections, 145
 medicine, 121
 physical activity, 30
 skin disorders, 145
Occupational asthma. *See* Asthma; Work-related asthma
Occupational cancer, 144-145
 bladder cancer risks and, 951
 lung cancer risk factor and, 810

Occupational disease, 138. *See also* Environmental disease
 pneumoconiosis and, 783
Occupational injury
 Healthy People 2010, 138
 implications for therapist, 141-143
 liver injury and, 140-141, 912
 risk factors for, 139b
Occupational pulmonary disease, classification of chemical agents of, 144
Occupational Safety and Health Administration (OSHA). *See* OSHA
Ocular mobility, abnormal. *See* Abnormal ocular mobility
Ocular system (visual), fall prevention and, 1307
Oculomotor nerve, 1486-1487
 traumatic brain injury and, 1486
Offloading, diabetic ulcer treatment and, 501
Ogilvie's syndrome, functional intestinal obstruction and, 874-875
OHDs. *See* Oral hypoglycemic drugs
Older adults
 adverse drug reaction and, 152, 155b
 appendicitis and, 876
 asthma diagnosis and, 771
 circulating lymphocytes and, 248
 constipation and, 829
 gastroesophageal reflux disorder and, 835, 839
 headache and, 1564
 hemophilia therapy and, 727
 hypokalemia and, 188
 hyponatremia and, 927
 infectious diseases and, 301, 306, 316
 influenza and, 251
 NSAIDs and, 157
 skin care and, 396
 tubercle bacillus and, 754
 urinary tract infection and, 928
Olecranon bursal infection, bursae infection manifestation and, 1197
Olfactory function, parkinsonism clinical manifestations and, 1442
Olfactory nerve, traumatic brain injury and, 1486
Oligoarthritis. *See* Juvenile idiopathic arthritis, pauciarticular (PaJIA)
Oligodendrocytes
 glial cells and, 1372
 macroglia nerve cell subtype and, 1320, 1321, 1321f
Oligodendroglioma, 1376
 gliomas overview and, 1372
 incidence of, 1370
Omega-3 fatty acids, stroke risk reduction and, 1452
Omentectomy, ovarian cancer treatment and, 1009
Oncogenes
 genetic DNA and, 358
 gliomas etiology and, 1372
 soft tissue sarcomas and, 1225
Oncogenesis, theory of, 358
Oncologic emergencies, therapist challenges and, 380
Oncology
 clinical manifestations of, 363-368
 definitions of, 348-349
 etiology of, 352-353
 exercise and, 1649-1651
 implications for therapist, 377-385
 incidence of, 351-352
 invasion and metastases of, 359-363
 medical management of, 368-377
 neoplasm classification of, 349-351
 pathogenesis of, 357-359
Oncology (Continued)
 preventive, 10
 risk factors of, 353b, 353-357
Oncotic pressure, lung fluid movement and, 801
Oncotype DX, breast cancer gene profiling and, 1027
One to Ten Analogue Scale, fatigue measurement tools and, 1392
One-Legged Stance Test, 1304
Oophorectomy, ovarian cancer prevention and, 1008, 1009
Open biopsy, cancer diagnosis and, 369
Open lung maneuver, acute respiratory distress syndrome and, 804
Operant conditioning
 associate behavior learning and, 1351
 behavior and, 48
Operative complications, obesity and, 38b
OPG (osteoprotegerin). *See* Osteoprotegerin (OPG)
Opioid rotation, cancer pain control and, 365
OPO (organ procurement organization). *See* Organ procurement organization (OPO)
Opportunist pathogens, immunocompromise and, 305
Opsonization
 complement system and, 224
 phagocytosis and, 225, 225f, 226f
Optic neuritis, multiple sclerosis manifestations and, 1428
Optic system, toxicity and, 134t
Oral appliances, sleep disorder treatment and, 778
Oral bile acid therapy, cystic fibrosis-associated liver disease and, 794
Oral contraceptives, heart attack or stroke and, 527-528
Oral hypoglycemic drugs (OHDs)
 diabetes mellitus type 2 treatment and, 500
Oral renin inhibitors, antihypertensive medication and, 556
OraQuick Rapid HIV-1, HIV testing and, 268
Orchiectomy, radical, testicular cancer treatment and, 981
Orchitis, 978-979
Organ candidates
 criteria for, 1042-1043, 1043b, 1044b, 1045t
 donor candidate guidelines for, 1041b, 1041-1042
 pretransplant evaluation of, 1044, 1045t
Organ donation
 overview of, 1040-1041
 recovery of, 1042
 sources of, 1041
Organ Donation and Recovery Improvement Act (ODRIA, Public Law 108-216), 1039
Organ Donation Breakthrough Collaborative, 1040
Organ procurement and allocation
 criteria for organ candidates and, 1042-1044
 organ distribution and, 1039-1040
 organ donation and, 1040-1042
Organ Procurement and Transplant Network (OPTN), 1039
Organ procurement organization (OPO), organ distribution and, 1039-1040, 1042
Organ repair. *See also* Tissue repair; Trauma
 digestive tract, 230
 implications for therapist, 238-240
 lung, 230
Organ retransplantation, 1038-1039
Organ transplantation
 bladder transplantation, 1069
 exercise and sports
 guidelines for, 1057-1058, 1058t
 limitations of, 1059
 overview of, 1056
 posttransplant activity and, 1056-1057
 pretransplant activity and, 1055
 heart transplantation, 1074-1086
 intestine transplantation, 1096
 kidney transplantation, 1066-1069
 liver transplantation, 1070-1074
 lung transplantation, 1087-1094
 ovary transplantation, 1097
 pancreas transplantation, 1094-1096
 skin transplantation, 1096-1097
Organic mood disorder, 110
Organizational factors, ecologic model and, 18
Organophosphates, peripheral nervous system toxins and, 1630
Orthopnea
 dyspnea and, 520, 743
 pulmonary edema and, 802
Orthoses
 ankle-foot (AFO)
 manual ROM exercise and, 1528, 1529
 orthoses and, 1529f
 supramalleolar (SMO), cerebral palsy orthoses and, 1529
Orthostasis, physiologic stress and, 577
Orthostatic hypotension
 angina medication side-effects and, 552
 autonomic nervous dysfunction and, 576
 causes of, 576, 576b
 chronic fatigue syndrome and, 277
 clinical manifestations of, 577
 definition and overview, 576
 implications for therapist, 578
 postural hypotension assessment and, 578, 578f
Orthotic, dynamic ankle-foot (DAFO), cerebral palsy orthoses and, 1529
Ortolani maneuvers, hip dislocation and, 1127f, 1128
OSA (obstructive sleep apnea). *See* Obstructive sleep apnea
Oscillating plate therapy. *See* Vibration, whole body
Osgood-Schlatter disease
 etiologic factors and pathogenesis of, 1316
 medical management of, 1316f, 1316-1317
 overview of, 1315-1316
OSHA (Occupational Safety and Health Administration)
 asbestos regulation and, 785
 environmental health standards of, 122
 ergonomic guidelines of, 142
 latex in the workplace, 148
 mandated gloves and, 309
Osmotic pressure, pulmonary edema pathogenesis and, 801
Ossification
 heterotopic, traumatic brain injury and, 1487
 neurogenic heterotopic (NHO), spinal cord injuries and, 1238
Osteitis deformans. *See* Paget's disease
Osteo-protegerin (OPG)
 osteoporosis treatment and, 1168
 rheumatoid arthritis treatment and, 1272
Osteoarthritis (OA)
 articular cartilage and, 1103
 clinical manifestations of, 1252-1253

- Osteoarthritis (OA) (*Continued*)
 etiologic and risk factors of, 1251
 exercise, 1254-55
 aquatic physical therapy and, 1258
 education and, 1257-1258
 general concepts of, 1257
 specific exercise training and, 1258
 exercise and, 1254-55, 1257-1258
 implications for therapist, 1256-1258
 incidence of, 1250-1251
 medical management of, 1253f, 1253-1256, 1254b, 1254f
 overview of, 1250
 pathogenesis of, 1251-1252, 1252f
 tendon injury and, 234
- Osteoarthritis of the Basilar thumb joint, menopause and, 35, 991
- Osteoarthritis, exercise and, 1257-1258
- Osteoarthropathy, hypertrophic pulmonary
 cystic fibrosis and, 792
 NSCLC and, 812
- Osteoblastic sclerotic phase, Paget's disease pathogenesis and, 1176
- Osteoblastoma
 implications for therapist, 1212
 medical management of, 1206f, 1211-1212
 overview of, 1211, 1211f
- Osteoblasts, bone matrix and, 233
- Osteocartilaginous exostosis. *See also* Osteochondroma
- Osteochondritis dissecans, 1310. *See also* Legg-Calvé-Perthes disease
- Osteochondritis, *P. aeruginosa* and, 325
- Osteochondroma
 benign cartilaginous tumors and, 1227f, 1227-1228, 1228f
 pedunculated, osteochondroma diagnosis and, 1227, 1228f
 sessile, osteochondroma diagnosis and, 1227, 1228f
- Osteochondroses, 1310
- Osteoclasts (bonemacrophages)
 bone tissue and, 362
 fracture healing and, 232
 Paget's disease pathogenesis and, 1176
- Osteocytes
 bone fracture pathogenesis and, 1297
 bone remodeling and, 233
- Osteodystrophy
 hepatic, disease symptoms and, 882
 renal
 chronic kidney disease and, 943
 prevention of, 945
- Osteogenesis imperfecta (OI)
 clinical manifestations of, 1151-1152, 1152f
 etiologic factors and pathogenesis of, 1150-1151
 implications for therapist, 1153-1154
 medical management of, 1152-1153
 overview and incidence of, 1150, 1151t
- Osteogenic sarcoma. *See also* Osteosarcoma
 bone tumors and, 362
- Osteoid osteoma
 implications for therapist, 1210
 overview, incidence, and etiologic factors of, 1209, 1210f
 pathogenesis of, 1209-1210
- Osteomalacia
 definition of, 1173
 etiologic factors of, 1173-1174
 implications for therapist, 1176
 incidence and risk factors of, 1174b, 1174b
 medical management of, 1175
 pathogenesis of, 1174-1175f
- Osteomyelitis
 acute
 overview of, 1182
 treatment of, 1186
 acute hematogenous, incidence of, 1183
 chronic
 diagnosis of, 1185, 1185f
 incidence of, 1183
 overview of, 1182
 treatment of, 1186
 clinical manifestations of, 318, 1184-1185
 exogenous, etiologic factors and, 1183
 hematogenous, etiologic factors and, 1183
 implications for therapist, 1186-1187
 incidence of, 1183
 IV drug users and, 346
 medical management of, 1185-1186
 musculoskeletal system infection and, 1107
 overview of, 1182
 pathogenesis of, 1183-1184, 1184f
 risk factors of, 1183, 1183b
- Osteonecrosis
 anantiretroviral therapy and, 263
 etiological and risk factors of, 1310b, 1310-1311
 implications for therapist, 1312
 medical management of, 1311-1312
 overview and incidence of, 1310
 pathogenesis of, 1311, 1311f
- Osteonecrosis of the jaw (ONJ), oral bisphosphonate side effects and, 1179-1180
- Osteonectin
 bone marrow protein and, 972
 breast cancer metastases and, 1020
- Osteopenia
 disease, physical inactivity and, 1160
 incidence of, 1157
 liver transplantation and, 907
- Osteophyte
 Herberden's nodes and, 1252-1253
 osteoarthritis pathogenesis and, 1252, 1252f
- Osteoporosis
 bone fracture treatment and, 1299
 clinical manifestations of, 1163-1164
 complex regional pain syndrome and, 1635t
 cystic fibrosis and, 799
 definition and overview of, 1157
 diabetes mellitus and, 496
 exercise, 30, 1170-1172, 1172b
 National Osteoporosis Foundation and, 1169
 fracture and, 1163-1164
 gender and, 26
 hypertension and, 557
 IBD and, 857
 implications for therapist, 1169-1173
 incidence of, 1157-1159
 liver disease and, 882-883
 lung transplantation complications and, 1089
 medical management of, 1164b, 1164-1169, 1165t
 pathogenesis of, 1161-1163
 primary
 etiologic factors of, 1159
 overview of, 1157
 risk factors of, 1158b, 1159b, 1159-1161
 sarcoidosis calcium metabolism and, 808
 secondary
 etiologic factors of, 1159
 overview of, 1157
 treatment of, 1167
 steroids and, 162
- Osteoporosis circumscripta cranii, late stage Paget's disease and, 1180
- Osteoprotegerin (OPG), rheumatoid arthritis pathogenesis and, 1266
- Osteosarcoma
 clinical manifestations of, 1213, 1213f
 implications for therapist, 1216-1217, 1217f
 medical management of, 1213f, 1213-1216, 1214f
 overview of, 1212
 pathogenesis of, 1212-1213
- Osteotomy
 femoral, Legg-Calvé-Perthes disease and, 1315
 hemophilia joint treatment and, 727
 pelvic, Legg-Calvé-Perthes disease and, 1315
- Otitis, malignant external, 1592
- Otolith
 VEMP and, 1575-1576
 vestibular system etiology and, 1567, 1570f, 1571f
- Ototoxicity
 etiologic and risk factors of, 1585-1586
 implications for therapist, 1586
 medical management of, 1586
 overview of, 1585
- Ottawa Panel
 rheumatoid arthritis modalities and, 1276
 rheumatoid arthritis rehabilitation goals and, 1273
- Outfalls, water pollution and, 125
- Ovarian disorder
 cancer and, 1007-1009
 cystic disease and, 1005-1007
 varices and, 1009-1010
- Ovarian ablation, breast cancer treatment and, 1029
- Ovarian cancer
 etiology and risk factors of, 1007b, 1007-1008
 implications for therapist, 1009
 medical management of, 1008-1009
 overview of, 1007
- Ovarian cystic disease
 implications for therapist, 1007
 medical management of, 1006-1007
 overview of, 1005
- Ovarian varices, 1010, 1011f
- Ovaries, hormone secreting endocrine glands, 456
- Ovary transplantation, 1097
- Over-the-counter drugs (OTC)
 adverse drug reaction and, 155
 electrolyte imbalances and, 187
 NSAIDs and, 156, 156t
- Overlap syndrome, mixed connective tissue disease and, 1240
- Ovulation, ovarian cancer pathogenesis and, 1008
- Oxalate, renal stone formation and, 937
- Oxidation
 amyotrophic lateral sclerosis and, 1403
 cellular injury and, 202f
 free radicals and, 516
 skin and, 397
- Oxidative stress
 alcohol and, 904
 ALS bioassay identification and, 1408
 cellular dysfunction and, 1320
 coronary artery disease and, 531-532
 exercise and, 202, 203
 meningitis etiology and, 1353
- Parkinson's disease pathogenesis and, 1439
- Systemic sclerosis pathogenesis and, 781
- Oximetry, pulse, 1658, 1678-1679
- Oxygen
 arterial blood gas and, 1658-1659
 pulmonary edema treatment and, 802
 supplemental, 1679
- Oxygen metabolites. *See also* Free radicals
 asthma treatment and, 772
- Oxygen toxicity, 202
- Oxygen transport system
 deficits of, 746
 systemic disease and, 742
- Oxygenation, extracorporeal membrane (ECMO), 1082
- Oxygenator
 intravascular, acute respiratory distress syndrome and, 804
 intravenous membrane, 1091, 1091f
- Oxytocin, 44
 posterior pituitary and, 453-454
- Ozone, air pollution and, 124
- P**
- p53 gene, tumor suppressor gene and, 358
- Pacemaker, arrhythmia monitoring and, 590-591, 593-594
- Pacemakers, arrhythmia and, 590-591
- PAD. *See* Peripheral arterial disease (PAD)
- Page's disease
 clinical manifestations of, 1177-1178, 1178b, 1179f, 1180f
 definition of, 1176
 exercise and, 1181
 implications for therapist, 1181
 medical management of, 1178-1180f
 pathogenesis of, 1176, 1177f
- Page's disease of the breast
 breast cancer subtype and, 1017, 1017f
- Paget's disease neurologic manifestation and, 1178, 1180f
- PAI-1, clot prevention and, 560, 564
- Pain, 441, 442t, 831. *See also* Chronic pain
 abdominal. *See* Abdominal pain
 acute, 56
 appendicitis and, 876f
 blunt chest trauma diagnosis and, 782
 bone metastases and, 362, 1230
 complex regional pain syndrome and, 1635t
 glial cells and, 291
 HIV syndromes and, 263-266, 273
 ischemic, 831. *See also* Ischemic pain
 metastatic tumors and, 1230-1231
 multiple sclerosis manifestations and, 1429
 pain
 metastatic tumors and, 1230-1231
 multiple sclerosis manifestations and, 1429
 myofacial, traumatic brain injury pain and, 1485
 neurogenic, spinal cord injury and, 1510-1511
 neuropathic, 135
 recommended treatment for, 365
 pancreatic carcinoma and, 917
 pancreatitis and, 914, 916
 perception of, 55-56
 primary tumor manifestation and, 1204
 prostate cancer and, 972, 977
 referred
 hyperalgesia and, 831
 patterns of, 832
 peptic ulcer disease and, 845
 renal stones and, 938
 reporting of, 107
 right upper quadrant, right ventricular failure and, 571

- Pain (Continued)**
- sickle cell disease and, 733, 733b, 739
 - traumatic brain injury and, 1484-1485
 - Pain (abdominal)**
 - biliary colic and, 920
 - GI symptoms and, 831
 - pancreatitis and, 913, 915
 - right ventricular failure and, 571
 - Pain (back)**
 - endometriosis and, 996
 - obesity and, 38b
 - sciatica and, 1608
 - scoliosis and, 1112
 - Pain (epigastric)**
 - gastric cancer and, 847
 - gastritis and, 842, 844
 - Pain (musculoskeletal)**
 - cystic fibrosis and, 792
 - obesity and, 38b
 - spinal cord injury and, 1505
 - Pain (pelvic), pelvic floor dysfunction and, 1011**
 - Pain syndrome, complex regional.** *See* Complex regional pain syndrome (CRPS)
 - Painful legs and moving toes, traumatic brain injury pain and, 1485**
 - Palliative care**
 - cancer treatment and, 377, 383
 - hospice care and, 384
 - Pallidotomy, surgical dystonia treatment and, 1421**
 - Palmar erythema, hepatic disease and, 882**
 - Palmar lesions, syphilis and, 345f**
 - Palpitations**
 - cardiovascular disease and, 519, 522
 - Palsy**
 - cerebral. *See* Cerebral palsy
 - cranial nerve, sarcoidosis symptoms and, 808
 - gaze, multiple sclerosis manifestations and, 1429
 - progressive bulbar, amyotrophic lateral sclerosis and, 1405, 1405f
 - progressive supranuclear, parkinsonian characteristics and, 1447
 - retroepicondylar. *See* Palsy, tardy ulnar
 - Saturday night, 86, 1615
 - sleep, 1615
 - tardy ulnar
 - anatomy of, 1610, 1611f
 - clinical manifestations of, 1611, 1611f
 - medical management of, 1611-1612
 - Pancoast's tumors, 812, 815**
 - Pancreas**
 - cystic fibrosis and, 790, 918
 - diabetes mellitus and, 488-502, 912
 - functions of, 881
 - hyperglycemia and, 513-515
 - insulin resistance syndrome and, 512-513
 - location and functions of, 454f, 487
 - pancreatic cancer and, 916-918
 - pancreatitis and, 912-915
 - Pancreas islet beta-cell transplantation, pancreas transplantation and, 1094, 1095, 1096
 - Pancreas transplantation future trends of, 1095-1096
 - implications for therapist, 1096
 - indications of, 1094-1095
 - overview of, 1094
 - procedures for, 1095
 - Pancreatectomy, chronic pancreatitis treatment and, 916**
 - Pancreatic cancer**
 - implications for therapist, 883, 918
 - overview and incidence of, 916
 - Pancreatic elastase-1 (EL-1), pancreatic sufficiency diagnosis and, 792
 - Pancreaticoduodenectomy. *See* Whipple procedure
 - Pancreatitis**
 - acute
 - conditions associated with, 913b
 - implications for therapist, 914-915
 - incidence and etiology, 912
 - medical management of, 913-914
 - autoimmune chronic, 915
 - choledocholithiasis and, 922
 - chronic
 - implications for therapist, 916
 - medical management of, 915-916
 - pancreatic cancer and, 917
 - tissue, chronic destruction of, 915
 - Pancytopenia. *See also* Tests, blood**
 - chronic lymphocytic leukemia and, 700
 - Panels**
 - basic metabolic (BMP), 1639-1644, 1640t
 - comprehensive metabolic (CMP), 1639, 1644-1646
 - hepatic function, 1639, 1644-1646, 1645t
 - Panhypopituitarism. *See* Hypopituitarism**
 - Panic attacks. *See* Anxiety**
 - Panic disorder, 96**
 - Pannus**
 - rheumatoid arthritis pathogenesis and, 1265, 1265f
 - synovial membrane proliferation and, 1193-1194
 - PAP. *See* Pressure, pulmonary artery**
 - PAP (Papanicolaou smear)**
 - cervical cancer and, 1000, 1003
 - cervical cancer screening and, 1001, 1002t
 - Papanicolaou smear. *See* PAP (Papanicolaou smear)**
 - Papillary dermis, skin layers and, 392**
 - Papilloma, choroid plexus, 1380-1381**
 - Papillomas. *See* Human papillomavirus (HPV)**
 - Papillomata, lymph cysts and, 652f, 660**
 - Paracentesis, peritoneal fluid analysis and, 1667**
 - Paralysis, idiopathic facial. *See* Bell's palsy**
 - Parametritis, cellulitis and, 404**
 - Paraneoplastic acanthosis nigricans, gastric cancer and, 847f**
 - Paraneoplastic cerebellar degeneration (PCD), gynecological cancers and, 1008**
 - Paraneoplastic pemphigus syndrome, 451**
 - Paraneoplastic pemphigus, blisters and, 393**
 - Paraneoplastic stiff-person syndrome**
 - breast cancer and, 1021
 - small cell lung cancer and, 368
 - Paraneoplastic syndrome, 1365, 1399-1400**
 - acquired myopathy and, 1244
 - clinical manifestations of, 367-368
 - etiology of, 366-367
 - hormonal mechanisms of, 152
 - medical management of, 368
 - muscular and cutaneous malignancy of, 367
 - musculoskeletal manifestations of, 367, 367t
 - overview and definition of, 366
 - Paroxysmal atrial tachycardia (PAT). *See* Supraventricular tachycardia**
 - Paroxysmal supraventricular tachycardia (PSVT). *See* Supraventricular tachycardia**
 - Partial pressure of carbon dioxide (PCO_2), acid base measurement and, 192**
 - Particle radiation, cancer treatment modality and, 372**
 - Passive immunity, humoral immunity and, 242t, 248**
 - Passive-aggressive personality disorder, 100**
 - Patella alta, Osgood-Schlatter disease pathogenesis and, 1316**
 - Patent ductus arteriosus, acyanotic heart defect and, 587**
 - Pathogen**
 - definition of, 304
 - infectious, 7, 302
 - Pathogenesis**
 - obesity and, 34
 - of disease, 1
 - Pathogenic stretch, muscle injury and, 231**
 - Pathogenicity, disease induction and, 305**
 - Pathologic fracture**
 - definition of, 1201
 - metastatic tumor treatment and, 1232
 - overview of, 1294
 - Pathology**
 - definition of, 197
 - disablement model and, 4
 - implications for therapist, 152
 - medical model and, 17-18
 - micturition, types of, 955, 955b
 - spinal cord, multiple sclerosis diagnosis and, 1431, 1433f
 - systemic effects of, 150-152
 - Patient-controlled analgesia (PCA), cancer pain control and, 365**
 - Patient-Reported Outcome Measurement Information System (PROMIS), 23b**
 - Patient/Client Management Model, 1**
 - Pattern, stocking and glove, 1601f, 1620**
 - Pavementing, damaged capillary walls and, 1101**
 - Pavlik harness, developmental hip dysplasia treatment, 1128, 1128f**
 - PAWP. *See* Pressure, pulmonary artery wedge**
 - PBC. *See* Cirrhosis, primary biliary**
 - PBDEs (polybrominated diphenyl ethers), flame retardants and, 122-123**
 - PCOS. *See* Polycystic ovary syndrome (PCOS)**
 - PCR. *See* Polymerase chain reaction (PCR)**
 - PDC-E2 (Pyruvate dehydrogenase complex-E2), primary biliary cirrhosis and, 906**
 - PE. *See* Pulmonary embolism**
 - Peak flow meter**
 - asthma screening and, 1666
 - COPD monitoring and, 764
 - Peau d'orange (dimpling), breast cancer manifestations and, 1020, 1022f**
 - Pediculosis (lousiness) (*pediculus humanus*), implications for therapist, 409**
 - PEEP. *See* Positive end-expiratory pressure; Positive expiratory pressure (PEEP)**
 - Pelvic congestion syndrome, kidney transplantation complications and, 1067**
 - Pelvic floor disorder**
 - aging and, 927
 - arcus tendineus fascia pelvis (ATFP), 990
 - cystocele, rectocele and uterine prolapse and, 1013-1015
 - dysfunction
 - implications for therapist, 1012-1013
 - overview and etiological factors of, 1011, 1011b
 - pathogenesis of, 1011-1012
 - pelvic floor dysfunction and, 1011-1013
 - pelvic inflammatory disease and, 1010-1011
 - rehabilitation
 - constipation and, 831
 - cystocele, rectocele, uterine prolapse and, 1014

- Pelvic floor disorder (*Continued*)
 erectile dysfunction and, 984-985
 pelvic floor exercise and, 962
 prostate cancer and, 977
- Pelvic floor sling, pubococcygeal (PC) muscles, 1011, 1012f
- Pelvic inflammatory disease (PID)
 HIV and, 265
 infectious abdominal disorder and, 300
 medical management of, 1010-1011
 overview and incidence of, 1010
- Pelvic/sacral fracture, 1295-1296
- Pemphigus, blistering disease and, 451
- Penetrating missile injury, traumatic brain injury etiology and, 1478
- Penicillamine
 bronchiolitis and, 776
 treatment of systemic sclerosis and, 429
- Penile stress test, atherosclerosis and, 983
- Penis angina, erectile dysfunction and, 983
- People with Arthritis Can Exercise (PACE), National Arthritis Foundation and, 1275
- Pepsin (peptic), proteolytic enzyme and, 842
- Peptic ulcer disease
 definition and overview of, 842-843, 843f
 etiology and risk factors of, 843
 exercise and, 845
 implications for therapist, 845
 medical management of, 844-845
- Peptide, 9. *See also* Congestive heart failure
 atrial natriuretic (ANP), 1654
 B-type natriuretic, left ventricular dysfunction and, 527
 brain natriuretic (BNP), 1654
 cerebral spinal fluid and, 1667
 ednorphines and, 457
- Percent of heart rate reserve (%HRR),
 exercise intensity and, 507
- Percutaneous thermal ablation, renal cell carcinoma treatment and, 933
- Percutaneous transhepatic cholangiography, stone removal and, 923
- Percutaneous transluminal coronary angioplasty (PTCA)
 surgery and, 539, 539f, 543
 women and, 525
- Perfluorooctanoic acid (PFOA), environmental hazards of, 126
- Periarthritis
 diabetes mellitus and, 495
 endocrine system disease and, 460
 hyperthyroidism and, 467
- Pericardial effusion, blunt chest trauma and, 606
- Pericardial friction rub, pericarditis manifestations and, 606
- Pericardiocentesis, pericardial fluid analysis and, 1667
- Pericarditis
 causes of, 606, 606b
 collagen vascular disease and, 639
 implications for therapist, 607
- Pericardium disease, types of, 605
- Pericardium, description of, 520f, 605
- Periodontal disease, myocardial infarction and, 560
- Perilymphatic tissues, lymphedema vessels and, 653-654
- perilymph fistula manifestations and, Hennebert's sign, 1584
- Perimenopause, 986
- Perineurium
 aging peripheral nervous system and, 1596
 peripheral nervous system structure and, 1595
- Period of communicability, organism shed and, 302
- Periosteal, bone surface of, 232
- Periostitis, sunburst, Ewing's sarcoma and, 1220f
- Peripartum cardiomyopathy, 580
- Peripheral arterial disease (PAD)
 arterial tests and measurements of, 619-623
 clarification of, 610
- Peripheral arterioles, constriction control of, 554
- Peripheral artery disease
 exercise and, 623
 therapy, Cool laser revascularization for (CLI-Rpath), 502
- Peripheral cyanosis, 744
 arterial saturation and, 744
- Peripheral dysfunction
 aging peripheral nervous system and, 1596
 autonomic nervous system and, 1596
 pathogenesis and diagnosis of, 1599f, 1601
 signs and symptoms of, 1599-1601, 1600f, 1601f
- Peripheral edema
 cardiovascular disease and, 520-521, 523
 congestive heart failure and, 575
 cystic fibrosis exercise intolerance and, 803
- Peripheral hormone peptide YY (PYY), 34
- Peripheral nerves, repair of, 230
- Peripheral neuritis, pulmonary tuberculosis and, 757
- Peripheral neuropathy
 advanced HIV stages and, 263
 diabetes and, 495, 509
 rehabilitative therapy and, 272
 rheumatoid arthritis spine manifestations and, 1268
 vasculitic syndromes and, 615
- Peripheral vascular disease (PVD)
 claudication and, 521, 611
 erectile dysfunction and, 964
 implications for therapist, 635-636
 organization of, 610
- Peritoneal dialysis (PD), 945
 Continuous ambulatory Peritoneal dialysis (CAPD), 945
 Continuous cycling peritoneal dialysis (CCPD), 945
- Peritonitis, 878
 bacterial, 878
 biliary, cholangitis complications and, 923
 implications for therapist, 879
 secondary, classifications of, 878
- Perometer, lymphedema evaluation and, 665
- Persian Gulf illness (PGI), 149
- Persistent vegetative state (PVS)
 altered states of consciousness, 1333
 traumatic brain injury and, 1482
- Personality disorders, 75b, 100-101, 104
- Pert, Candace, 9
- Pes cavus
 Charcot-Marie-Tooth disease and, 1603, 1603f
 high arch deformity, 1602, 1603f
- Pessaries, urinary incontinence and, 960
- Pesticide, poisoning
 chronic lymphocytic leukemia and, 699
 food and, 126
- Pesticides, peripheral nervous system toxins and, 1630
- PET. *See* Positron emission tomography (PET)
- Petechia
 acute myelogenous leukemia and, 695
- Petechiae (*Continued*)
 endocarditis and and, 601
 signs of endocarditis and, 602
- Petrochemicals, xenobiotics and, 130
- Pettersson classification, hemophilic arthropathy and, 720, 720t
- Peutz-Jeghers syndrome, obstructive jaundice and, 925
- pH, arterial blood gas and, 1658-1659
- Phagocytes
 age and decreased function of, 250
 innate immunity and, 244-245
- Phagocytosis
 bacterial pneumonia and, 750
 biologic response to trauma and, 1101
 leukocytes and, 221, 224-225, 225f, 226f
 satellite cells and, 231
- Phagosome, phagocytosis and, 225
- Phalen's test, carpal tunnel syndrome and, 1605, 1608f
- Pharmaceuticals, OTC (over the counter), 56
- Pharmacotherapy
 cystic fibrosis and, 793, 793t
 osteoarthritis treatment and, 1255
- Phenylketonuria (PKU), metabolic neuronal disease and, 517
- Philadelphia chromosome (Ph), chronic myeloid leukemia and, 698
- PHN. *See* postherpetic neuralgia
- Phobia, social, somatoform dizziness and, 1589
- Photoangioplasty, atheromatous plaque and, 543
- Photodynamic therapy (PDT), basal cell carcinoma and, 413
- Photophobia, migraine without aura manifestation and, 1554
- Phrenic nerve damage, lung transplantation complications and, 1090
- Physeal arrest, premature, developmental hip dysplasia prognosis and, 1129
- Physical abuse
 definition of, 40
 elderly and, 42
 IPV and, 42
- Physical activity. *Also see* Exercise.
 aerobic capacity and, 30
 Alzheimer's disease and, 1417, 1418
 congestive heart failure prevention and, 572
 gallstone prevention and, 921
 implications for therapist, 32b
 multiple sclerosis and, 1436
 obesity and, 38b
 prevalence of, 31
- Physical disability, 7b
- Physical exercise and, Parkinson's disease risk factors and, 1438
- Physical fitness
 definition of, 29
 musculoskeletal performance and, 30
- Physical inactivity
 coronary artery disease and, 530
 obesity and, 33
 osteoporosis risk factor and, 1160
- Physical settings, ecologic model and, 18
- Physical stress theory, cell injury and, 201
- Physical therapists
 cancer treatment evaluation and, 379
 cautions for osteoporosis and, 1173
 developmental hip dysplasia and, 1129, 1129b
 lymphedema intervention and, 665-666
 musculoskeletal diseases summary and, 1200
- Physical therapists (*Continued*)
 roles of, 11b
 sarcopenia and, 1103
 scoliosis orthotics evaluation and, 1115
 sexual dysfunction management and, 994-995
 use of ventricular assistive devices and, 1086
- Physical therapy
 GBS treatment and, 1623
 modalities of, 239
 pelvic floor dysfunction and, 1012
 preoperative lung transplantation and, 1092
 prostate cancer and, 977
- Physical-environmental factors, behavior, 18
- Physiologic function
 modes of control and, 28b
 sex related, 25
 stress and, 48
- Physis (growth plate), growth cartilage injuries and, 1236
- Phytoestrogens, hormone replacement therapy and, 989
- Pica, lead and, 136
- Pick's disease, cognitive change dementia and, 1411
- Piedmont fracture, fracture types and definitions of, 1295b
- Pig, xenotransplantation and, 1045
- Pigment stones, gallstone type of, 919
- Pigmentary disorders, 450-451
- Pigmentation, Addison's disease and, 480
- Pinch-an-inch test
 appendicitis diagnosis and, 877, 877f
 diverticular disease and, 863, 877f
- Pinealoma, 1381-1382
- Piper Fatigue Scale, fatigue measurement tools and, 1392
- Pituitary
 anterior
 human growth hormone and, 454
 pituitary gland and, 456f, 461
 anterior lobe
 adenohypophysis, 458
 adenohypophysis and, 458
 gland
 anatomic change and, 458
 anterior lobe disorders of, 461-463
 posterior lobe disorders of, 464-465
 role of, 454f, 456f, 461
 posterior lobes
 hypothalamus and, 453
 pituitary gland and, 461
- Pituitary tumors, systemic effects of, 461
- PKD. *See* Kidney disease, polycystic (PKD)
- Plagioccephaly-torticollis
 deformation, torticollis clinical manifestation and, 1145, 1146f
- Planned obsolescence theory, aging and, 24
- Plant alkaloids, chemotherapeutic agents and, 174
- Plant fiber, hypersensitivity pneumonitis and, 786
- Plaque
 acute or chronic lesions of
 multiple sclerosis and, 1427, 1432f
 atherosclerotic, coronary artery disease and, 535, 535f
 pleural calcified, asbestos and, 784
- Plasma cell dyscrasias. *See also* Hematologic disorders
 multiple myeloma and, 1223
- Plasma cells, B lymphocytes and, 246
- Plasma colloidal osmotic pressure, Starling's Law and, 644

Plasma exchange (PE), GBS treatment and, 1623
 Plasma hydrostatic pressure, Starling's Law and, 644
 Plasma IL-6, exercise intensity and, 254
 Plasma protease system, chemical inflammatory mediators, 223-224
 Plasmacytomas, multiple myeloma manifestations and, 710
 Plasmalemma, cell injury and, 208
 Plasmapheresis
 GBS treatment and, 1623
 myasthenia gravis and, 1632
 Plasmin
 complement system and, 224
 pulmonary embolism treatment and, 817
 Plasminogen activator inhibitor (PAI-1), platelet release of, 536
 Plastic Surgery Advisory Panel, safety data evaluation and, 1191
 Platelet aggregation, age related changes of, 250
 Platelet Function Analyzer 100, von Willebrand's disease and, 717
 Platelet-activating factor (PAF), inflammation and, 221. *See also* Inflammation, chemical mediators of
 Platelet-derived growth factor (PDGF), tissue healing and, 213
 Platelets, 1648. *See also* Blood count, complete
 blood coagulation and, 223
 disorders of, 680
 function of, 729
 innate immune response and, 245
 Pleural effusion
 definition of, 825f, 825-826
 implications for therapist, 826-827
 medical management of, 826
 Pleural empyema, 827. *See also* Pleural effusion
 Pleural fibrosis, 827
 Pleural space disorders
 pleural effusion and, 825-827
 pleural empyema and, 827
 pleural fibrosis and, 827
 pleurisy and, 824-825
 pneumothorax and, 822-824
 Pleurisy
 definition and etiology of, 824
 implications for therapist, 825
 pathogenesis of, 825
 purulent (empyema), pus formation and, 825
 wet, pleural effusion and, 825, 825f
 Pleurocentesis, pleural fluid analysis and, 1667
 Pleurodesis, pneumothorax treatment and, 824
 PLISSIT model, depression and, 116
 PLWS. *See* Pulsed lavage with suction
 PMR (Progressive muscle relaxation), 50
 PNETs. *See* Tumors, primitive neuroectodermal (PNETs)
 Pneumococcal disease, immunization and, 319b, 322
 Pneumoconiosis
 implications for therapist, 785
 inorganic dust and, 783
 medical management of, 785
 risk factors of, 784
Pneumocystis carinii pneumonia (PCP)
 implications for therapist, 752
 progressive pneumonia and, 751
Pneumocystis trophozoite, sporozoan parasite and, 752
 Pneumocystis type I, lung repair and, 230
 Pneumonia
 aspiration, impaired anatomic defense and, 750

Pneumonia (Continued)
 bacterial, respiratory epithelium and, 750
 fungal
 fungi and, 750
 pneumonia treatment and, 751
 implications for therapist, 751
 medical management of, 750-751
 overview and etiology of, 749
 pneumonia objectives and, 751
 risk factors of, 749
 spinal cord injury deaths and, 1505-1506, 1513
 types of, 750
 viral, primary infection and, 750
 walking, 750
Pneumonia vaccine, *S. pneumoniae* treatment and, 751
 Pneumonitis, 758
 Pneumothorax
 definition of, 822, 823f
 implications for therapist, 824
 open, 822
 pathogenesis of, 745f, 822
 primary spontaneous (PSP)
 definition of, 822
 treatment of, 824
 secondary spontaneous (SSP)
 definition of, 822
 treatment of, 824
 tension, 824
 traumatic, 822
Pneumothroax, iatrogenic, transthoracic needle lung biopsy and, 822
 PNI. *See* Psychoneuroimmunology (PNI)
 Polio. *See also* Poliomyelitis
 amyotrophic lateral sclerosis and, 1403
 Poliomyelitis, overview of, 1625
 Pollution credits, air pollution and, 130
 Polyarteritis nodosa
 collagen vascular disease and, 640
 medical management, 612
 overview, 611
 Polyarthralgia, diffuse scleroderma and, 429
 Polybrominated diphenyl ethers (PBDEs), flame retardants and. *See* PBDEs
 Polychlorinated biphenyls (PCBs), non-Hodgkin's lymphoma environmental contaminant and, 707
 Polycystic kidney disease
 autosomal dominant
 (ADpolycystic kidney disease), renal cystic disease manifestation and, 935-936
 autosomal recessive (ARpolycystic kidney disease), renal cystic disease manifestation and, 935
 Polycystic ovary syndrome (PCOS) endometrial carcinoma risk factor, 999
 incidence of, 1006
 multiple ovarian cysts and, 1005
 pathogenesis of, 1006
 Polycythemia vera (PV)
 definition, overview, etiology and, 713-714
 implications for therapist, 714-715
 medical management and, 714
 Polydipsia, diabetes and, 492
 Polymer fume fever, occupational diseases and, 786-787
 Polymerase chain reaction (PCR)
 Ewing's sarcoma diagnosis and, 1220
 hepatitis B virus DNA and, 897
 herpes simplex encephalitis diagnosis and, 1359
 immunologic testing and, 1661
 meningitis diagnosis and, 1354
 treatment of *S. aureus* and, 318

Polymyalgia rheumatica (PMR)
 arteritis and, 612
 clinical manifestations of, 1241-1242
 implications for therapist, 1242
 medical management of, 1242
 overview of, 1241
 Polymyositis (PM)
 clinical manifestations of, 1196
 muscle effects of, 432
 type of myositis and, 1195, 1195b
 Polymyositis and dermatomyositis
 clinical manifestations of, 431-432
 definition and overview, 431, 431b
 implications for therapist, 161t, 395b, 433
 medical management of, 432-433
 Polyneuropathy
 critical illness (CIP), peripheral nerve illness and, 1245
 diabetic, 1617. *See also* Neuropathy, chronic sensorimotor
 malignant diseases, implications for therapist, 1629
 neuropathy classification and, 1599
 stocking and glove pattern of, 1601f
 Polynuclear aromatic hydrocarbons (PAHs), causal agent of lung cancer and, 810
 Polyp
 adenomatous
 biliary neoplasms and, 924
 colorectal cancer and, 863-865, 865f
 intestinal, 863
 pedunculated, 864, 865f
 Polyphenols, Alzheimer's disease treatment and, 1417
 Polyradiculitis, neuropathy classification and, 1599
 Polyradiculoneuropathy
 demyelinating (CIDP). *See* Guillain-Barré syndrome
 inflammatory demyelinating (AIDP). *See* Guillain-Barré syndrome
 Polysomnography, sleep apnea syndrome and, 778
 Polyvinyl chloride (PVC)
 environmental hazards of, 126
 Pons, intracerebral hemorrhage syndromes and, 1466
 Popliteal cyst. *See also* Baker cyst (popliteal cyst)
 benign soft tissue tumors and, 1223
 Porphyria cutanea tarda, dioxin and, 127f
 Porphyrias, 518
 Portal hypertension. *See* Hypertension, portal
 Portal of entry, pathogen host and, 305
 Portal of exit, parasite reservoir and, 305
 Portal vein bactremia, liver abscess and, 911
 Portosystemic encephalopathy. *See* hepatic encephalopathy
 Positioning
 cerebral palsy and, 1526-1527, 1528f
 Huntington's disease and, 1425
 intracranial surgery acute phase and, 1390
 lung transplantation care and, 1092
 muscular dystrophy treatment and, 1139
 torticollis treatment and, 1146
 Positive end-expiratory pressure (PEEP)
 airway clearance technique and, 795, 795f
 altered breathing patterns and, 745
 Positive end-expiratory pressure (PEEP) (Continued)
 blunt chest trauma treatment and, 782
 cor pulmonale and, 820
 Positron emission tomography (PET), 118
 breast cancer diagnosis and, 1024
 cardiac physiology and, 564
 CNS disorder diagnosis, 1346
 fluorodeoxyglucose (FDG-PET), 1384
 Hodgkin's lymphoma treatment and, 705
 Huntington's disease diagnosis of, 1424
 ischemic stroke diagnosis and, 1459-1460
 non-Hodgkin's lymphoma treatment and, 708
 primary brain tumor diagnosis and, 1384
 prostate cancer diagnosis and, 973-974
 thrombolytic therapy effects and, 1462-1463
 traumatic brain injury diagnosis and, 1489
 Post-polio syndrome
 clinical manifestations of, 1625, 1625f
 definition of, 1624-1625
 implications for therapist, 1625-1626
 medical management of, 1625
 menopause and, 993
 overview of, 1624
 Post-polio syndrome (PPS). *See* Poliomyelitis
 Postbreast therapy pain syndrome (PBTPS), breast cancer surgery and, 1032
 Posterior cerebral artery syndrome, ischemic stroke syndromes and, 1456-1457, 1457f
 Posterior cord syndrome, spinal cord injury syndrome and, 1503
 Posterior lobe disorders
 diabetes insipidus, 464
 Syndrome of inappropriate antidiuretic hormone secretion (SIADH), 464-465
 Postexposure prophylaxis
 bloodborne viral pathogens and, 326
 HIV use of, 267, 271-272, 327
 Postherpetic neuralgia (PHN)
 herpes zoster and, 404, 405
 medical management of, 334
 shingles and, 333, 333f
 Postherpetic pain, herpes zoster and, 404
 Postinfarction angina, anginal pain and, 548, 548b
 Postinfection syndrome, Lyme disease, 341
 Postmastectomy pain syndrome (PMPS), breast cancer surgery and, 1032
 Postoperative respiratory failure, 806. *See also* Acute respiratory distress syndrome (ARDS)
 Postphlebitic syndrome. *See* Chronic venous insufficiency
 Postprandial hypotension, postural hypotension and, 576
 Postradiation therapy, 172-173
 Posttransplant complications
 causes of death and, 1051f
 classification of, 1051
 gastrointestinal problems and, 1055-1056
 graft rejection and, 1052-1054
 graft-versus-host disease and, 1054-1055
 histocompatibility and, 1052
 ischemic reperfusion injury and, 1051-1052
 wound healing and, 1056
 Posttransplant lymphoproliferative disease (PTLD), 1077

Posttraumatic stress disorder (PTSD). *See* PTSD

Posttraumatic syndrome, headache and, clinical manifestations of, 1562-1563, 1563b

Posture

 kyphotic, liver transplantation outpatient care and, 1074

 parkinsonism clinical manifestations and, 1441, 1442f, 1442b

Posturing

 decerebrate, traumatic brain injury and, 1487

 decorticate, traumatic brain injury and, 1487

Posturography

 vestibulospinal reflex testing and, 1576

Potassium

 basic metabolic panel and, 1640

 cerebral spinal fluid and, 1667

 electrolyte imbalances and, 186t, 188t

 hypokalemia and, 189, 558

 implications for therapist and, 1638t, 1640-1641

 increased blood pressure and, 556

 molecular structure of, 732

 muscular activities and, 185

Potassium efflux, sickle cell disease and, 732

Potassium hydroxide (KOII), gram stain and, 1663

Potential spaces, fluid imbalance and, 183

Potential, vestibular-evoked myogenic (VEMP), otolith function testing and, 1575

Pott's disease

 extrapulmonary pulmonary tuberculosis and, 1198

 pulmonary tuberculosis and, 180, 757

Pott's fracture, fracture types and definitions of, 1295b

PPI (proton pump inhibitors). *See* Proton pump inhibitors (PPIs)

Prader-Willi syndrome, 34b

Prealbumin, pressure ulcers and, 445

Precancerous lesions, cancer and, 357

Precautions

 airborne infection isolation and, 1670-1671

 barrier, 1671-1672, 1672b

 historical perspective and, 1669

 preventive environment and, 1671

 protective environment and, 1671

 standard, 1670, 1670t

 therapist exposure and, 1671-1673

 infected worker guidelines and, 1671-1672

 transmission and, 1671

 transmission-based, 1670

 universal precautions and, 1669

Precollectors, lymphatic vessel system and, 643, 644, 645f

Predictive factors, 2

Prednisone, transplantation medications and, 1047, 1048f

Pregnancy

 appendicitis and, 877

 Bell's palsy and, 1609

 cardiac client and, 639

 ectopic

 implications for therapist, 1005

 overview of, 1004, 1004f

 gallstone formation and, 919. *See also* Intrahepatic cholestasis of pregnancy

 Hodgkin's lymphoma and, 703-706

 intracerebral hemorrhage risk factors and, 1465

 IPV and, 42

 RSV and, 777

 secondhand smoke exposure and, 787

 tubal. *See* Pregnancy, ectopic

Pregnancy mask (melasma). *See* Melasma

Preinfarction angina, anginal pain and, 548, 548b, 551

Premature ovarian failure, premature menopause and, 987

Premenstrual syndrome (PMS), thyroid gland and, 466

Prenatal diagnosis, DNA chip technology and, 12

Prescriptive exercise, beneficial role of, 11b

 psychologic benefits of, 11b

 valvular heart disease and, 599

Pressure

 cardiovascular, 1658, 1658t

 central venous (CVP), 1658

 non-Hodgkin's lymphoma chemotherapy and, 708

 pulmonary artery (PAP), 1658

 pulmonary artery wedge (PAWP), 1658

Pressure of arterial carbon dioxide (PaCO_2), chronic bronchitis and, 762, 765

Pressure ulcers

 etiology and risk of, 444-445, 446t, 447t

 implications for therapist, 449-450

 incidence of, 443-444

 medical management of, 447-449

 myelomeningocele and, 1119, 1120b

 prevention of, 448b, 449f

 sacral hollow and, 803

 staging of, 442-443, 443t, 443f, 444b, 445f

 treatment of, 448-449, 450f

 wounds of, 445, 447f

Prevalence, number of pressure ulcers and, 444

Preventive drug therapy. *See* Treatment of latent pulmonary tuberculosis infection

Preventive medicine, categories of, 10

Priapism, sickle cell disease and, 735

Primal adrenal insufficiency (Addison's disease)

 definition and overview of, 479

 fluid imbalance and, 192t, 193t, 481

 hypercortisolism and, 161t, 162t, 481

 implications for therapist, 480-481

 infections and, 299b, 481

 medical management of, 480

Primary (essential) hypertension

 etiology of, 553

 hypertensive vascular disease types of, 552

 risk factors of, 553, 554b

Primary bony spicules (hard callus), fracture healing and, 233

Primary brain tumor, therapist implications. *See also* Tumors, primary brain

 acute postoperative positioning and, 1390

 complications of intracranial surgery of, 1389-1390

 intervention preparation and, 1390, 1391t

 psychosocial impact and, 1392

 rehabilitation and, 1389, 1390-1393

 steroid effects and, 1392

Primary cardiac tumors. *See* Myocardial neoplasm

Primary cardiomyopathies, classifications of, 579, 580t

Primary demyelinating disorder, multiple sclerosis pathogenesis and, 1426

Primary gastric lymphoma, 845

Primary groups, social ecology and, 18

Primary hemostasis, definition of, 716

Primary hyperparathyroidism, parathyroid gland and, 475

Primary immunodeficiency, 255, 256f

Primary lesion

 skin and, 392

 treatment of, 418

Primary lymphedema (idiopathic)

 category of, 650

 causes of, 651, 651t

Primary prevention, 11b

Primary union, wound closure and, 228, 229f

Primary/Secondary gain, factitious disorder and, 99

Principle pathogens, defense systems and, 305

Prion disease

 definition of, 1362

 medical management of, 1363

Prion protein (PrPsc), prion disease and, 1362

Prions, infectious diseases and, 303

Probiotics

 irritable bowel syndrome and, 861

 malabsorption treatment and, 850

 urinary tract infection prevention and, 930

Procedural learning, movement repetition and, 1351

Prodromes, mood swings and, 115

Progesterone receptor-positive (PR+), hormonal sensitivity and, 1025

Progestin therapy, endometriosis treatment and, 999

Prognathism, jaw protrusion and, 461

Programmed-based, aging and, 24

Progressive muscle relaxation (PMR). *See* PMR

Progressive resistance exercise (PRE), COPD therapy and, 388b, 763

Progressive systemic sclerosis (PSS), 180, 426

Prolactin, effector hormone and, 453, 457-458

Proliferative phase, tendon healing and, 234

PROMIS (Patient-Reported Outcome Measurement Information System), 23b

PROMIS, rheumatoid arthritis study and, 1271

Prone position, acute respiratory distress syndrome and, 805-806

Prophylactic antibiotic therapy, infectious disease transmission and, 309

Proprioception, joint, aging and, 1103-1104

Proprioceptive system (somatosensory), sensory disturbances and, 1226

Prostaglandin

 bone metastasis and, 364

 inflammation mediator and, 221, 222f

 migraine headache and, 1554

 peptic ulcer etiology and, 843

Prostate cancer

 clinical manifestations of, 972

 exercise and, 978

 hormone refractory, chemotherapy and, 975

 hormone-resistant (HRPC), docetaxel chemotherapy and, 975

 implications for therapist, 976-978

 medical management of, 973-976, 978, 978b

 metastatic, prognosis of, 976

 organ-specific metastasis of, 972, 1229

 overview and incidence of, 970-971

Protein C and S. *See* Coagulation

Protein drugs, immunosuppressive agent and, 158

Protein mutation, aneurysms and, 608

Protein purified derivative (PPD). *See also* Tuberculin skin test

 tuberculin skin test and, 754, 756

Protein zero (P0), Charcot-Marie-Tooth (CMT) disease and, 1602

Proteins

 animal-derived matrix, transplantation bioethical considerations and,

 1049-1050

 phosphorylation of, 212

Proteoglycans

 aging articular cartilage and, 1103

 cartilage strength and, 235

Prostate cancer (*Continued*)

 pathogenesis of, 971-972

 risk factors of, 971, 971b

Prostate Cancer prevention Trial (PCPT), prostate cancer prevention and, 973

Prostate disorders

 benign prostatic hyperplasia and, 967-970

 prostate cancer and, 970-978

 prostatitis and, 964-967

Prostate-specific antigen (PSA)

 acute prostatitis and, 966

 BPH and, 968

 prostate cancer prevention and, 973

 tumor marker and, 371

Prostatitis

 acute bacterial

 prostatitis category I and, 964

 treatment of, 966

 acute chronic

 prostatitis category II and, 964-965

 chronic/chronic pelvic pain syndrome (CP/CPPS)

 etiology of, 965

 prostatitis category III, 965

 treatment of, 966

 nonbacterial. *See* Prostatitis, CP/CPPS

 noninflammatory, prostatitis category IIIB and, 965

Prostheses and implant infections, 339

 clinical manifestations of, 1189

 etiologic factors and pathogenesis of, 1188-1189

 implications for therapist, 1190-1191

 incidence of, 1188

 medical management of, 1189-1190

 overview of, 1187-1188

Protein

 ABCG5/G8 transporter, 920

 amyloid precursor (APP), Alzheimer's disease

 pathogenesis and, 1413

 ATT and, 766, 767

 bone morphogenetic (BMP), 1238

 C-reactive (CRP). *See also* Homocysteine (Hcy)

 atherosclerotic disease tests and, 1655-1656, 1656t

 implications for therapist, 1656

Protein 22, peripheral myelin (PMP22), Charcot-Marie-Tooth (CMT) disease and, 1602

Protein C and S. *See* Coagulation

Protein drugs, immunosuppressive agent and, 158

Protein mutation, aneurysms and, 608

Protein purified derivative (PPD). *See also* Tuberculin skin test

 tuberculin skin test and, 754, 756

Protein zero (P0), Charcot-Marie-

Tooth (CMT) disease and, 1602

Proteins

 animal-derived matrix, transplantation bioethical considerations and,

 1049-1050

 phosphorylation of, 212

Proteoglycans (Continued)
disk degeneration and, 238
tissue repair and, 209, 233, 235, 235f

Prothrombin time, 1653

Proton pump inhibitors (PPIs), GERD treatment and, 835-836, 836t

Protooncogenes. *See* oncogenes

Protozoa, infectious diseases and, 303

Pruritus
contact dermatitis and, 399-400, 400f
intrahepatic cholestasis of pregnancy and, 908
primary biliary cirrhosis and, 906
skin disease and, 392, 394, 394b, 395b

PSA (prostate-specific antigen). *See* Prostate-specific antigen (PSA)

PSA doubling time (PSADT),
hormone refractory prostate cancer and, 975

Pseudo-Cushing's syndrome, 482

Pseudobulbar palsy, amyotrophic lateral sclerosis and, 1404-1405, 1405f

Pseudodementia, 113

Pseudofracture, hepatic disease symptoms and, 882

Pseudogout
gout overview and, 1291
periarticular jointing structures and, 472

Pseudohypoparathyroidism,
hypocalcemia and, 478

Pseudomembranous enteritis, small intestine plaque and, 859

Pseudomonas aeruginosa
biofilm production and, 793
drug resistant bacteria and, 298
implications for therapist, 326
medical management of, 325
overview, 323

Pseudomonas infections (Pseudomonas aeruginosa), implications for therapist, 324

Pseudorosette formation, ependymoma and, 1376

Psoas abscess
hernia and, 873
intraabdominal infections and, 857

Psoriasis
definition and incidence of, 421, 421f
implications for therapist, 423
psoriatic arthritis and, 1288, 1289
psychologic considerations, 424
treatment of, 422-423

Psoriatic arthritis
clinical manifestations of, 1288, 1288f
implications for therapist, 1289
medical management of, 1288-1289, 1289b
overview and incidence of, 1288
psoriasis and, 422, 423

Psychogenic hearing disorder, 1590

Psychogenic illness, world events and, 55

Psychogenic pain disorder, 99, 101, 107

Psychogenic pain, stress and, 48

Psychoneuroimmunology (PNI)
cancer and, 357
gastrointestinal system and, 828
immune responses and, 110, 197
posttransplant psychoemotional stress, 1050
theory of, 9

Psychophysiological disorders, 97-105
implications for therapist, 103-105

Psychosocial Adjustment to Illness Scale, intervention measurement tools and, 1392

Psychosocial considerations
cardiac surgery and, 638
lymphedema and, 672b, 672-673

Psychosocial factors, asthma pathogenesis and, 770

Psychosocial theory, 8

Psychosocial therapy, depression and, 114

Psychosocial-spiritual well-being
depressed immune function and, 93b, 252
oncology/cancer and, 377

Psychotherapy
somatoform dizziness treatment and, 1591
traumatic brain injury rehabilitation and, 1492

Psychotic disorders, 75b

Psychotropic drugs, extrapyramidal effects and, 116

PTCA (percutaneous transluminal coronary angioplasty). *See* Percutaneous transluminal coronary angioplasty

PTH (parathyroid hormone). *See* Parathyroid hormone

PTLD. See Posttransplant lymphoproliferative disease (PTLD)

Ptosis, myasthenia gravis and, 1631

PTSD (posttraumatic stress disorder)
cardiac arrest and, 594
emotional instability and, 1335
heart transplantation and, 1077
Iraq War and, 149
pretransplant psychoemotional stress, 94-96, 1050
substance abuse and, 75
symptoms of, 95-96

Public policy, social ecology and, 18

Pubococcygeal (PC) muscles, pelvic floor dysfunction and, 1011, 1012f

Puerperal sepsis, 321

Pulmonary capillary wedge pressure (PCWP), acute respiratory distress syndrome and, 805

Pulmonary congestion
congestive heart failure and, 569
exercise and, 599

Pulmonary disease
altered breathing patterns and, 744t, 745
cystic fibrosis and, 791, 792b
implications for therapist, 745-746
signs and symptoms of, 742-746, 744t, 744b

Pulmonary edema. *See also* Pulmonary congestion
acute respiratory distress syndrome and, 803
definition and incidence of, 800
exercise and, 599
formation of, 801f
implications for therapist, 802-803
near drowning and, 788
pathogenesis of, 800-801, 800-802, 801f

Pulmonary embolism (PE). *See* Deep venous thrombosis (DVT)
cor pulmonale and, 821
deep venous thrombosis and, 626-627
definition and incidence of, 816
free floating thrombus and, 626
implications for therapist, 818
medical management of, 817-818

Pulmonary embolism, cor pulmonale and, 820

Pulmonary fibrosis. *See also* Idiopathic pulmonary fibrosis
definition and overview of, 780
implications for therapist, 780
Pulmonary function, testing of, 1664-1666, 1665t

Pulmonary heart disease. *See* cor pulmonale

Pulmonary hypertension (PH)
cor pulmonale and, 820
definition and incidence of, 818-819

Pulmonary hypertension (PH) (Continued)
implications for therapist, 820
medical management of, 819-820

Pulmonary hypertension, primary (PPH), 818-819

Pulmonary infection, lung transplantation complications and, 1090

Pulmonary parenchyma, environmental and occupational disease and, 783

Pulmonary radiation fibrosis, 169

Pulmonary rehabilitation
apnea and, 779
COPD and, 762

Pulmonary system, aging and implications for therapist, 748-749
pulmonary complications and, 748

Pulmonary toxicity, chemotherapy and, 176
transplantation and, 1064

pulmonary tuberculosis
extrapulmonary, HIV and, 757
miliary, 754
implications for therapist, 756
pulmonary tuberculosis prevention and, 755, 757b
multi-drug resistant, 753
pulmonary tuberculosis treatment and, 756

Pulmonary tuberculosis (TB), 180
definition of, 752
implications for therapist, 756
pathogenesis of, 754
prevention of, 755, 757b
reactivated, secondary reinfection and, 752
risk factors of, 753
silicosis and, 785

pulmonary tuberculosis bacterium inhalation of, 758

pulmonary tuberculosis reactor, positive pulmonary tuberculosis skin test and, 758

Pulmonary vasculature disorder
collagen vascular disease, 821-822
cor pulmonale, 820-821
pulmonary embolism and infarction, 816-818
pulmonary hypertension, 818-820

Pulmonary venous hypertension, pulmonary hypertension classification and, 818

Pulsation therapy, external counter, 544t

Pulse
paradoxical, 1677-1678
rate. *See* Heart rate

Pulse oximetry
asthma management and, 771
COPD monitoring and, 764
oxygen saturation and, 192

Pulse pressure, coronary artery disease and, 534

Pulsed lavage with suction (PLWS)
burn irrigation and debridement and, 441, 441f
pressure ulcers and, 441f, 450

Punding, parkinsonism treatment and, 1445

Pupillary light response
traumatic brain injury diagnosis and, 1488
traumatic brain injury in children and, 1493

Purines
gout pathogenesis and, 1292

Purkinje's cell
coordinated movement disorders and, 1329

Prion disease pathogenesis and, 1363

Purpura
adverse drug reaction and, 153, 153f

NSAIDs and, 153f
overview of, 679
rheumatoid vasculitis and, 179

Pus, phagocytosis and, 220t, 225

PUIS Tool, pressure ulcer assessment and, 445

Putamen, intracerebral hemorrhage syndromes and, 1465-1466

PuVA
psoriasis treatment and, 422
squamous cell epithelioma and, 423

PVC. See Polyvinyl chloride (PVC)

PVD. See Peripheral vascular disease

Pyleography, intravenous (IVP), renal cell carcinoma diagnosis and, 932-933

Pyelonephritis, 931-932
chronic, vesicoureteral reflux and, 931

Pyknosis, cell nucleus damage and, 205

Pyloric stenosis (PS)
definition and overview of, 847, 847f
medical management of, 848

Pyloric stenosis, hypertrophic, sphincter and, 847

Pyrogens, hypothalamus and, 299

Pyuria, urinary tract infection and, 930

Q

Q angle, Osgood-Schlatter disease pathogenesis and, 1316

QOL. See Quality of Life

QPR for Suicide Prevention, 119b

QT interval, ventricular arrhythmia and, 525

Quality of Life (QOL)
erectile dysfunction and, 984
osteoporosis and, 1172
physical therapy and, 384

Quantiferon-TB Gold test (QFT-G), pulmonary tuberculosis diagnosis and, 756

Quick flick exercise, pelvic floor rehabilitation and, 772

R

Race
breast cancer incidence and, 1017
breast cancer risk factor and, 1019
defined as, 21
life expectancy and, 25
polymyalgia rheumatica and, 1241
stroke incidence and, 1449
systemic lupus erythematosus and, 284

Racial/Ethnic disparities in health care, 21-23

Radiation
burns, causes of, 435
cancer and, 353
cardiac complications and, 640
connective tissue, 170
dermatitis, 169f, 169-170
esophagitis and enterocolitis, 167
exercise and, 386
exposure, brain tumors and, 1372
hazards of, 172-173, 385
heart disease, 168
implications for therapist, 172
lung disease, 168, 780
nervous system, 171
partial breast, 1028, 1028f
pregnancy and, 172
primary tumor treatment and, 1207
prostate cancer and, 975
recall reactions, 170, 170f
spinal metastasis and, 1399

Radiation fractionation, cancer treatment and, 372-373

Radiation pneumonitis, 168

Radiation syndrome, acute, 145

Radiation therapy (RT)
basal cell carcinoma and, 413
breast cancer treatment and, 1027-1028, 1028f
cancer treatment modality and, 371, 372f

- Radiation therapy (RT) (*Continued*)
gallbladder cancer treatment and, 925
Hodgkin's lymphoma treatment and, 704
lymphedema risk factor and, 661
lymphanopenia and, 256
primary brain tumor treatment and, 1386f, 1386-1387, 1387f
types of, 372
- Radiation therapy intensity-modulated external-beam (IMRT), 975, 1386-1387
- Radiation therapy three-dimensional conformal (3DCRT), 975, 1386
- Radical prostatectomy, prostate cancer treatment and, 974
- Radiculoneuropathy, neuropathy classification and, 1599
- Radiculopathy
carpal tunnel syndrome and, 1605
lumbar spine pain and, 1261
sciatica and, 1608
- Radioactive iodine (RAI), hyperthyroidism therapy and, 468
- Radioactive iodine uptake (RIU), hyperthyroidism diagnosis and, 468
- Radioimmunotherapy, non-Hodgkin's lymphoma treatment and, 708
- Radioiodine therapy, side effects of, 469
- Radionecrosis, cerebral, 171
- Radionuclide imaging
bone fracture diagnosis and, 1299
scintigraphic studies and, 564
- Radiotherapy
gamma knife, primary brain tumor treatment and, 1386
linear accelerator-based, primary brain tumor treatment and, 1386
spinal metastasis treatment and, 1398
- Radon
indoor air pollution and, 124
lung cancer risk factor and, 810
- Rai system, chronic lymphocytic leukemia diagnosis and, 700
- Rales
delayed drowning syndrome and, 788
pulmonary edema diagnosis and, 802
pulmonary tuberculosis symptoms and, 754
- Raloxifene, osteoporosis treatment and, 1168
- Rancho Los Amigos Levels of Cognitive Function (LOCF), 208
- traumatic brain injury cognitive impairments and, 1483-1484, 1484t
- Range of motion (ROM)
hemipathic arthropathy and, 725, 726t
postoperative exercise and, 547
spinal cord injury therapy and, 1514
traumatic brain injury and, 1494
- Rapid eye movement (REM)
depression and, 112
fibromyalgia and, 291
latency of, 113
sleep apnea syndrome and, 778
sleep behavior disorder, 1339, 1339b
parkinsonism and, 1442
- Rash
atopic dermatitis and, 398
butterfly, systemic lupus erythematosus and, 285, 286f, 392, 426f
skin disease and, 392-393, 394
- Rate of perceived exertion (RPE)
congestive heart failure and, 575, 575t
- Rate of perceived exertion (RPE) (*Continued*)
exercise intensity and, 507, 566
heart rate monitoring and, 1677
- Rathke's pouch, craniopharyngiomas pathogenesis and, 1382
- Ratio, international normalized (INR), 1653
- Raynaud's disease, 633
- Raynaud's phenomenon, 633. *See also* Thromboangiitis obliterans clinical manifestations of, 633-634, 634f
overview of, 633, 639b
systemic sclerosis and, 428b, 428-429
- Reabsorption, lymphatic system and, 642
- Reactions to blood
acute hemolytic transfusion reaction and, 682
allergic reaction and, 682
anaphylaxis and, 682
delayed hemolytic transfusion, 682
febrile nonhemolytic reaction and, 681
- septic reactions and, 682-683
transfusion-related acute lung injury and, 681-682
- Reactive airways dysfunction syndrome, asthma and, 784
- Reactive arthritis
antibiotic-associated colitis and, 859
implications for therapist, 1290
medical management of, 1289-1290
overview of, 1289
reactive (aseptic), definition of, 1192
- rheumatoid (RA). *See also* Rheumatoid arthritis
sarcoidosis and, 808
systemic lupus erythematosus and, 285
tuberculous treatment of, 1198, 1199f
- Reactive cervical lymphadenopathy
lymphatic system disorders and, 650
lymphatic system inflammation and, 650
- Reactive hyperemia, pressure ulcers and, 445
- Reciprocal determinism, 50
- Recombinant human deoxyribonuclease I (rhDNAase I), cystic fibrosis treatment and, 793
- Recombinant human erythropoietin (rHuEpo), blood transfusions and, 681
- Recombinant virus, gene therapy and, 14f
- Rectal abscess and fistula, 879
- Rectal examination, digital. *See also* Digital rectal examination (DRE)
Rectal fissure, 879
- Rectocele
clinical manifestation of, 1013
herniation of the rectum and, 1013, 1014f
treatment of, 1014
- Rectum
hemorrhoids, 879-880
implications for therapist, 879-880
rectal abscesses and fistulas, 879
rectal fissure, 879
- Red blood cells
indexes of, 688
- Redundancy, angiogenesis inhibitors and, 375
- Reed-Sternberg cell
Hodgkin's lymphoma and, 701f, 701-702
Hodgkin's lymphoma diagnosis and, 704
- Reference range, laboratory testing and, 1639
- Reflex
deep tendon (DTR)
chronic sensorimotor neuropathy and, 1619
peripheral nervous system dysfunction, 1600, 1601t, 1602t
- vestibulo-ocular (VOR)
dizziness history and, 1572
ototoxicity and, 1586
vestibular disorder etiology and, 1569, 1572f, 1573f
- vestibulospinal (VSR)
posturography and, 1576
vestibular system and, 1570
- Reflex sympathetic dystrophy (RSD). *See also* Complex regional pain syndrome (CRPS)
etiology of, 1634
- Reflux esophagitis, gastroesophageal reflux disease and, 834
- Reflux nephropathy, renal insufficiency and, 931
- Refractory tachycardia, pacemakers and, 590
- Regeneration, tissue cells of, 227
- Regurgitation (insufficiency)
exercise and, 600
heart valve impairment and, 594
- Rehabilitation
activity based (ABR), spinal cord injury therapy and, 1514-1515
cancer, rehabilitation team and, 1392
fractures and, fracture treatment and, 1300
stroke. *See* Stroke rehabilitation
- Rehabilitation ergonomics, 139
- Rehabilitation phase, burn client and, 439
- Rehabilitation Services, disparities in, 22
- Reiter syndrome. *See also* Reactive arthritis
antibiotic-associated colitis and, 859
implications for therapist, 1291
medical management of, 1291
overview of, 1290
- Rejection
acute, 1053, 1053t
lung transplantation
complication and, 1053t, 1090
chronic, 1053, 1053t
lung transplantation
complications and, 1090
- hyperacute
cardiac transplantation and, 1076
immune system humoral responses and, 1052
lung transplantation
complications and, 1090
- kidney transplantation
complications and, 1067
- Relief behaviors, 44
- Religious beliefs, health and, 27
- Remodeling phase, fracture healing and, 233
- Remote effects. *See* Paraneoplastic syndrome
- Renal and urologic systems
aging and, 927-928
bladder and urethra disorders of, 950-963
infections of, 928-932
renal disorders of, 932-950
- Renal calculi
implications for therapist, 939
medical management of, 938-939
overview of, 937
- Renal cancer
renal cell carcinoma, 932-934
Wilms' tumor and, 934-935
- Renal cell carcinoma (RCC)
implications for therapist, 934
medical management of, 932-934
- Renal cell carcinoma (RCC) (*Continued*)
overview and incidence of, 932
staging of, 933
- Renal changes, left-sided heart failure and, 571
- Renal cystic disease
implications for therapist, 937
medical management of, 936-937
overview and classification of, 935
- Renal disorders
cancer and, 932-935
chronic kidney disease and, 939-948
glomerular disease and, 949-950
renal calculi and, 937-939
renal cystic disease and, 935-937
- Renal dysfunction
heart transplantation
complications and, 1077
kidney transplantation
complications and, 1067
- Renal failure
chronic, 1621
laboratory values and, 948
metabolic acidosis and, 195
- Renal parenchymal mass, renal cell carcinoma and, 932, 933f
- Renal replacement therapy, ESRT treatment and, 945
- Renal system
aging and, 927
cutaneous burn pathogenesis and, 437
diabetes and, 493
systemic lupus erythematosus and, 287
- Renal toxicity, chemotherapy and, 176
- Renin-angiotensin system
vasoconstriction and, 554
- Renin-angiotensin-aldosterone system, congestive heart failure third compensatory phase and, 569
- Repair, connective tissue and, 227
- Reparative phase, fracture healing and, 232-233
- Repetitive strain injury (RSI), musculoskeletal disorder and, 140
- Repiphysis prosthesis, pediatric osteosarcoma treatment and, 1214
- Reproductive glands, aging endocrine system and, 459
- Reproductive hormone axis, fibromyalgia and, 291
- Reproductive toxicity
environmental hazards and, 133
toxicity manifestations of, 134t
- Rescue doses, definition of, 365
- Resection
clavical, thoracic outlet syndrome and, 1614-1615
surgical
pancreatic cancer and, 917-918
primary tumor treatment and, 1207
Wilms' tumor treatment and, 935
- transsphenoidal medical management of, 1384-1388, 1385f, 1386f
primary brain tumor surgical treatment and, 1385, 1386f
- transurethral, bladder cancer treatment and, 952, 954
- Reservoir, organism environment and, 305
- Residual disease, leukemia and, 694
- Respiration
electrophrenic, spinal cord injury and, 1510
lung function and, 742
- Respirator, particulate, 1672
- Respiratory changes
amyotrophic lateral sclerosis and, 1409

Respiratory (Continued)
 parkinsonism clinical manifestations and, 1442, 1445
 muscle strength, measurement of, 747
 muscles, dystonia manifestations and, 1420
 rate of, 1678, 1678t, 1679f
 abnormal response and, 1675b, 1678
 Respiratory acidosis, 192-194, 196
 Respiratory alkalosis, 193t, 194-195
 Respiratory disease, summary of differences of, 790t
 Respiratory distress syndrome atelectasis and, 799-800 pneumothorax and, 824
 Respiratory host defense system, pneumonia and, 749-750
 Respiratory protective equipment (RPE), air pollution and, 136
 Respiratory syncytial virus (RSV), 338-339
 bronchiolitis obliterans and, 776
 Respiratory system acid-based equilibrium and, 194 age-related alterations and, 747-748
 cutaneous burn pathogenesis and, 437
 overview of, 742-746, 743f
 spiroometry and, 760
 toxicity manifestations of, 134t
 Respiratory tract infection, myocardial infarction and, 560
 Restenosis, cardiac rehabilitation and, 540-543
 Resting angina. *See Decubitus angina*
 Restless leg syndrome, parkinsonian characteristics and, 1447
 Restrictive lung disease exercise testing and, 780 implications for therapist, 779-780
 overview of, 779
 Restrictive nonhypertrophied cardiomyopathy, 581-582 mixed cardiomyopathies and, 579, 580t
 Resuscitation period, burn client and, 439
 Reticular dermis, skin layers and, 392, 393t
 Reticulocytosis, red blood cell loss and, 1648
 Reticuloendothelial system, meningitis etiology and, 1353
 Retinoblastoma, gliomas risk factors and, 1372
 Retinoids, chemopreventive agents and, 413
 Retinopathy, diabetes and, 493-494
 Reverse transcriptase enzyme, HIV and, 260, 261f, 350, 417, 417t
 Reverse transcriptase polymerase chain reaction (RT-PCR) assay, 418
 Reverse transcription-polymerase chain reaction (RT-PCR), prostate cancer detection and, 974
 Reversible cell injury, 203-205, 204f
 cellular adaptations of, 204, 205f
 Rey's syndrome aspirin toxicity in children and, 912
 blood ammonia and, 1646
 Reynolds Risk Score, preventive treatment and, 526
 Reynolds' pentad, acute cholangitis and, 922
 Rhabdomyolysis, 1243
 hypothyroidism and, 473
 medical management of, 1243
 myotis exercise treatment and, 433
 overview and definition of, 1242, 1243b

Rhabdomyolysis (Continued)
 potassium and, 191
 statins and, 548
 Rhabdomyosarcoma benign soft tissue tumors and, 1224t, 1224-1225
 childhood cancers and, 390
 Rheumatic diseases gout and, 1291-1293
 juvenile idiopathic arthritis and, 1276-1280
 overview of, 1264-1265
 psoriatic arthritis and, 1288-1289
 reactive arthritis and, 1289-1290
 Reiter syndrome and, 1290-1291
 rheumatoid arthritis and, 1265-1276
 Sjögren's syndrome and, 1286-1288
 spondyloarthropathies and, 1280-1286
 Rheumatic fever clinical manifestation of, 604
 endocarditis and, 603, 603f
 implications for therapist, 605
 pathogenesis of, 603-604
 Rheumatoid arthritis (RA) acute, classification of, 1270, 1270t
 autoimmune disease and, 179-180
 bronchiectasis and, 775
 cartilage healing and, 235
 clinical manifestations cutaneous and, 1267-1268, 1268f
 extraarticular and, 1268-1269, 1269f
 joints and, 1267, 1267f
 neurologic and, 1268
 soft tissue and, 1267
 spine and, 1267
 collagen vascular disease and, 640
 Crohn's disease and, 854
 endocrine disease and, 459
 exercise and aerobic exercise and, 1276 aquatic therapy and, 1276 exercise prescription for, 1275 general concepts of, 1275 overview of, 1274-1275 strength training and, 1275-1276
 IgG antibody and, 226
 implications for therapist, 1272-1276 cervical spine involvement and, 1273
 exercise and, 1274-1276 joint pain medical screening and, 1272-1273 medications and, 1276 modalities and, 1276 patient/client education and, 1273 postoperative and, 1274 rehabilitation and, 1273b, 1273-1274 remission and, 1274 inflammation mediators and, 225 medical management of, 1269f, 1269-1272 overview of, 1265 pathogenesis of, 1265f, 1265-1266 sleep apnea and, 779 treatment of CAM/CIM and, 1272 overview of, 1270 pharmacotherapy and, 1270-1271, 1271b
 Rheumatoid factor, rheumatoid arthritis pathogenesis and, 1265
 Rheumatoid nodule, 179, 179f
 Rheumatoid factor, 1662
 Rhinosinusitis, bronchiectasis and, 775
 Rhizotomy dorsal, cerebral palsy treatment and, 1524
 surgical dystonia treatment and, 1421
 Rhonchi asthma monitoring and, 774 delayed drowning syndrome and, 788
 Rib, fractured airway clearance techniques and, 783 blunt chest trauma and, 782 pain control and, 283
 Ribonuclear protein, (RNP), mixed connective tissue disease and, 1240
 Ribonucleic acid (RNA) amyotrophic lateral sclerosis and, 1403
 DNA and, 13f
 viruses and, 199, 199f, 302
 Ribosomes, and DNA, 13f
 RICE (rest, ice, compression) principle, range of motion and, 725, 726t
 Richettsiae, animal pathogens and, 303
 Rickets, adult form. *See Osteomalacia*
 Rickettsia, Rickettsiaceae family and, 303
 Right hemisphere syndrome, higher brain function deficits and, 1332
 Right lymphatic duct, lymphatic vessel system and, 646
 Right middle lobe syndrome, atelectasis and, 799
 Right orbital prefrontal cortex (ROPC). *See ROPC*
 Right-sided heart failure. *See also Heart failure* clinical manifestation of, 569t congestive heart failure and, 567 pathophysiologic mechanism of, 570f
 Rigidity, parkinsonism clinical manifestations and, 1441
 Riluzole, amyotrophic lateral sclerosis and, 1407
 Ringerz system, astrocytomas classification system and, 1365
 Risk factors, modifiable, 26-35
 Risser sign, diagnosing scoliosis and, 1113
 Ritual abuse, definition of, 58b
 RNA (ribonucleic acid). *See ribonucleic acid*
 Rocker bottom foot deformity, neural tube defects and, 1122f, 1123f
 Rods, intramedullary, osteogenesis imperfecta treatment and, 1152, 1153f
 Roos test, thoracic outlet syndrome and, 1613, 1614t
 ROPC (right orbital prefrontal cortex) definition of, 65 healing of, 68-69
 Rope analogy of dissociation brain healing and, 66-69, 67f trauma color codes and, 67
 Rosacea, gastrointestinal (GI) disturbances and, 402
 Ross procedure, homograft replacement and, 598
 Rotational atherectomy atherosclerosis surgery and, 540
 Rotational deformity, scoliosis curvature and, 1113, 1113f
 Rotationplasty pediatric osteosarcoma treatment and, 1214, 1215f preoperative assessment and, 1216
 Rotator cuff tendonitis/tears, menopause and, 991
 Rotoblator, rotational atherectomy and, 540
 Rough endoplasmic reticulum (RER), cell injury and, 204
 Roux-En-Y gastric bypass (RYGB), 36
 RPE (rate of perceived exertion). *See Rate of perceived exertion*

R/T (radiation therapy). *See Radiation therapy*
 Rubber glove dermatitis, 146f
 Rubber latex allergy (LA), 145-147
 implications for therapist, 147-148
 risk factors of, 146b
 spina bifida and, 1125
 Rule of nines, burn size determination and, 435, 436f

S

S. aureus. *See Staphylococcus aureus (S. aureus)*
SA. *See Sinoatrial node*
 Safe Drinking Water Act, 125
 Safety valve insufficiency, lymph vascular insufficiency, 637
 SAIDH. *See Syndrome of inappropriate antidiuretic hormone*
 Saline, hypertonic, cystic fibrosis treatment and, 793
 Salpingitis, fallopian tube inflammation and, 1004
 Salpingoophorectomy, bilateral, 999
 Salt, pulmonary edema and, 802
 Salter-Thomson classification, Legg-Calvé-Perthes disease diagnosis and, 1314
 SAM. *See Methionine and S-adenosylmethionine*
 Saponylolissthesia, degenerative, 1260
 Sarcoidosis clinical manifestation of, 806-807, 807b
 definition of, 806
 extrapulmonary, 807, 807f, 807b
 implications for therapist, 808
 medical management of, 807-808
 noncaseating granulomas and, 180, 806
 pulmonary, 807, 807f, 807b
 Sarcolemmal abnormality, fibromyalgia and, 296
 Satellite cells, skeletal muscles and, 231
 Sausage toe, osteomyelitis clinical manifestation and, 1184
 Saw palmetto plant, benign prostatic hyperplasia and, 969
 Scabies (*sarcopes scabiei*) implications for therapist, 408
 medical management of, 408
 Scale and Falls Efficacy Scale, 1305
 Scalenection, thoracic outlet syndrome and, 1614
 Scanning speech, coordinated movement disorders and, 1330
 Scar tissue healing and, 227
 hypotrophic/hypertrophic, 212, 229, 439
 implications for therapist, 230
 myocardial infarction and, 561, 561t
 skin contractures and, 227
 spinal cord injury demyelination and, 1500
 Scarcopenia effects of, 1102
 exercise and, 1102-1103
 overview and definition of, 1101-1102
 Scarletina, streptococci and, 300
 Scarlet fever, 320
 Scarring complex partial seizure and, 1534
 dural, 1500
 Scars, glial, 229
 Scheuermann's disease, structural kyphosis in adolescence and, 1116
 Schirmer's test, Sjögren's syndrome diagnosis and, 1287
 Schizophrenia, 109-108
 Schober test, ankylosing spondylitis diagnosis and, 1283

- Schwann cell
macroglioma nerve cell subtype and, 1320, 1321
myelination, protein mutations and, 1602
neurinomas and, 1379
neurofibromas and, 1223
peripheral nervous system structure and, 1595
- Schwanoma
benign soft tissue tumors and, 1223
intradural-extramedullary tumors and, 1394
malignant, 1224
neurinoma overview and, 1379
- Sciatica
implications for therapist, 1609
incidence and etiology of, 1608
lumbar spine pain and, 1261
medical management of, 1608-1609
- SCI.C (small cell lung cancer). *See also* Lung cancer
characteristics of, 809
clinical manifestation of, 811
oat cell carcinoma and, 809
staging of, 813
- Scleroderma
chemically induced, 427
classification of, 427b
collagen vascular disease and, 640
edematous stage of, 428
exercise and, 430
graft-versus-host disease and, 1054
implications for therapist, 781
stages of, 428
subgroups of, 180
subtypes of, 426
- Scleroderma esophagus, 837-838
symptoms of, 1054b
- Sclerosis
mesial temporal, complex partial seizure and, 1534, 1534f
primary lateral, amyotrophic lateral sclerosis and, 1405f, 1405-1406
- Sclerotic stage, scleroderma and, 428
- Scoliometer, scoliosis curvature measurement and, 1113, 1113f
- Scoliosis
adolescent idiopathic, 1111
adult, 1111, 1114
postoperative scoliosis treatment and and, 1115
bracing options and, 1114t
clinical manifestations of, 1112-1113
etiological factors of, 1111-1112
implications for therapist, 1114-1115
infantile idiopathic, 1111
medical management of, 1113-1114
pathogenesis of, 1112, 1112f
structural, 1111, 1113
syringomyelia and, 1501
- Screening
breast cancer and, 1031
osteoporosis medical management and, 1166, 1170
Page's disease assessment and, 1181
primary tumor assessment and, 1208
sickle cell disease prenatal and, 737
universal sickle cell disease and, 736
- Scripps Health, Imposter 16 study and, 1196
- Scriptaid, amyotrophic lateral sclerosis and, 1407
- Seasonal affective disorder (SAD), 111
exercise and, 115
light therapy and, 114
- Seborrheic keratosis
benign tumors and, 410
bleeding of, 419
- Second impact syndrome, traumatic brain injury guidelines and, 1488
- Second line defense, inflammatory process and, 306
- Second National Acute Spinal Cord Injury Study, 1510
- Secondary adrenal insufficiency, 481
- Secondary adrenocortical insufficiency
hypopituitarism and, 463
- Secondary hemostasis
clotting factors VIII and IX and, 718
definition of, 716
- Secondary hyperparathyroidism, parathyroid gland and, 475
- Secondary hypertension
causes of, 553, 553b
hypertensive vascular disease types of, 552
- Secondary immunodeficiency, 255, 256f
- Secondary lesions, skin and, 392
- Secondary lymphedema (acquired)
category of, 650
causes of, 652-653
diagnosis of, 658-659
- Secondary prevention, 11b
- Secondary union, wound closure and, 228, 229f
- Secondhand smoke, 77
- Sedation, acute respiratory distress syndrome and, 804
- Sedative-hypnotics, elderly and abuse of, 77
- Seed vs soil theory, cancer metastases of, 359, 972
- Segawa's dystonia. *See* Dystonia, idiopathic
- Segmental instrumentation, scoliosis treatment and, 1115
- Seizure
complex partial, 1541-1542, 1542f
definition of, 1532
generalized, 1542-1543
infant and childhood epilepsy and, 1545
near drowning and, 788
partial, symptoms of, 1539
simple partial, 1541
traumatic brain injury subacute treatment and, 1491
- Selective estrogen-receptor modulators (SERMs), 1168
endometrial carcinoma and, 999
estrogen replacement and, 1168
hormone replacement therapy and, 988-989
- Selective serotonin reuptake inhibitors (SSRIs). *See also* SSRIs
eating disorder treatment and, 91
emphysema and, 767
PTSD treatment and, 96
side effects of, 114t
- Selegiline, Parkinson's disease treatment and, 1444
- Self-antigen disorders, type II hypersensitivity of, 278, 281f
- Self-breast examination (SBE), breast cancer detection and, 1022, 1023b
- Self-contained breathing apparatus (SCBA), 143
- Self-efficacy, behavior change and, 50
- Semen banking, Hodgkin's lymphoma treatment and, 704
- Semmes-Weinstein monofilament testing
carpal tunnel syndrome and, 1605
peripheral neuropathy and, 509, 510f
risk of fall testing and, 1304
thoracic outlet syndrome and, 1615
- Senescence
cellular metabolism and, 24, 198
skin changes and, 396
- Sensitive enzyme immunoassay (EIA), Lyme disease and, 342
- Sensitized T cells, lymphocyte production of, 247
- Sensory action potential (SNAP), diabetic neuropathy and, 1619
- Sensory changes, multiple sclerosis manifestations and, 1428
- Sensory disturbances
clinical implications and, 1363
CNS disorder manifestations and, 1326
- Sensory neurons, lymphocyte function and, 253
- Sensory neuropathy, diabetes and, 496
- Sensory retraining, dystonia therapy and, 1421
- Sentinel lymph node (SLN) biopsy, cancer diagnosis and, 369, 418
- Sentinel lymph node biopsy (SLNB)
breast cancer staging and, 1024-1025, 1025t
lymphedema incidence and, 658
- Sepsis
acute respiratory distress syndrome and, 804
blood toxins and, 199
CNS infectious disease and, 1352
systemic infections and, 221
- Septa, emphysema destruction of, 766
- Septic reactions, blood transfusion and, 682-683
- Sequencing, antiretroviral drug order of, 268
- Sequential therapy, systemic psoriasis treatment and, 423
- Sequestration
sickle cell manifestation and, 733, 733b, 736
splenic, child sickle cell disease and, 738
- Sequestrum, necrotic tissue and, 1184, 1184f
- Serotonin
CNS amines and, 1325
menopausal decrease and, 988
migraine headache pathogenesis and, 1553
- SERMs (selective estrogen-receptor modulators). *See* Selective estrogen-receptor modulators (SERMs)
- Seroconversion
arthritis and, 265
HIV and, 260
- Serology, viral hepatitis diagnosis and, 897, 898t
- Serotonin
cancer-related fatigue and, 366
chemical mediator of inflammation and, 221
depression and, 118
fibromyalgia and, 289-290
gut and, 230, 861
irritable bowel syndrome and, 861
neuroimaging and, 119
- Serum bilirubin, liver impairment and, 881
- Serum cholesterol
coronary artery disease and, 530, 531t
- Serum osmolality, dehydration and, 184
- Serum protein, liver cirrhosis and, 802
- Serum testing, AATD emphysema and, 767
- Sexual abuse, 40
physical therapist intervention and, 995
- Sexual activity
amyotrophic lateral sclerosis and, 1409
cardiac disease and, 567
multiple sclerosis manifestations and, 1429
- Sexual activity (*Continued*)
spinal cord injury and, 1409
urinary tract infection risk factors and, 928
- Sexual and reproductive behaviors, cancer and, 356
- Sexual and reproductive disorders, hypopituitarism and, 463
- Sexual dysfunction, physical therapists management of, 994-995
- Sexually transmitted disease (STD), 26. *See also* sexually transmitted infections (STI)
AIDS and, 258
cervical cancer and, 1001
ectopic pregnancy and, 1004
HPV and, 1000
implications for therapist, 346
medical management of, 343-345
overview and incidence of, 343
pelvic inflammatory disease and, 1010
screening, diagnosis, treatment of, 345-346
- Sexually transmitted infection (STI). *See also* sexually transmitted diseases
implications for therapist, 346
incidence of, 329t
overview of, 343-346, 344f
pelvic inflammatory disease and, 1010
- Sexually transmitted infections and gonorrhea, 329t, 344f
hepatitis B virus (HBV), 329t
syphilis and, 329t-330t, 344f
- SF-36 Health Status Profile, headache disability measurement and, 1547
- SI-36 life satisfaction scale, dystonia therapy outcomes rating scale and, 1421
- Shaken baby syndrome (SB), 40-41
- Shaker head-lifting exercise, dysphagia and, 832, 832f
- Shearing, skin integument and, 445
- Shell shock. *See* PTSD
- Shell viral assay, diagnosis of CMV and, 336
- Shingles (herpesvirus type 3). *See also* Herpes zoster
clinical manifestation of, 332, 333f
varicella zoster virus (VZV) and, 332, 404, 1626
- Shingles vaccine, Zostavax and, 334
- Shock
cardiogenic
implications for therapist, 639
stages of, 638-639
ventricular assist devices and, 1085
definition of, 679, 680t
- Shock therapy. *See* ECT
- Short arms, glial cells and, 1372. *See also* Oligodendrocyte
- Short tau inversion recovery (STIR), ankylosing spondylitis diagnosis and, 1283
- Short Test of Mental Status, Alzheimer's disease diagnosis and, 1416
- Short-bowel syndrome. *See* Short-gut syndrome
- Short-gut syndrome
malabsorption and, 848
multiple digestive organ replacement and, 1096
TPN treatment and, 850
- Short-stretch compression bandages, lymphedema and, 666
- Shortness of breath (SOB). *See also* Dyspnea
chronic bronchitis and, 765
pulmonary capacity and, 748
- Shoulder impingement syndrome, 158
- Shoulder/arm function, breast cancer surgery and, 1034

- Shunting, ventriculoperitoneal, neural tube defects and, 1121, 1122f, 1124-1125, 1125b
- Shwachman scores, modified, cystic fibrosis scoring system and, 793
- Sick building syndrome, 124
- Sick sinus syndrome, abnormal cardiac rhythms and, 588, 589-590
- Sickle cell anemia
- gallstone treatment and, 920
 - pediatric, sickle cell disease and, 733, 735b
- Sickle cell disease (SCD)
- implications for therapist, 735b, 738-739
 - medical management of, 736-738
 - overview and incidence of, 730
 - risk factors of, 731, 731f, 731-733
 - sickled erythrocytes and, 688, 688f
 - stroke incidence and, 1449
- Sickle cell disease, exercise and, 680, 738
- Sickle cell trait, thalassemias and, 739-741
- Sickle turbidity test, sickle cell disease testing and, 736-737
- Side effects, drugs and, 152
- SIDS (sudden infant death syndrome), tobacco and, 77
- Signal transducer activator of transcription (STAT), asthma genetic treatment and, 772
- Silent ischemia, peripheral artery disease and, 617
- Silicon dioxide. *See* Silicosis
- Silicone, contact dermatitis and, 399, 400
- Silicosis
- clinical manifestation of, 785
 - occupational lung diseases and, 784
- Silicotic nodules, silica exposure and, 784
- Sillence classification, osteogenesis imperfecta diagnosis and, 1151t, 1152
- Silver collar workers, 138
- therapeutic interventions and, 142
- Single-photon emission computed tomography (SPECT)
- cardiac prognostic testing and, 520, 565
- CNS disorder diagnosis and, 1346
- primary brain tumor diagnosis and, 1384
- Sinoatrial (SA) node, arrhythmia overview and, 588
- Sinus arrhythmia
- abnormal cardiac rhythms and, 589
- Sinus node dysfunction, sick sinus syndrome and, 590
- Sirolimus, transplantation medications and, 1047-1048
- Sit-to-Stand Test, 1304
- Sjögren's syndrome
- etiology and risk factors of, 1286-1287
 - implications for therapist, 1287-1288
 - medical management of, 1287
 - overview of, 1286
- RA extraarticular manifestations and, 1268
- Skeletal muscle
- control and inhibition of, 232
 - injury of, 231
 - regeneration of, 231
- Skeletal system, chronic kidney disease and, 941-943, 942t, 943f
- Skin
- aging changes of, 393f, 396-397, 398t
 - care of, 395b, 423
 - complex regional pain syndrome and, 1635t
 - cortisone, secondary lymphedema and, 653
 - Continued*
- Skin (Continued)
- diabetic problems and, 495
 - hepatic system and, 881
 - human cadaver allograft, skin transplantation and, 1096
 - innate immunity and, 242f, 244
 - melanin and, 450
 - polycythemia vera and, 716
 - sarcoidosis symptoms and, 807f, 807b
 - Continued*
- Skin cancer
- ABCD screening examination, 377, 419, 419b
 - ABCD screening examination and, 377, 419, 419b
 - benign tumors, 410-411
 - guidelines for prevention of, 419b
 - Kaposi's sarcoma, 419-420
 - malignant melanoma, 414-419
 - malignant neoplasms, 411-414
 - types of, 410, 411b
- Skin care
- GBS treatment and, 1623
 - lymphedema therapy and, 662t, 669-670
 - neural tube defects and, 1124
 - occlusive disease and, 621b
- Skin disease, 392-394
- Skin disorders
- atopic dermatitis, 398-399
 - contact dermatitis, 399-400
 - documentation of, 394-395, 396b
 - environmental dermatoses, 401-402
 - immune dysfunction and, 421-433
 - rosacea, 402
 - signs and symptoms of, 394b
 - stasis dermatitis, 401
- Skin disorders with immune dysfunction
- lupus erythematosus, 424-425
 - polymyositis and dermatomyositis, 431-433
 - psoriasis, 421-423
 - systemic sclerosis, 426-430
- Skin infections
- bacterial infections, 402-404
 - contagion and, 403t
 - fungal infections (dermatophytes), 407-408
 - other parasitic infections, 408-409
- Pseudomonas and, 324, 325f
- staphylococcus and, 318
- viral infections, 404-406
- Skin lesions
- cutaneous lupus erythematosus and, 424-425
 - etiologic factors of, 392, 393b
 - implications for therapist, 394-396
- Skin transplantation, 1096-1097
- Skin turgor, fluid imbalance and, 190, 190f
- Skin ulcers, rheumatoid vasculitis and, 179
- SLE. *See* Systemic lupus erythematosus
- Sleep apnea
- central, sleep-disordered breathing and, 777
 - mixed, sleep-disordered breathing and, 777
 - obstructive (OSA), sleep-disordered breathing and, 777
- Sleep apnea syndrome, pathogenesis of, 778
- Sleep disorders
- apnea and, 777-778
 - elderly and, 77
 - electromagnetic field and, 131
 - fibromyalgia and, 291
 - Huntington's disease and, 1423
 - hypertension and, 554
 - spinal cord injury and, 1409-1410
- Sleep-disordered breathing. *See also* Apnea; Sleep apnea
- coronary artery disease and, 532
 - definition, 777
 - hypertension and, 555
- Sleep-disordered breathing (Continued)
- implications for therapist, 779
 - medical management of, 778-779
- Slickens, water pollution and, 125
- Slipped capital femoral epiphysis (SCFE), chondrolysis and, 1250
- SLIM (syndrome of limited joint mobility). *See* Syndrome of limited joint mobility
- SLIM (syndrome of limited joint mobility). *See* Syndrome of limited joint mobility
- Small airways disease. *See* Bronchiolitis
- Small cell lung cancer. *See* SCLC (small cell lung cancer)
- Small-molecule drugs, immunosuppressive agent and, 158
- Small-molecule therapy, 15
- Smog, air pollution and, 124
- Smoke inhalation
- cutaneous burn pathogenesis and, 437
 - environmental diseases and, 786-787
- Smoke inhalation injury, 787
- Smoking (cigarette). *See also* Tobacco use.
- adenocarcinoma and, 809
 - air pollution and, 124
 - asthma and, 768
 - bladder cancer and, 952
 - cessation of, 84, 84t
 - COPD and, 761
 - cor pulmonale and, 820
 - coronary artery disease and, 529, 537
 - CRP and, 533
 - delayed bone healing and, 1301
 - delayed wound healing and, 511
 - diabetes mellitus type 2 and, 491
 - elderly and, 78
 - emphysema and, 765-767
 - gender and, 26
 - lung cancer deaths and, 809
 - pancreatic cancer and, 917
 - Parkinson's disease risk factors and, 1438
 - pneumoconiosis and, 785
 - pneumonia and, 749
 - pneumonitis and, 786
 - risk of lung cancer and, 809-810
 - sarcoidosis aggravation and, 808
 - skin wrinkles and, 396
 - stroke risk factor and, 1452
 - thromboangiitis obliterans and, 614-615
- Smooth pursuit
- ocular dysmetria and, 1331
 - vestibular disorder diagnosis and, 1574-1575
- SMS (Symptom magnification syndrome), 107-109
- Soap, antimicrobial, transient organisms and, 319
- SOB (shortness of breath). *See* Shortness of breath
- Social climate, ecologic model and, 18
- Social Cognitive Theory (SCT), health behavior change and, 50
- Social ecology, factors of, 18
- Social structures, individual and, 19f
- Social support, 52
- implications for therapists, 52
- Social-Ecologic Theory, four assumptions of, 18
- Sociocultural, influence on behavior, 18
- Sociodemographics, 19
- rehabilitation service disparities and, 22
- Socioeconomic status
- cystic fibrosis and, 789
 - depressed immune function and, 93b, 252
 - health and, 27
- Sodium
- ascites and, 890
 - basic metabolic panel and, 1640
 - cerebral spinal fluid and, 1666
 - cystic fibrosis and, 789, 790
 - electrolyte imbalances and, 185, 186t, 188t
- Soft tissue disorders
- connective tissue disease and, 1240-1241
 - heterotopic ossification and, 1237-1240
 - myofacial pain syndrome and, 1246-1250
 - myopathy and, 1243-1246
 - polymyalgia rheumatica and, 1241-1242
 - rhabdomyolysis and, 1242-1243
 - soft tissue injuries and, 1235-1236
- Soft tissue injuries, 1235-1236
- implications for therapist, 1236-1237
- Soil, contaminated, 126
- Solar radiation, skin cancer and, 410, 410b
- Soluble inflammatory mediators
- age related changes and, 250
 - innate response system and, 245
- Somatic mutation theory
- chromosomal abnormalities and, 357
- Somatization disorder (Briquet's syndrome), 99
- diagnostic criteria for, 98b
- Somatoform disorder, 97-99, 99, 101t, 103
- chronic pain and, 106
 - clinical strategies for, 105
 - Munchausen syndrome by proxy (MSBP), 99
 - preferred practice and, 103
 - unconscious symptom magnification and, 108
- Somatoform pain disorder, 98
- somatization disorder and, 98
- Somatostatin analogues (drug therapy), acromegaly and, 463
- Somatostatin, islets of Langerhans and, 488, 488t
- Somogyi effect, insulin dosage and, 503
- Sorbital, diabetic neuropathy and, 1618
- Sparing. *See also* Burns, child abuse
- spinal cord injury and, 1502
- Spasm
- cryptogenic infantile, infantile and childhood epilepsy and, 1543
 - laryngeal, dry drowning and, 787
 - symptomatic infantile, infantile and childhood epilepsy and, 1543
- Spasticity
- cerebral palsy classification and, 1517
 - control of, 1510
 - ischemic stroke prophylaxis and, 1463
 - multiple sclerosis manifestations and, 1428, 1436
 - spinal cord injury and, 1510
 - spinal cord injury muscle tone changes and, 1504
- Spatial organization, parkinsonism clinical manifestations and, 1442
- Special Olympics, Down syndrome and, 1110
- SPECT. *See* Single-photon emission computed tomography (SPECT)
- Spectroscopy
- magnetic (MRS), fatty infiltration measurement and, 1099
 - near-infrared (NIRS), CNS disorder diagnosis and, 1346, 1347t
- Spermicidal agents, urinary tract infection and, 929
- SPECT (single-photon emission tomography), 1231

Spherocytosis, red blood cell shape and, 1648
 Spheroids, amyotrophic lateral sclerosis and, 1403
 Sphincter, artificial urinary (ALIS), radical prostatectomy and, 976
 Sphincterotomy
 bile duct stones and, 914
 endoscopic (EST), acute cholangitis treatment and, 923
 Spider veins
 varicose veins and, 397f, 629
 Spina bifida aperta, visible neural tube defect, 1118
 Spina bifida occulta, clinical manifestations of, 1118
 definition of, 1116, 1117f
 incidence of, 1117
 Spinal cord
 metastatic involvement of, 362-363
 vascular disorders, 1471-1473
 Spinal cord compression
 multiple myeloma neurologic complications and, 710, 713
 oncologic emergencies and, 380
 Spinal cord injury
 clinical manifestations
 autonomic nervous system changes and, 1504
 bowel and bladder control and, 1506, 1507f
 fatigue and, 1505
 injury level and, 1501-1502, 1502f, 1503b, 1515b
 metabolic conditions and, 1506
 muscle tone changes and, 1504
 pressure ulcers and, 1506
 respiratory complications and, 1505-1506
 sexuality and, 1506
 skeletal changes and, 1504-1505, 1505f
 sleep disorders and, 1506-1507
 spinal cord injury and, 1506, 1507f
 syndromes of, 1502-1504
 pathogenesis
 blood flow changes and, 1499
 demyelination and, 1500
 dural scarring and, 1500
 edema and, 1499, 1500f
 grey matter and, 1500
 neural function and, 1500-1501
 neuapraxia and, 1501
 primary injury of, 1498-1499
 secondary injury of, 1499, 1499f
 syringomyelia and, 1501
 treatment
 complication management of, 1509-1510
 emergent care of, 1509-1510, 1510b
 overview of, 1508-1509
 pain management of, 1510-1511
 spinal cord repair strategies and, 1511-1512, 1512f
 stem cell transplantation and, 1512
 Spinal cord injury (SCI)
 steroid use and, 164
 substance abuse and, 76, 82
 traumatic
 autonomic nervous system and, 1341
 brain injury and, 1489, 1489f
 clinical manifestations of, 1401-1507
 definition and etiologic factors of, 1497f, 1497-1498, 1498f
 implications for therapist, 1513-1516, 1514f, 1514b, 1515b
 incidence and risk factors of, 1496-1497, 1497f
 medical assessment of, 1507-1513, 1508f, 1509f

Spinal cord injury (SCI) (Continued)
 pathogenesis of, 1498-1499
 ventilatory support and, 745
 Spinal cord injury above T5 or T6, complete, voiding dysfunction and, 956
 Spinal cord lesions at the level of S2 and below, 956
 Spinal fusion
 disk surgery and, 1262
 neural tube defects and, 1121, 1122f, 1123f
 Spinal muscular atrophy (SMA)
 implications for therapist, 1143-1144, 1144f
 medical management of, 1141-1143, 1143f
 overview of, 1141, 1142t
 Spine
 cervical, RA neurologic manifestations and, 1268
 lumbar
 disk degeneration disease and, 1261-1262
 posttransplant exercise and, 1057
 Spinocerebellum, coordinated movement disorders and, 1329
 Spirilla (spirochetes), spiral-shaped bacterial cells, 302
 Spiritual Development
 health and, 71-72
 implications for therapist, 72-73
 Spirometry
 asthma diagnosis and, 771
 COPD testing and, 759
 Spleen, thrombotic occlusions and, 735
 Splenectomy, iatrogenic immunodeficiency and, 256
 Splenomegaly
 acute myelogenous leukemia and, 695
 breathing and, 680
 chronic myeloid leukemia and, 698
 essential thrombocythemia and, 715
 exercise precautions and, 689
 hematologic disease and, 679
 rheumatoid arthritis rehabilitation and, 1274
 Splint
 dynamic, 725
 static, range of motion and, 725
 Splinter hemorrhages
 distal vasospasm and, 601
 signs of endocarditis and, 602
 Splinting
 dystonia therapy and, 1422
 muscular dystrophy treatment and, 1139
 rectocele practice and, 1013
 torticollis treatment and, 1146
 Spondylitis Assoc. of America, sleeping surface recommendations and, 1286
 Spondyloarthropathies (SpAs)
 ankylosing spondylitis and, 1280-1286
 overview of, 1280, 1281b
 Spondyloarthropathy (bronze diabetes), endocrine system disease and, 460
 Spondylolisthesis
 degenerative, intervertebral disk degeneration and, 1260, 1261f, 1263
 lytic, 1260, 1261f
 Spontaneous bacterial peritonitis (SBP), ascites treatment and, 890
 Spontaneous healing (miracles), 72
 Spontaneous pneumothorax, paraseptal empyema and, 765
 Spousal abuse, alcohol and, 80
 Sputum cytology, lung cancer diagnosis and, 813
 Sputum, purulent
 bronchiectasis and, 775
 cough and, 742, 750
 Sputum, purulent (Continued)
 cystic fibrosis and, 791
 lung abscess and, 758
 occupational asthma diagnosis and, 771
 prevention of, 755, 757b
 tubercle bacillus and, 753
 Squamous cell carcinoma. *See also*
 Basal cell carcinoma; Esophageal cancer
 definition and overview, 413, 413f
 medical management of, 410b, 414, 414t
 non-small cell lung cancer and, 811
 SSc. *See* Systemic sclerosis
 SSRIs. *See also* Selective serotonin reuptake inhibitors
 treatment of bipolar disorder and, 115
 St. Anne-Mayo (Daumas-Duport). CNS neoplasm classifications and, 1365
 St. Vitus' dance. *See* Chorea, rheumatic fever
 Stable cells, division of, 227
 Stacking, anabolic-androgenic steroids and, 163
 Stage 2 Lyme disease, disseminated infection, 341, 341b
 Stage 3 Lyme disease, persistent infection, 341, 341f
 Stage 1 Lyme disease, 340
 Stage 1 lymphedema, pitting edema and, 650, 650b
 Stage II lymphedema, nonpitting edema and, 650, 650b
 Stage III lymphedema, lymphostatic elephantiasis and, 650, 650b, 659
 Stage O (latent) lymphedema, impaired lymph transport and, 650, 650b
 Staging
 breast cancer diagnosis and, 1024-1025, 1025t
 primary tumor medical management and, 1206
 Stalking, 40
 Stanford Coronary Risk Intervention Project (SCRIP), coronary artery disease and, 540
 Stanford V, advanced Hodgkin's lymphoma treatment and, 705
 Staphylococcal infections
 cellulitis and, 403
 implications for the therapist, 318-319
 medical management of, 318
 risk factors of, 316, 317t
Staphylococcus aureus (*S. aureus*)
 atopic dermatitis and, 3998-3999
 infectious arthritis and, 1193
 IV drug users and, 346
 linezolid and, 310
 manifestations of, 318, 318f
 methicillin-resistant (MRSA) bacteria, 298
 pathogenesis of, 317
 prostheses and implant infections and, 1188
 vancomycin resistant bacteria, 298
 STAR (National Cancer Institute's Study of Tamoxifen and Raloxifene)
 breast cancer hormonal therapy and, 1029
 endometrial carcinoma and, 999
 Starling's theory of fluid dynamics
 exercise warmup and cool down and, 1081
 four pressures of, 644
 lung fluid movement and, 801
 Stasis, blood flow and, 219
 Static lumbar flexion, viscoelastic creep and, 141
 Statins
 diabetes mellitus type 2 treatment of, 501
 lipid-lowering agents and, 1462
 Statins (Continued)
 peripheral artery disease treatment and, 619
 side effects of, 548
 Stasis dermatitis, 401, 401f
 Status asthmaticus, acute asthma attack and, 771, 772
 Status asthmaticus, therapy and, 774
 Status migrainosus (SM), migraine headache and, 1556
 STD. *See* Sexually transmitted disease (STD)
 Steam inhalation, pneumoconioses and, 786
 Steatorrhea, malabsorption manifestation and, 849
 Steinert type, myotonic dystrophy and, 1134
 Stem cell transplantation (SCT)
 biotherapy and, 374
 chemotherapy and, 177
 sickle cell disease and, 737
 Stem cell transplantation, peripheral blood (PBSC)
 complications of, 1064
 procedures for transplantation and, 1062-1063
 Stem cells
 adult, tissue repair and, 1348
 bone marrow and, 374
 CNS damage control and, 1348
 embryonic
 CNS disorder treatment and, 1348
 spinal cord repair and, 1511
 transplantation bioethical considerations of, 1049, 1063
 human umbilical cord blood (hUCB), spinal cord repair and, 1512
 somatic. *See* Stem cells, adult types of and, 1060f, 10060
 umbilical cord blood. *See* Blood, umbilical cord
 Stemmer's sign
 lipedema and, 658f, 676
 lymphedema diagnosis and, 658, 658f
 Stenosis
 small intestine, 875
 spinal, intervertebral disk degeneration and, 1260, 1261f, 1263
 valvular
 exercise and, 599-600
 heart valve impairment and, 594
 Stent-graft, endoluminal, aneurysm procedure and, 610
 Stenting, rectocele practice and, 1013
 Stents, colonization of, 543
 Stereotactic mammotome biopsy, cancer diagnosis and, 369
 Stereotactic radiosurgery, primary brain tumor treatment and, 1386
 Sternal precautions, cardiac rehabilitation and, 545, 545b
 Sternotomy, cardiac surgery and, 637
 Steroid psychosis, 166
 Steroid, anabolic-androgenic (AAS), 163-164
 Steroid-induced myopathy, glucocorticoids and, 161-162, 162t, 164
 Stewart-Treves syndrome. *See* Angiosarcoma
 STI. *See* Sexually transmitted infection
 Stiff hand syndrome
 diabetes and, 494, 509
 Stiff-person syndrome. *See* Paraneoplastic stiff-person syndrome
 Still's disease. *See also* Juvenile idiopathic arthritis, systemic-onset (Jolla)
 clinical manifestations of, 1277, 1278b

- Stimulants, 86
 Stimulation
 functional electric (FES)
 - spasticity control and, 1510
 - spinal cord therapy and, 1515
 vagal nerve, epilepsy treatment and, 1538
 Stomach
 congenital conditions and, 847-848
 gastric cancer and, 845-847
 gastitis and, 841-842
 peptic ulcer disease and, 842-845
 Stones
 black pigment, unconjugated
 - bilirubin and, 920
 brown pigment, bacteria and
 - formation of, 920
 cholesterol, formation of, 919
 primary common duct, gallbladder
 - absence and, 922
 ureteral, kidney stone movement and, 937
 uric acid, renal stone treatment and, 939
 Stool, light, jaundice and, 881
 Strain
 definition of, 1235
 muscle injury and, 231
 second-degree (moderate),
 - definition of, 1235
 third-degree (severe), 1235
 Stratum corneum
 epidermis and, 393f, 397
 psoriasis and, 421
 skin transplantation and, 1097
 Strength training, hemophilic arthropathy and, 725
 Strep throat (*streptococcal pharyngitis*), 319-320
 rheumatic fever and, 603, 604
 Streptococcal cellulitis, 320-321
 Streptococcal infections. *See also*
 group A streptococci
 endocarditis and, 601
 implications for therapist, 321
Streptococcus pyogenes (GAS) and, 319, 319b
 Streptococcal myositis, 321
 Streptococcal necrotizing fasciitis (NF), classification of, 321
Streptococcus pneumoniae, 314b, 322, 322b
 pneumonia diagnosis and, 750
 Stress
 cancer and, 357
 components of, 46t
 coronary artery disease and, 531-532
 cyclic model of, 45f
 definition of, 44
 depressed immune function and, 93b, 252
 disease and 47-48
 fibromyalgia and, 289
 fight or flight response. *See Fight or flight stress response*
 heartburn and, 831
 herpes simplex latency and, 328
 implications for therapist, 50-53
 inflammatory bowel disease and, 853
 irritable bowel syndrome and, 859
 massage and, 365
 memory problems and, 1338-1339
 neuroendocrine response and, 456-458
 primal adrenal insufficiency and, 480
 psychosocial theory and, 8
 spirituality and, 73
 Stress fracture
 clinical manifestations of, 1297-1298
 complications of, 1298
 medical management of, 1298-1301
 overview of, 1294, 1297
 Stress fracture (Continued)
 therapists implications and, 1307-1308, 1308b
 Stress hormones, 48
 acute neurotrauma and, 1339
 neuroendocrine system and, 181
 Stress proteins, ischemic damage and, 133
 Stress response
 chronic, 45. *See also* Stress.
 neuroendocrine-neuroimmune, 47
 Stress response system
 early life factors and, 45, 59
 hazardous substances and, 133
 homeostatic balance and, 45
 neuroendocrine-neuroimmune
 - stress response and, 47
 Stressors, 46-48
 Stripping the veins, varicose veins treatment and, 631
 Stroke, 151, 1449, 1451f. *See also*
 Cerebrovascular accident;
 Cerebrovascular disease
 clinical manifestations of, 1452-1453, 1453b
 epidural hematoma and, 1471
 implications for therapist, 1474-1476
 incidence of, 1449, 1451f
 intracerebral hemorrhage and, 1463-1468
 ischemia and, 198
 ischemic. *See* Ischemic stroke
 ischemic stroke, 1453-1463
 migraine headache and, 1552
 overview and definition of, 1449, 1450f
 risk factors of, 1449-1452, 1451f
 sickle cell disease and, 734-735, 737-738
 subarachnoid hemorrhage and, 1468-1471
 subdural hemorrhage and, 1471
 ventricular assistive device
 - complications and, 1085-1086
 Stroke rehabilitation
 examination and, 1474, 1475f
 intervention and, 1474-1476
 Stroke volume, cardiac output and, 523
 Strontium and, metastatic bone disease and, 372
 Sub-acute dermatitis, primary stage of, 401
 Subarachnoid hemorrhage (SAH)
 berry aneurysm and, 1469,
 1469f
 clinical manifestations of, 1468-1469
 etiological and risk factors of, 1468
 headache and, 1548
 medical management of, 1469
 medical management of, 1469
 overview and definition of, 1468
 treatment of, 1470-1471
 types of, 1469-1471
 venous malformations and, 1470
 Subcutaneous calcification (calcinoses), scleroderma and, 428
 Subdural hematoma, chronic (CSH), 1471, 1473f
 Subdural hemorrhage, 1471, 1472f
 Subluxation
 atlantoaxial, rheumatoid arthritis and, 1267
 definition of, 1236
 Substance abuse, 39, 75b
 definition of, 75
 delayed wound healing and, 511
 effects of, 79t
 impaired professionals and, 86
 implications for therapist and, 81-87
 treatment of, 80
 Substance P, nociceptive information transmission and, 289
 Substance-related disorders, 75b
 Substantia nigra
 free radicals and, 202
 Parkinson's disease pathogenesis and, 1439, 1440, 1440f
 Substance use disorder (SUD), 75
 Sudden infant death syndrome (SIDS)
 secondhand smoke exposure and, 787
 tobacco and, 77
 Suicide, 118-120
 bipolar disorder and, 117
 definition of
 - Huntington's disease and, 1424-1425
 implications for therapist, 119-120
 medical management of
 - multiple sclerosis prognosis and, 1436
 older adults and, 118
 rate of, 115
 risk factors for, 118, 118b
 side effects of, 114t
 Suicide prevention, QPR, 119
 Sun exposure (UV radiation)
 breast cancer prevention and, 1022
 chronic cutaneous lupus erythematosus and, 424
 cutaneous lupus erythematosus and, 424
 liver spots and, 451
 precancerous conditions and, 411
 sarcoïdosis avoidance of, 808
 tubercle bacillus and, 753
 Sundowning, Alzheimer's disease
 agitation and, 1418
 Superficial inferior epigastric artery (SIEA) flap, breast reconstruction and, 1026
 Superficial spreading melanoma (SSM), type of melanoma, 415, 415f
 Superficial venous thrombosis, venous thrombosis type of, 624, 624f
 Superior semicircular canal dehiscence syndrome, 1585, 1585f
 Superior vena cava syndrome (SVCS)
 lung cancer metastasis and, 812
 non-Hodgkin's lymphoma and, 707
 oncologic emergencies and, 380
 Superoxide dismutase
 copper and zinc (SOD1),
 - amyotrophic lateral sclerosis and, 1403
 Down syndrome and, 1108-1109
 Supplementation,
 glucosamine-chondroitin
 aging articular cartilage and, 1103
 osteoarthritis treatment and, 1255
 Supportive care, cancer treatment and, 377
 Suppuration, tertiary wound closure and, 229f. *See also* Pus
 Supraventricular arrhythmia (atrial), arrhythmia classification and, 588
 Surfactant, insufficient pulmonary, atelectasis and, 799
 Surgery
 appendicitis and, 877
 atelectasis and, 800
 benign prostatic hyperplasia and, 969
 cancer treatment modality and, 371
 cardiac client and, 637
 carpal tunnel treatment and, 1607
 colorectal cancer treatment and, 867
 coronary artery atherosclerosis and, 539, 539f, 540f
 endometrial cancer treatment and, 999
 fracture treatment and, 1300
 gastric adenocarcinoma and, 846
 Surgery (Continued)
 GERD treatment and, 836
 hemophilia and, 727
 hernia and, 873
 lymphedema and, 660
 minimally invasive, bloodless
 - medicine and, 683
 myocardial ischemia and, 539f, 572
 neurotmesis and
 - cable grafts and, 1617
 - interfascicular grafts and, 1617
 orthopedic
 - cerebral palsy treatment and, 1524
 - neural tube defects and, 1121
 osteoarthritis treatment and, 1256
 peripheral artery disease treatment and, 619, 622f
 primary brain tumor treatment and, 1384-1386, 1385f
 renal cell carcinoma and, 933-934
 scoliosis and, 1114
 secondary lymphedema and, 653, 653f
 sleep apnea and, 778
 T cell suppression and, 252
 thoracic outlet syndrome and, 1614, 1615b
 transposition, tardy ulnar palsy and, 1612
 valvular postoperative considerations and, 600
 Survey of Activities and Fear of Falling in the Elderly (SAFE), 1305
 Survival, cancer outcomes and, 376
 Suturing, GERD treatment and, 836
 SVT (supraventricular tachycardia).
 See Supraventricular tachycardia
 Swallowing
 amyotrophic lateral sclerosis and, 1404, 1409
 traumatic brain injury and, 1494
 Swelling
 ion homeostasis and, 203
 osteoarthritis manifestation and, 1252
 primary tumor manifestation and, 1204
 Swimming
 dystonia therapy and, 1422
 exercise-induced asthma and, 772
 Sydenham's chorea. *See Chorea, rheumatic fever*
 Sympathetic nervous system (SNS), healing and, 214
 Sympathomimetics, cystic fibrosis treatment and, 793
 Symptom control, ischemic stroke prophylaxis and, 1463
 Symptom distress (SD), cancer treatment side-effects, 378
 Symptom magnification syndrome (SMS), 107, 108
 Symptom magnifiers, malingering and, 100
 Synaptic activity, injured neurons and, 1349
 Synaptic loss, Alzheimer's disease pathogenesis and, 1413
 Synaptogenesis, regenerative, injured axons and, 1349
 Synchrocyclotron proton beam therapy, primary brain tumor treatment and, 1387
 Syncope, cardiac
 cardiovascular disease and, 520-521, 523
 screening for, 593
 sinus node dysfunction and, 590
 Syndrome of inappropriate antidiuretic hormone (SIADH)
 causes of, 465
 hyponatremia and, 189, 464
 implications for therapist, 465
 posterior lobe disorders and, 464-465
 serum hormones and, 1660

Syndrome of limited joint mobility (SLJM)
diabetic complications and, 494
treatment of, 509

Syndrome X. *See also Metabolic syndrome*
metabolic syndrome and, 512

Syngeneic (isograft) transplantation, genetically identical
transplantation source and,
1037-1038, 1038b

Synovectomy
isotopic, target joint treatment
and, 727
rheumatoid arthritis treatment
and, 1271-1272
target joint treatment and, 720b,
723, 727

Synovial joint
hemophilia and, 719
osteoarthritis pathogenesis and,
1251
rheumatoid arthritis pathogenesis
and, 1265, 1266

Synovial membrane
components of, 237
hemophilic arthropathy and, 720

Synovial sarcoma, benign soft tissue tumors and, 1225

Synthetases, cellular enzymes and,
310

Syphilis
clinical manifestations of, 345f
incidence of, 343
sexually transmitted infections
and, 329t-330t, 344f

Syringomyelia
Down syndrome and, 1109
spinal cord injury and, 1508
spinal cord injury decompressive
surgery and, 1511
spinal cord injury sleep disorder
and, 1409-1410

Systemic chemotherapeutic agents,
categories of

Systemic chemotherapy, 173

Systemic inflammatory response syndrome (SIRS), 181

Systemic lupus erythematosus (SLE).
See also Antibodies, antinuclear; Coagulation
acute cutaneous lupus erythematosus and, 424
antinuclear antibodies and, 281,
285, 287
aseptic meningitis and, 1353
autoantibodies and, 283
cardiopulmonary system and, 286
chronic cutaneous lupus erythematosus and, 424
definition and overview, 284
etiology of, 285
graft-versus-host disease and,
1054
implications for therapist, 288
lupus carditis and, 578-579, 639
lupus cerebritis and, 3
medical management of, 287
pericarditis and, 639
type III hypersensitivity and, 278

Systemic sclerosis (SS) lung disease.
See Scleroderma, systemic

Systemic sclerosis (SSc)
clinical manifestations, 428
etiology, incidence and risk
factors, 427
implications for therapist,
430-431
medical management of, 429
pathogenesis, 427-428
skin thickening and, 429f

Systemic therapy, radiation therapy
delivery system and, 372

Systemic toxicity, environmental hazards and, 134t

Systolic heart failure, congestive heart failure and, 567

Systolic pressure
hypertension and, 552, 555
vital signs monitoring and, 566

T

T lymphocytes
aging and, 301
autoimmune hepatitis type 1 and,
902
cell destruction and, 199, 199f
immune system and, 247, 249f,
250f, 690
medications and, 252
psoriasis and, 422
sarcoidosis and, 806

T₃ toxicosis, hyperthyroidism and,
468

T-helper cells, cytokine secretion and, 769

T-score, average peak bone mass and, 1166

Tachy-psych effect, trauma and, 95

Tachycardia
heart rate and, 589
hyperthyroidism and, 466
traumatic brain injury and, 1491
treatment of, 590

Tachypnea
infection and, 300
pleurisy and, 825
restrictive lung disease and, 779

Tacrolimus, calcineurin inhibitors and, 1047

Taenia solium, myositis cause and, 1195

Taeniae coli, diverticula and, 862

Tai Chi, osteoporosis exercise and, 1171

TAILORx (Trial Assigning Individualized Options for Treatment, breast cancer gene profiling and, 1027

Talampbane, amyotrophic lateral sclerosis and, 1407

Talipes equinovarus. See Clubfoot deformity

Tamoxifen (Nolvadex)
hormonal therapy and, 375,
1028-1029
secondary prevention and, 369

Tamoxifen therapy, endometrial carcinoma risk factor, 999

Tardive dyskinesia, motor tics and, 153, 155

Tardy ulnar palsy, elbow fracture and, 1610

Target cells, thalassemia anemia and, 688, 688f

Target joints, hemophilia and, 722

Task performance, parkinsonism clinical manifestations and, 1442

Task-specific inhibition, motor control and, 232

Tattooing, HIV and, 259

Taut bands, myofascial trigger points and, 1247

Tay-Sachs disease, 21

TB. See Pulmonary tuberculosis (TB)

TCAs. See Tricyclic antidepressant

TCC. See Total contact cast

TEE. See Transesophageal echocardiography

Telangiectasia. See Spider veins

Teletherapy, radiation therapy delivery system and, 372

Telomerase inhibitor, cancer and, 24

Telomerase, human cancer cells and, 354, 358

Telomere length, lifespan and, 354

Telomere theory of aging, 24, 197,
354

Temperature
aquatic, 1684
core, biologic reactions of, 434
monitoring guidelines of, 1675t,
1675-1676

Temporomandibular joint (TMJ),
cervicogenic headache and,
1561

Tend-and-befriend stress response,
44

Tendinitis
calcific. *See Calcific tendinitis*
musculoskeletal disorder and, 141

Tendinopathy
Achilles tendon and, 495
diabetes mellitus and, 495

Tendo-Achilles lengthening (TAL),
plantar ulcer healing and, 501

Tendon
Achilles
hypothyroidism and, 471, 471t
osteogenic synovitis and, 477
aging and, 1103
injury
premorbidity tensile strength and,
234
soft tissue injury and, 1235
tissue repair and, 233-234

rupture
fluoroquinolone-induced, 1237
soft tissue injury and, 1235

Tendonitis
patellar tendon, Osgood-Schlatter disease and, 1316
soft tissue injury and, 1235

Tendons and ligaments
composition of, 233
rupture of, 238-239

Tenosynovitis, endocrine disease and, 460

Tenotomy, Legg-Calvé-Perthes disease treatment and, 1315

Tension-type headache
etiology and risk factors of, 1550
medical management of,
1550-1551
overview, definition, incidence of,
1547, 1548-1550

Teratomas, 1383

Terminal ileum, Crohn's disease and, 857

Terminally ill patient, WHO guidelines of, 384

Terminology, current procedural (CPT) codes, 1639

Tertiary hyperparathyroidism, parathyroid gland and, 475

Tertiary prevention, 11b

Test
mucin clot, 1667
renal function. *See also BUN (blood urea nitrogen)*
implications for the therapist,
1644

sensory organization, posturography and, 1576,
1576f

stress, 1677

Testes
disorders of
epididymitis and, 979
erectile dysfunction and,
982-985
orchitis and, 978-979
testicular cancer and, 980-982
testicular torsion and, 979-980
hormone secreting endocrine glands, 456

Testicular cancer
clinical manifestations of, 981
implications for the therapist, 982
medical management of, 981-982
overview and incidence of, 980

Testicular torsion, 979-980
implications for therapist, 980

Testosterone
male sex hormone and, 458
ovary production of, 988
sleep-disordered breathing and,
777

Tests
cardiovascular
atherosclerotic disease risk factors
homocysteine, 1655
lipids, 1654-1655
congestive heart failure, 1654
pulmonary function, 1665-1666,
1665t

red blood cell
hematocrit and, 1648, 1649
hemoglobin and, 1648, 1649
iron and, 1649

Tests (Continued)
red blood cell shape and, 1648
reticulocyte count and, 1648
vitamin B12 and folic acid and,
1649

white blood
basophils and eosinophils and,
1652
lymphocytes and, 1652
neutrophils and, 1651-1652

Tests and values
antineutrial antibodies and, 1662
basic metabolic panel and,
1639-1640
blood glucose and, 1641-1643
implications for therapist,
1643-1644
blood urea nitrogen, creatinine and,
1644

chloride and, 1641
magnesium and, 1641
potassium and, 1640
implications for therapist,
1640-1641

renal function tests and,
implications for therapist,
1644

sodium and, 1640

blood tests
implication for therapist, 1647t,
1649-1651, 1650t
red blood cell tests and,
1648-1649

cardiovascular lab tests and
atherosclerotic disease and
C-reactive protein and,
1655-1656
homocysteine and, 1655
lipids and, 1654-1655

cardiac enzymes and markers and
C-reactive protein and, 1656
creatine kinase and,
1656-1657

comprehensive metabolic panel and
hepatic function panel and,
implications for therapist, 1646

erythrocyte sedimentation rate and
white blood cell tests and

basophils and eosinophils and, 1652

lymphocytes and, 1652

neutrophils and, 1651-1652

fluid analysis, cerebrospinal fluid, appearance and, 1666-1667

hemostasis and
coagulation studies and,
implications for therapist,
1653t, 1654

components of coagulation and
coagulation factors and,
1653

immunologic diagnosis and
cancer screening and
polymerase chain reaction,
1661

tumor-associated antigens and, 1661-1662

implications for therapist
blood tests
blood marrow aspiration and,
1651

hemoglobin and hematocrit and, 1649

oncology patient considerations and, 1649-1651

platelets and, 1649

white blood cell count and, 1649

cardiovascular lab tests and
atherosclerotic disease and
1654

blood oxygenation and, 1658

cardiovascular pressures and, 1658

congestive heart failure and, 1654

Tests and values (*Continued*)
 complete blood count, 1646
 platelets and, 1648
 red blood cells, 1646-1648
 white blood cells, 1648
 comprehensive metabolic panel and, hepatic function panel and, 1644-1646
 drug screening and, 1663
 erythrocyte sedimentation rate, 1651
 fluid analysis
 cerebrospinal fluid, 1666
 implications for therapist, 1668
 implications for the therapist pleural and pericardial fluid analysis and, 1667, 1668t
 synovial fluid analysis and, 1667
 hemostasis and, 1652
 coagulation inhibitions and, 1653
 coagulation tests, 1653
 components of coagulation and, 1653
 immunologic diagnosis and cancer screening and, 1661
 rheumatoid factor and, 1662
 laboratory tests abbreviations of, 1638, 1638t, 1638b
 limitations of, 1639
 purpose of, 1639
 microbiologic studies cultures and, 1663-1664
 gram stain and, 1663
 implications for therapist, 1664
 overview of, 1637
 primary tumor diagnosis and, 1206
 pulmonary function tests, 1664-1666
 serum hormones and, 1660
 implications for therapist, 1660-1661
 urinalysis and, 1662 color and appearance of, 1662
 glucose and ketones and, 1663 specific gravity of, 1662-1663
 laboratory tests, APACHE and, 1638-1639
 red blood cells, tests of
 Tetany Conn's syndrome and, 484
 hypocalcemia and, 190, 190f
 hypothyroidism and, 478
 Tethered cord syndrome neural tube defect manifestation and, 1119
 signs and symptoms of, 1125, 1125b
 Tetrahydrocanabinol (THC), breast cancer treatment and, 1029
 Tetralogy of Fallot cyanotic heart defect and, 587, 588
 TGCT1, testicular cancer gene and, 980
 Thalamotomy, surgical dystonia treatment and, 1421
 Thalamus brainstem structure and, 1335-1336
 epilepsy pathogenesis and, 1534
 intracerebral hemorrhage syndromes and, 1466
 Thalassemia diagnosis of, 688f, 740
 microcytic RBC index, 688, 688f
 prognosis of, 741
 sickle cell trait and, 739-741
 thalassemia treatment and, 741
 Thalassemia trait, 740
 Thalidomide, multiple myeloma therapy and, 711

Theory of aging. *See also* Cellular aging oxidative (free radical), 250 Theory of dysfunctional senescence, 354 Theory of Planned Behavior (TPB), 49-50 Theory of Reasoned Action (TRA), 49 TheraCLEC-Total (TCT), cystic fibrosis treatment and, 791 Therapeutic angiogenesis, vascular endothelial growth factor and, 543 Therapist cystic fibrosis family/patient education and, 797 guidelines for, 74 personal boundaries and, 73 prevention and wellness and, 11b renal/urinary tract disorders and, 927 signs and symptoms of, 927, 928b urinary incontinence assessment and, 961 viral hepatitis exposure and, 899 Thermal injuries burns, 435-440 cold injuries, 433-434 Thermister, autonomic nervous system modulation and, 295 Thermotherapy, benign prostatic hyperplasia and, 970 Thiamine, alcoholic neuropathy and, 1620 Third line defense, infection immune response and, 306 Third space fluid, fluid imbalance and, 183 Thoracic aneurysm, 607 Thoracic duct, lymphatic vessel system and, 646 Thoracic outlet syndrome (TOS) clinical manifestations of, 1612, 1613f definition of, 1612, 1612f implications for therapist, 1615 medical management of electrophysiologic studies, 1613, 1614b radiographic tests, 1613 Thoracic spine disease, angina mimicry and, 551 Thoracic trauma. *See* Blunt chest trauma Thoratec, right/left ventricular assistive device and, 1083, 1085f Thromboangiitis obliterans (Buerger's disease). *See also* Arteriosclerosis obliterans arterial occlusive disease and, 616 peripheral blood vessel vasculitis and, 614-615, 617f, 621b Thrombocytopenia, essential (ET), 715-716 implications for therapist, 716 Thrombocytopenia acute myelogenous leukemia and, 695 causes of, 728, 728b exercise and, 1650t exercise guidelines and, 1649, 1650t implications for therapist, 728 leukemia and, 693, 694f low platelet count and, 1648 oncologic emergencies and, 380 Thrombocytopenic purpura, overview of, 679 Thrombocytosis, essential thrombocythemia and, 715 Thrombolytic therapy, intracerebral hemorrhage risk factor and, 1464 Thrombophlebitis deep venous thrombosis management and, 628, 629 PE monitoring and, 629

Thromboplastin time, activated partial (aPTT), 1653 Thrombosis clot formation and, 539 deep venous (DVT) immobilization and, 239 spinal cord injury and, 1506 disseminated intravascular coagulation and, 729 ischemic stroke pathogenesis and, 1453 polycythemia vera and, 716 Thrombus definition of, 678 ischemia and, 198 red, coronary artery disease and, 536 types of, 625-626 Thymic involution, age related immunity decline and, 250 Thymine, molecular language and, 13 Thymus acute lymphocytic leukemia and, 697 myasthenia gravis and, 1632 Thyroglobulin goiter and, 473 thyroid hormone precursor and, 466 Thyroid cancer, 474-475 implications for therapist, 475 Thyroid gland goiter and, 473-474 hyperthyroidism and, 466-470 hypothyroidism and, 470-472 iodinated thyroid hormones and, 454 location of, 454f, 465 thyroid cancer and, 474 thyroiditis and, 474 Thyroid storm, hyperthyroidism and, 466 Thyroid-stimulating hormone (TSH) goiter and, 473 hyperthyroidism and, 468 hypothalamic hormones and, 453 hypothyroidism and, 471 testing for, 1660 Thyroid-stimulating immunoglobulins (TSI), hyperthyroidism and, 466 Thyroid/parathyroid disease, endocrinesystem and, 460 Thyroiditis acute suppurative, 474 implications for therapist, 474 lymphocytic, 474 Sub-acute granulomatous, 474 Thyrotropin, hypothalamic-releasing hormone and, 472 Thyroxine (T₄) hypothyroidism and, 471 iodinated thyroid hormone, 454 thyroid production of, 465 Tibia turn-up osteosarcoma treatment and, 1214, 1215f preoperative assessment and, 1216 Tibial and common peroneal arteries, occlusive disease and, 618 Tic douloureux, 1627-1627 Ticks, Lyme disease and, 340 Tietze's syndrome, angina mimicry and, 551 TILT. *See* Toxicant-induced loss of tolerance (TILT) theory Tilt-table testing, orthostatic hypotension and, 577 Timed Up and Go Test (TUGT), 1304 Tinea (chronic fungus), lymphedema complications and, 657, 657f Tinea, dermatophytoses and, 403t, 407 Tinel's test, carpal tunnel syndrome and, 1605-1606, 1608f

Tinetti's Performance-Oriented Mobility Assessment (POMA), 1305 Tinnitus, depressive disorders and, 1591 Tissue biopsy breast cancer diagnosis and, 1024 cancer diagnosis and, 369-371 colloidal osmotic pressure, Starling's Law and, 644 engineering bladder transplantation and, 1069 regenerative medicine and, 1046 hydrostatic pressure (HP), Starling's Law and, 644 hypoxia, organ systems and, 124 nodularity, fibrocystic breasts and, 1015 plasminogen activator, thrombolytic therapy and, 564 remodeling collagen and, 227-228 muscle regeneration and, 231 typing, histocompatibility and, 1052 Tissue (joint and connective) osteoarthritis pathogenesis and, 1251 stiffness, flexibility and, 1103 Tissue (lymphoid), 248, 249f Tissue healing comorbidities and, 213 contraction/contracture of, 227 growth factors of, 212-213, 213b, 227 implications for therapist, 214-215 injury and, 223f medications and, 238 nutrition and, 213 Tissue injury delayed-type hypersensitivity and, 238f disseminated intravascular coagulation extrinsic pathway, 729 pressure ulcers and, 445f prevention of, 238 pulmonary edema and, 802 Tissue repair. *See also* Organ repair Trauma, biologic response to disks and, 237-238 immobilization and, 239, 240t implications for therapist, 238-240 rehabilitation and, 238 scar tissue and, 228-229, 561, 561t skeletal muscle and, 230-232 synovial membrane and, 237 tendons, ligaments and, 233-235 Tissue-type plasminogen activator (t-PA), alcohol and, 532 TNF. *See* Tumor necrosis factor (TNF) TNF-related apoptosis-inducing ligand (TRAIL), 358 TNM system of staging breast cancer staging and, 1025 non small cell lung cancer staging and, 813 pancreatic cancer categories and, 917 primary tumor staging and, 1206 renal cell carcinoma staging and, 933, 933f solid cancer tumors and, 350, 417, 417t testicular cancer diagnosis and, 981 Tobacco. *See also* Smoking (cigarette) addiction and, 77 cancer and, 355, 810 delayed bone healing and, 1301 health effects of, 83 lung cancer prevention and, 813

- Tobacco (*Continued*)
 osteoporosis risk factor and, 1160
 pancreatic cancer and, 917
 peptic ulcer risk factor and, 843
 Tolerance, addiction and, 76
 Tonometer, lymphedema evaluation and, 665
 Tophi, gout clinical manifestations and, 1292, 1294f
 Topoisomerase II inhibitor, acute myelogenous leukemia and, 695
Torsades de pointes. *See* Ventricular arrhythmia
 Torticollis
 definition and overview of, 1145, 1145f
 medical management of, 1145-1147, 1147f
 tubular orthoses for (TOT), 1146, 1146f
 Torture
 definition of, 58b
 trauma and, 55
 Torus fracture, fracture types and definitions of, 1295b
 Total body irradiation, 166
 Total body surface area (TBSA), burns and, 435, 436f
 Total contact cast (TCC), plantar ulcer healing and, 501, 510
 Total knee arthroplasty (TKA), 38b
 Total parenteral nutrition, cholelithiasis risk and, 919
 Total tissue pressure (TTP), lymph functional impairment and, 655
 Totally implantable venous intravenous access device (TIVAD), 793
 Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), cervical dystonia rating scale and, 1421
 Toxic exposure
 Parkinson's disease risk factors and, 1438
 parkinsonisms and, 1447
 Toxic oil syndrome, localized scleroderma and, 427
 Toxic Release Inventory (TRI), 123
 Toxic-induced loss of tolerance (TILT) theory, 149
 Toxicity
 cell injury and, 201
 chronic environmental hazards of, 134
 developmental, environmental hazards and, 133
 digitalis
 chronic heart failure
 medications and, 541t-542t, 576
 cor pulmonale and, 821
 drug induced, theophylline and, 773
 environmental, 134t
 from environmental hazards, 134
 hepatic. *See* Hepatic toxicity
 oxygen, 202
 radiation, 166t
 renal, chemotherapy and, 176
 Toxins
 lead neuropathy, 1629-1630
 pesticides and organophosphates, 1630
 TPN (total parenteral nutrition). *See* Total parenteral nutrition (TPN)
 Tracheal deviation, pulmonary tuberculosis evaluation and, 757
 Tracheal gas insufflation, acute respiratory distress syndrome and, 804
 Tracheobronchial tree, acute bronchitis and, 759
 Tracheoesophageal fistula (TEF), congenital esophageal condition, 840, 840f
 Training
 ambulation and endurance, heart transplantation exercise and, 1079
 Training (*Continued*)
 balance, fall prevention and, 1305
 endurance, aging and, 1105
 interval, 1674
 progressive resistance (PRT)
 frequency, intensity, duration and, 1105
 sarcopenia and, 1102
 specific exercise guidelines and, 1105
 strength
 fall prevention and, 1305
 muscle function and, 1102, 1105
 rheumatoid arthritis and, 1275-1276
 Training intensity measurement, physical activity and, 296
 Transcutaneous electrical nerve stimulation (TENS)
 chest wall or lung injury and, 283
 HIV rehab therapy and, 272
 pancreatic cancer therapy and, 918
 PT modalities and, 239
 spinal cord injury and, 1511
 Transesophageal echocardiography (TEE)
 cardiac emboli detection and, 590
 heart imaging and, 564
 Transfer, magnetization, spinal cord injury diagnosis and, 1507
 Transfusion
 beta-thalassemia major and, 740
 delayed hemolytic, 682
 diagnosis of, 688f, 740
 exchange, sickle cell disease of, 737
 Transfusion reaction, acute hemolytic, 682, 682b
 Transient ischemic attack (TIA). *See also* Ischemic stroke; Stroke
 aging and, 927
 Transjugular intrahepatic portosystemic shunt (TIPS)
 esophageal varices treatment and, 840
 gastroesophageal varices treatment and, 887
 Transmission based precautions, modes of transmission and, 307, 307b, 308t
 Transmission, chain of infection control of, 306-315
 host susceptibility and, 306
 implications for therapist, 310-315
 pathogens of, 304-305
 portals of, 305
 Transmural inflammatory disease, Crohn's disease and, 854
 Transmyocardial revascularization (TMR), angina treatment and, 551
 Transnational competence (TC), 24
 Transplant benefit, organ distribution policy and, 1040
 Transplant coronary artery disease (allograft vasculopathy), 1076
 chronic heart transplantation rejection and, 1076, 1076f
 Transplant, renal. *See* Kidney transplantation
 prognosis for, 106
 Transplantation
 advances and research in, 1045-1048
 allogeneic stem cell and, 934
 allogeneic, prognosis for, 1064
 autologous
 juvenile idiopathic arthritis
 treatment and, 1279
 prognosis for, 1064
 same individual transplantation and, 1037, 1038b
 source of donation and, 1061-1062
 autologous chondrocyte, degenerative disk treatment and, 1262
 bilateral sequential, 1088
 Transplantation (*Continued*)
 biopsychosocial implications of, 1048-1051, 1049-1050
 legal and ethical considerations of, 1048-1049, 1049b
 psychoemotional considerations of, 1050-1051
 bladder. *See* Bladder transplantation
 bone marrow
 chimerism and, 1048
 complications of, 1064
 source of transplantable stem cells and, 1060, 1061
 cardiac. *See* Cardiac transplantation
 cell, parkinsonism treatment and, 1445
 combined organ, 1038, 1038b
 exercise, activity, sports and, 1056-1059
 heart. *See* Heart transplantation
 heart valve impairment and, 594
 heart-lung, lung transplantation procedure and, 1088
 hematopoietic cell (HSCT)
 complications of, 1063b, 1063-1064
 definition and overview, 1059-1060
 exercise after, 1065-1066
 future trends of, 1064-1065
 implications for the therapist, 1065-1066
 indications for, 1060-1061, 1061f
 infection and, 1066
 preventive environment and, 1671
 procedures of, 1062-1063
 sources of, 1061-1062
 heterotopic homologous, grafting of donor organ and, 1038, 1038b
 immunosuppressive medications and, 158-160
 intestine. *See* Intestine transplantation
 kidney. *See* Kidney transplantation
 liver. *See* Liver transplantation
 lobes from living donors, lung transplantation procedure and, 1088
 lung. *See* Lung transplantation
 organ, 1066-1097
 organ procurement and allocation, 1039-1044
 orthotopic homologous, grafting of donor organ and, 1038, 1038b
 ovary. *See* Ovary transplantation
 overview and incidence of, 1037, 1038t
 pancreas. *See* Pancreas transplantation
 pancreatic islet cells and, 502
 pediatric, 1039
 peripheral blood stem cell, graft-versus-host disease and, 1054
 posttransplant complications of, 1051-1056
 primary biliary cirrhosis treatment and, 907
 primary pulmonary hypertension and, 819
 pulmonary vascular disease and, 794
 single lung, 1088
 skin. *See* Skin transplantation
 solid organ
 cancers in, 1055
 gastrointestinal problems and, 1055-1056
 stem cell. *See also* Transplantation, hematopoietic cell (HSCT)
 breast cancer treatment and, 1028
 spinal cord repair and, 1512
 systemic sclerosis treatment and, 781
 Transplantation (*Continued*)
 types of, 1037-1039, 1038b
 combined-organ and, 1038, 1038b
 organ retransplantation and, 1038-1039
 pediatric and, 1039
 Transplantation advances and research
 medications and, 1046-1048
 overview of, 1045
 tissue engineering and, 1046
 xenotransplantation and, 1045-1046
 Transplantations, autologues, 1061, 1061f
 Transposition of the great vessels (TGV). *See* Cyanotic heart defect
 Transtheoretical Model (TTM), 50
 Transthoracic needle lung biopsy
 iatrogenic pneumothorax and, 822
 pleural effusion diagnosis and, 826
 Transudation, vascular alterations and, 218, 218f
 Transurethral ethanol ablation of the prostate (TEAP), 970
 Transurethral incision of the prostate (TUIP), 969
 Transurethral microwave therapy (TUMT), 969-970
 Transurethral resection of the prostate (TURP), 969
 Transverse friction massage, physical therapy modalities and, 239
 Transverse rectus abdominal muscle (TRAM). *See also* TRAM (transverse rectus abdominis myocutaneous flap)
 mastectomy reconstruction and, 660
 Transverse rectus abdominis myocutaneous (TRAM) flap
 breast reconstruction and, 1026, 1027f
 free, 1027f
 pedicled, 1027f
 side effects of, 1032-1033
 Trastuzumab (Herceptin)
 breast cancer treatment and, 1029
 cardiotoxicity and, 176
 chemotherapy and, 174
 Trauma, 781
 aneurysms and, 608
 biologic response to, 1100-1101.
See also Organ repair; Tissue repair
 brain development and, 58
 cardiac injuries and, 583
 cell injury and, 200-201
 chest wall or lung and, 782
 color codes of, 59-61, 60t, 61b
 combat, 55
 developmental, 59
 facial nerve, traumatic brain injury and, 1487
 liver injury and, 912
 nutrition and, 213
 Osgood-Schlatter disease and, 1316
 PTSD and, 94-96
 spinal, neural malfunction and, 1507-1508
 terminology, 58b
 Trauma disorders, cumulative (CTDs), 140
 Traumatic brain injury
 clinical manifestations
 cranial nerve damage and, 1485-1487
 heterotopic ossification and, 1487
 medical complications of, 1487
 motor deficits and, 1487
 signs and symptoms of, 1481-1485
 pathogenesis
 compressive damage of, 1481,
 1481f, 1482t
 parenchymal changes of, 1480-1481

Traumatic brain injury (Continued)
 vascular changes of, 1479f,
 1479-1480, 1480f
 signs and symptoms
 cognitive and behavioral
 impairments and,
 1483-1484
 concussion and, 1481-1482
 levels of consciousness and,
 1482-1483
 pain and, 1484-1485
 treatment
 acute care and, 1489-1491,
 1490f, 1494
 community reentry and, 1492,
 1494
 rehabilitation and, 1484t, 1491-
 1492, 1494

Traumatic brain injury (TBI)
 children and, 1493-1494
 clinical manifestations of,
 1481-1487
 dizziness and, 1587-1588
 etiologic factors of, 1478
 implications for therapist,
 1494-1495
 incidence and risk factors of,
 1477-1478
 medical management of,
 1487-1493
 overview and definition of, 1477
 pathogenesis of, 1479f, 1479-1481
 rehabilitation of, 80
 steroid use and, 164
 stimulants and, 86
 substance abuse and, 80, 82
 types of, 207

Traumatic spinal cord injury. See
 Spinal cord injury, traumatic

Tremor, benign essential,
 parkinsonian characteristics and,
 1447

Tremors, postural-kinetic, traumatic
 brain injury and, 1487

Trendelenburg's position
 lung transplantation and, 1092
 thrombophlebitis treatment and,
 629

Trichinosis, myositis and, 1196

Tricuspid atresia, cyanotic heart defect
 and, 587

Tricuspid stenosis and regurgitation,
 599

Tricyclic antidepressant (TCA),
 114t
 death by overdose and, 119

Tricyclic antidepressant (TCAs),
 exercise and, 117

Trigeminal Neuralgia Association,
 1627

Trigeminal neuralgia, multiple
 sclerosis manifestations and,
 1429-1430

Trigger points
 fibromyalgia and, 292, 292f
 myofascial. *See TrP (myofacial*
trigger points)
 serratus anterior muscle and, 815

Triglycerides
 atherosclerotic disease risk factors
 and. *See Lipids*
 women's heart disease and, 528

Triiodothyronine (T_3)
 hypothyroidism and, 471
 iodinated thyroid hormone, 454
 thyroid production of, 465

Tripsin, pancreatic enzymes and,
 913

Triptan, migraine treatment and,
 1557

Trisomy 21. *See also* Down syndrome
 chromosome 21 meiosis and,
 1108

Trophoneurosis, systemic sclerosis
 and, 427

Tropic (stimulating) hormones,
 ACTH (adrenocorticotrophic
 hormone) and, 453

Troponin, 1657. *See also* Creatine
 kinase

Trousseau's sign
 hypocalcemia and, 190, 190f
 malabsorption syndrome and, 850
 neural irritability and, 196
 osteomalacia pathogenesis and,
 1174
 stomach cancer and, 846

TrP (myofacial trigger points). *See*
also Trigger points, myofacial
(TrP)
 medical management of, 1247-
 1249, 1248b, 1249b
 overview of, 1246
 pathogenesis of, 1246-1247

TRUS-guided biopsy, prostate cancer
 diagnosis and, 973

Trypsinogen, acute pancreatitis and,
 912

TSH. See Thyroid-stimulating
hormone (TSH)

Tubercle bacillus
 causative agent of, 753, 754f
 diagnosis of, 755

primary pulmonary tuberculosis
 infection and, 752

Tuberculin skin test
 pulmonary tuberculosis diagnosis
 and, 755-756
 pulmonary tuberculosis treatment
 and, 756

Tuberculosis
 exercise and, 757
 extrapulmonary
 implications for therapist,
 1198-1200
 medical management of, 1198
 overview of, 1197-1198
 particulate respirator and,
 1672

Tuberculosis (skeletal)
 implications for therapist,
 1198-1200

medical management of, 1198
overview and incidence of, 1198

Tuberculosis infection, latent (LTBI),
 755, 757b

Tuberculosis spondylitis, treatment
 of, 1198, 1199f

Tuberculous arthritis, treatment of,
 1198, 1199f

TUIP. See Transurethral incision of
the prostate (TUIP)

Tumor
 giant cell. *See* Giant cell tumor
 nerve sheath, benign soft tissue
 tumors and, 1223
 peripheral pulmonary, lung cancer
 and, 812

Tumor angiogenesis, primary tumors
 and, 360, 361f

Tumor biochemistry, 358-359

Tumor lysis syndrome (TLS),
 oncologic emergencies and, 380

Tumor lysis syndrome, cytotoxic
 drugs and, 176

Tumor markers, cancer diagnosis
 and, 371

Tumor necrosis factor (TNF)
 anorexia and, 363
 apoptosis and, 358
 Crohn's disease and, 854
 cytokines and, 222, 222b
 infectious arthritis pathogenesis
 and, 1193
 muscle wasting and, 767
 polymyalgia rheumatica and, 1241

Tumor suppressor genes,
 chromosomes and, 358

Tumor-node-metastasis (TNM)
 staging, AJCC and, 867

Tumors
 arising from brain structure
 chordoma and, 1383
 choroid plexus papilloma and,
 1380-1381
 craniopharyngiomas and, 1382
 epidermoid and dermoid
 tumors (cysts) and, 1382
 hemangioblastoma and, 1383
 meningioma and, 1376-1377

Tumors (Continued)
 neurinoma, neuroma and,
 1379-1380
 other brain tumor types and,
 1383-1384
 pinealoma and, 1381-1382
 pituitary adenoma and,
 1377-1379
 primary CNS lymphoma and,
 1383
 atypical teratoid rhabdoid
 (ATRTs), 1383
 benign, 1366
 benign gastrointestinal, 863
 benign primary brain, incidence
 and prevalence of, 1367
 benign soft tissue, 1223-1224
 bone, 1203
 cartilaginous
 benign cartilaginous tumors,
 1226-1228
 malignant cartilaginous tumors,
 1228
 colorectal, classification of, 864,
 864b
 definition of, 348-349
 dysembryoplastic neuroepithelial
 (DNETs), 1383
 embryonal. *See* Tumors, primitive
 neuroectodermal (PNETs)
 epidermoid and dermoid, 1382
 extradural-extramedullary, 1395,
 1395t
 general
 classification by cell type, 349,
 349t
 therapist role and, 377-378
 germ cell, 1383
 glomus, neoplasia and, 1587
 intradural-extramedullary, 1394
 pathogenesis of, 1394, 1394f
 malignant
 adenocarcinoma of the colon
 and, 864-868
 overview of, 863-864, 1366
 primary intestinal lymphoma
 and, 868
 malignant primary brain,
 incidence and prevalence of,
 1367

malignant soft tissue
 etiology and risk factors of,
 1225
 medical management of, 1225-
 1226, 1232f
 overview and incidence of,
 1224
 types of, 1224t, 1224-1225

metastatic. See also Metastasis,
 brain; Metastasis, spinal
 clinical manifestations of,
 1230-1231
 implications for therapist,
 1233-1234
 incidence and etiology of, 1230,
 1396-1397
 medical management of,
 1231-1233
 overview of, 1229-1230
 pathogenesis of, 1397, 1397f
 neoplasm and, 151
 occipital lobe, low-grade
 astrocytoma manifestation
 and, 1373

pediatric. See also Astrocytomas
 clinical manifestations of,
 1400-1401
 diagnosis and treatment of,
 1401
 incidence and pathogenesis of,
 1400, 1401f
 peptides and, 189
 pituitary, systemic effects of, 461
 primary benign bone, 1209
 osteoblastoma and, 1210-1212
 osteoid osteoma and,
 1209-1210

primary brain. See also Primary
brain tumor, therapist
 implications

Tumors (Continued)
 clinical manifestations of,
 1368b, 1368-1369, 1370f,
 1371t
 diagnosis of, 1384
 implications for therapist,
 1388-1393
 incidence and prevalence of,
 1367
 medical management of, 1384-
 1388, 1385f, 1386f, 1387f
 pathogenesis of, 1367-1368,
 1368b
primary intraspinal
 clinical manifestations of, 1395
 extradural-extramedullary
 tumors and, 1395
 implications for therapist, 1395-
 1396, 1396b, 1399
 intradural-extramedullary
 tumors and, 1394
 intradural-intramedullary
 tumors and, 1393-1394
 overview of, 1393, 1393f, 1394f
primary lung, four types of, 809
primary malignant bone
 chondrosarcoma and, 1218
 chordoma and, 1221
 Ewing's sarcoma and,
 1219-1221
 giant cell tumor and, 1221-1222
 osteosarcoma and, 1212-1216
 overview of, 1212, 1212t
primary musculoskeletal
 clinical manifestations of, 1204
 etiology and pathogenesis of,
 1203-1204
 implications for therapist,
 1208-1209
 incidence of, 1201-1203, 1202t
 medical management of, 1205-
 1208, 1397-1398
 overview of, 1201, 1202t, 1203f
 rehabilitation and, 1208
 risk factors of, 1203

primary soft tissue
 benign soft tissue tumors and,
 1223-1224
 cartilaginous tumors and,
 1226-1228
 fibrous lesions and, 1228-1229
 malignant soft tissue tumors
 and, 1224-1226

primitive neuroectodermal
 (PNETs), 1366
 intradural-extramedullary
 pathogenesis of, 1394f
 medulloblastoma pediatric
 tumors and, 1400
 medulloblastoma and, 1376
 retroperitoneal primary, testicular
 cancer manifestation and, 981
 soft tissue, 1203-1204
 specific primary brain
 gliomas and, 1370-1376
 supporting brain structure
 tumors and, 1376-1383
 spinal cord, primary intraspinal
 manifestation of, 1395,
 1396b

Tunica vaginalis, testicular torsion
 and, 979

Tuning fork, diabetic neuropathy
 diagnosis and, 1619

TUR (transurethral resection). See
Resection, transurethral (TUR)

Turner's syndrome, X chromosome
 and, 718

TURP (transurethral resection of the
prostate). See Transurethral
resection of the prostate (TURP)

Type A personality, 45, 51

Type D personality, coronary artery
 disease and, 532

Type I retrovirus (HIV). See HIV

Tyramine, migraine headache and,
 1554

Tyrosine kinase, chronic myeloid
 leukemia and, 698

U

- U.S. Department of Health and Human Services (DHHS). *See* DHHS.
- UI-RNP, connective tissue serum antibodies and, 1240
- UCLA (University of California, Los Angeles). *See* University of California, Los Angeles
- UCLA Integrated Staging System ECOG and, 933
- renal cell carcinoma prognosis and, 934
- UDCA (ursodeoxycholic acid). *See* Ursodeoxycholic acid
- UEMSD. *See* Upper extremity musculoskeletal disorder
- UI. *See* Urinary incontinence (UI)
- Ulcer
- duodenal (DU)
 - H. pylori* and, 844
 - incidence of, 843
 - peptic ulcer, type of, 842
 - neuropathic foot, diabetic neuropathy and, 1620
 - pressure. *See* Pressure ulcers
 - stress, prolonged stress and, 842-843
- Ulcer (gastric) (GU)
- common sites of, 843f
 - incidence of, 843
 - NSAIDs ingestion and, 844
- Ulceration, diabetic sensory neuropathy and, 497, 497f
- Ulcerative colitis (UC), 852. *See also* Inflammatory bowel disease (IBD)
- colon mucosa inflammatory disorder and, 852
 - colon resection and, 856
 - comparative characteristics of, 853t
 - continuous colon involvement and, 854
 - smoking as protective factor and, 853
 - spectrum of severity of, 854, 855f, 856f
- Ulcerative pancolitis, entire colon inflammatory disorder and, 852
- Ulcerative proctitis, rectum inflammatory disorder and, 852
- Ulcers
- pressure. *See also* Pressure ulcers
 - neural tube defect manifestation and, 1119
 - spinal cord injury and, 1506
 - sacral, 445
- Ullrich-negative congenital muscular dystrophy, without brain involvement and, 1134
- Ultrafiltration, lymphatic system and, 642
- Ultrasonography
- endoscopic (EUS)
 - chronic pancreatitis diagnosis and, 916-917
 - gallstone diagnosis and, 920
 - primary tumor diagnosis and, 1206
 - transcranial Doppler, CNS disorder diagnosis and, 1346
 - transrectal (TRUS), prostatitis diagnosis and, 966
- Ultrasound
- breast cancer diagnosis and, 1024
 - calcific tendinitis and, 469
 - fracture treatment and, 1300
 - myofascial pain syndrome treatment and, 1249
 - transabdominal, diagnosis of gallstones and, 920
 - tumor contraindication and, 383
 - wound healing and, 212
- Ultrasound elastography, tissue strain and, 1024
- Ultraviolet (UV) radiation, skin and, 392
- Undifferentiated somatoform disorder, 98, 99

- United airway disease. *See* Work-related upper airway disease
- United Network for Organ Sharing (UNOS)
- cardiac transplantation prognosis and, 1078
 - declining heart transplants and, 1074
 - organ allocation status list and, 1042-1043, 1043b
 - organ distribution and, 794, 1039-1040, 1040f, 1042
- University of California, Los Angeles (UCLA), renal cell carcinoma staging and, 933
- University of Oxford ABCD scale, stroke prognosis and, 1443b, 1453
- Unna's boot, scabies and, 408, 409f
- UNOS (United Network for Organ Sharing). *See* United Network for Organ Sharing (UNOS)
- Unresolved trauma
- physical therapists and, 73
 - signs of, 61-63, 62t
- Unstable angina. *See* Preinfarction angina
- Upper extremity musculoskeletal disorder (UEMSD), 141
- 142
- Uremia, chronic kidney disease and, 941
- Urethral meatus, vaginal proximity and, 928
- Urethritis, urethra infection and, 928
- Urethrocele, bladder neck prolapse and, 1013
- Urge Impact Scale (URIS), quality of life issues and, 961
- URI. *See also* Upper respiratory infection
- acute bronchitis and, 759
 - bacterial pneumonia and, 750
- Uric acid
- gout pathogenesis and, 1292
- Urinalysis
- color and appearance of, 1662
 - glucose and ketones of, 1663, 1663t
 - prostatis diagnosis and, 966
 - specific gravity of, 1662-1663
- Urinary incontinence (UI)
- definition and overview of, 957
 - implications for therapist, 961-963
 - ischemic stroke treatment and, 1463
 - medical management of, 959-961
 - pathogenesis and clinical manifestations of, 958-959
 - risk factors of, 957-958, 958b
- Urinary stone disease. *See* Renal calculi
- Urinary tract
- lower, bladder, urethra and, 927, 928f
 - upper, kidneys, ureters and, 927, 928f
- Urinary tract infection (UTI)
- asymptomatic inflammatory prostatitis and, 965
 - implications for therapist, 930-931
 - medical management of, 929-930
 - pyelonephritis and, 931
 - risk factors of, 929, 929b
 - signs and symptoms of, 927, 928b
 - spinal cord injury and, 1506, 1513b
 - urethra and, 927
- Urinary tract system, toxicity of, 134t
- Urine. *See also* Urinalysis; Urinary tract, lower
- dark, jaundice and, 881
 - dehydration and, 184
 - diabetes insipidus and, 464
 - structures of excretion and, 927
- Urodynamic testing, neurogenic bladder disorders and, 956
- Uroflowmetry, benign prostatic hyperplasia assessment and, 968

- Ursodeoxycholic acid (UDCA)
- gallstone treatment and, 921
 - primary biliary cirrhosis treatment and, 907
- Urticaria, skin disease and, 392
- Uterine fibroid embolization (UFE), uterine fibroid treatment and, 998
- Uterine fibroids, 998, 998f
- Uterine prolapse
- bulging of the uterus and, 1013, 1014f
 - clinical manifestations of, 1014
 - cystocele/rectocele, 1013-1015
 - clinical manifestations of, 1013-1014
 - implications for therapist, 1015
 - medical management of, 1014
 - overview of, 1013
- Uterus and fallopian tube disorders
- cervical cancer and, 1000-1004
 - ectopic pregnancy and, 1004-1005
 - endometriosis and, 995-997
 - uterine fibroids and, 998
- UTI. *See* Urinary tract infection (UTI)
- UV light (phototherapy), psoriasis treatment and, 422
- UV radiation. *See also* Sun exposure malignant melanoma and, 416, 418, 419b
- squamous cell radiation and, 413
- Ulveitis, ankylosing spondylitis manifestation and, 1283

V

- V/Q ratio (ventilation/perfusion ratio). *See also* Ventilation/perfusion (V/Q) ratio
- acute respiratory distress syndrome and, 805
 - pneumoconioses exercise and, 786
- V2, maxillary nerve, 1627
- Vaccination
- concept of, 241
 - influenza and, 311t, 338
 - pneumonia and, 751, 761
 - preexposure Hepatitis B virus and, 326
 - sickle cell disease treatment and, 737
 - varicella and, 334, 405
- Vaccine
- cervical cancer and, 1002
 - prostate cancer treatment and, 976
- Vagal nerve stimulator, treatment of depression and, 114
- Valine, sickle cell defect and, 731
- Valsalva maneuver
- bladder cancer treatment and, 953
 - cystocele, rectocele, uterine prolapse and, 1015
 - hiatal hernia and, 834
 - intraabdominal pressure and, 521
 - lung cancer metastases and, 815
- Value, expected, laboratory testing and, 1639
- Valvotomy, balloon
- aortic stenosis and, 598
 - mitral stenosis and, 595
- Valvular heart disease, exercise testing and, 599
- Variant angina, anginal pain and, 548, 548b
- Variceal bleeding, esophageal varices and, 839
- Varicella vaccine, varicella immunity and, 311t, 334
- Varicella zoster virus (VZV) (herpesvirus type 3). *See also* chickenpox; shingles
- implications for therapist, 334-335
 - incidence of, 332, 404
 - medical management of, 334
 - pathogenesis of, 404
- Varicella zoster virus (VZV), chickenpox, herpesvirus type 3 and, 332, 333f

- Varicose veins. *See also* Esophageal Varices
- clinical manifestations of, 620t, 630, 630f
 - definition and incidence, 629
 - implications for therapist, 631
- Vas deferens, cystic fibrosis and, 788, 792
- Vasa nervorum, peripheral nerve arteries and, 612
- Vascular alterations, inflammation and, 218-219
- Vascular depression, 112
- Vascular disease
- intestinal ischemia, 851
 - of the liver, 908
- Vascular endothelial growth factor (VEGF)
- biotherapy and, 375
 - cancer cells and, 361
 - gene therapy and, 14, 543
 - high-grade astrocytoma and, 1373
 - Kaposi's sarcoma and, 420
- Vascular loop, osteomyelitis
- pathogenesis of, 1183-1184, 1184f
- Vascular neoplasms, 636
- Vascular pathologic condition, systemic sclerosis pathogenesis and, 428
- Vasculitis syndromes, 179
- Vasculitis
- pathology of, 1627
 - PVD inflammatory disorder and, 224f, 611, 612t, 615
 - rheumatoid arthritis and, 179
 - neurology of, 180
 - systemic lupus erythematosus and, 285, 286f
 - vasculitic neuropathy and, 1628
- Vaso-occlusive, sickle cell manifestation and, 733, 733b
- Vasodepressor syncope. *See* neurocardiogenic syncope
- Vasodilators
- angina medications and, 557
 - pulmonary hypertension treatment and, 819
- Vasomotor disease. *See* Venus disease
- Vasomotor disorders
- implications for therapist, 635
 - Raynaud's disease and, 633
 - Raynaud's phenomenon and, 633-634
- Vasopressin, antidiuretic hormone and, 461
- Vasopressin, arginine (AVP), systemic illnesses and, 182
- Vasospastic angina, anginal pain and, 548, 548b
- Vasovagal attack. *See* neurocardiogenic syncope
- Vasovagal syncope, cardiovascular disease and, 520-521
- Vasulopathy, coronary arterial, chronic transplant rejection and, 1076
- Vater complex, tracheoesophageal fistula, 840
- VCF. *See* Fracture, vertebral compression (VCF)
- vCJD. *See* CJD, variant (vCJD)
- Vectorborne transmission, infection mode and, 305
- Vectors, gene therapy and, 14-15
- Vegetations
- chordae tendineae and, 604
 - surface endocardium and, 601
- Vegetative state (VS), traumatic brain injury and, 1482
- VEGF. *See* vascular endothelial growth factor (VEGF)
- Vehicle transmission, infection mode and, 305
- Velocity
- nerve conduction (NCV)
 - nerve conduction (NCV) testing, carpal tunnel syndrome and, 1606

Velocity nerve conduction (NCV), diabetic neuropathy and, 1603, 1618
altered axonal myelination and, 1596
testing of, 1606
toxic polyneuropathy and, 135
VEMP (vestibular-evoked myogenic potential). *See* Potential, vestibular-evoked myogenic (VEMP)
Venorectal reflex (VAR), lipedema pathophysiology and, 676
Venous aneurysm, 607, 608f
Venous disease
chronic venous insufficiency, 631-633
varicose veins, 629-631
venous thrombosis and
pulmonary embolus, 624-629
Venous insufficiency (CVI), chronic.
See Chronic venous insufficiency (CVI)
Venous malformations,
subarachnoid hemorrhage type and, 1470
Venous occlusion, thrombocytopenia and, 716
Venous thrombosis and pulmonary embolus
definition and overview, 624
etiology and risk factors of, 624-627, 625f
implications for therapist, 628-629
medical management of, 627t, 627-628
Venous thrombosis, upper extremity, 627
Ventilation
Guillain-Barré syndrome (GBS), 1624
lung function and, 742
maximum voluntary test, 1666
Ventilation/perfusion (V/Q) ratio
bronchiectasis pathogenesis and, 774
chronic bronchitis and, 765
Ventilator-induced injury, 783
Ventilatory support, tracheostomy and, 745
Ventricle, anterior left, coronary artery thrombosis and, 560, 561f
Ventricular arrhythmia (*torsades de pointes*)
arrhythmia classification and, 588
QT interval and, 525
Ventricular assist device (VAD), pulsatile and nonpulsatile, 1083-1084
Ventricular assistive device (VAD)
complications and prognosis of, 1085-1086
components of, 1084-1085
exercise guidelines and, 1086
hyperacute graft rejection and, 1052
implications for therapist, 1086
indications for, 1052-1085
infection and, 1085
rehabilitation potential and, 1085
types of, 1082-1085, 1083f, 1084f, 1085f
Ventricular assistive device, pulsatile and nonpulsatile, 1083-1084
Ventricular dilation, congestive heart failure and, 568
Ventricular fibrillation, abnormal cardiac rhythms and, 589
Ventricular resynchronization therapy, intraventricular conduction disturbance and, 591
Ventricular septal defect, acyanotic heart defect and, 587
Ventricular, left assistive device (LVAD), 544f, 572, 573f
Venus disease, peripheral vascular disease and, 610

Vertebral and posterior inferior cerebellar artery syndrome, ischemic stroke syndromes and, 1457-1458, 1458f
Vertebral body repositioning therapy (VBRT), perilymph fistula therapy and, 1585
Vertebral compression fracture (VCF), 1296
complications of, 1298, 1308
osteoporosis spinal-related and, 1163, 1163f, 1167f
treatment of, 1299
Vertebrobasilar insufficiency, 1591
Vertebroplasty, acute vertebral fracture treatment and, 1299
Vertical gastric banding (VGB), 36
Vertigo
benign paroxysmal positional (BPPV)
clinical manifestations of, 1577, 1578b
implications for therapist, 1580
incidence and risk factors of, 1577
pathogenesis of, 1577-1578, 1578b
central position, 1579
multiple sclerosis manifestations and, 1429
Vest Clearance System. *See* Chest wall oscillation vest
Vestibular disorders
autoimmune ear disease and, 1587
benign paroxysmal positional vertigo and, 1577-1580
comorbid disorders with vestibular consequences and, 1591-1594
definition and overview of, 1566
endolymphatic hydrops and
Menière's syndrome, 1581-1584
incidence, etiology and risk factors of, 1566-1571, 1567b, 1568f, 1569f, 1570f, 1571f, 1572f, 1573f
infection and, 1580-1581
mal de débarquement and, 1586-1587
medical management of, 1571-1577
bithermal calorimetry test and, 1574
electrocotography and, 1576
history and, 1571-1573
imaging and, 1576
rotational chair testing and, 1574
subjective visual vertical or horizontal and, 1574-1575
vestibular-evoked myogenic potentials and, 1575-1576
video nystagmography or electronystagmography and, 1573-1574
neoplasia and, 1587
otoxicity and, 1585-1586
perilymph fistula and, 1584-1585
psychologic disorders and, 1588-1591
superior semicircular canal dehiscence syndrome and, 1585
traumatic brain injury and, 1587-1588
Vestibular dysfunction
therapeutic examination and, 1592-1593
therapeutic intervention and, 1593-1594
traumatic brain injury and, 1487
Vestibular impairment, fall prevention and, 1307
Vestibular loss, congenital, 1591
Vestibulocerebellum, coordinated movement disorders and, 1329
Vibration
pollution and, 131, 136
whole body, osteoporosis treatment and, 1169

Vibration exercise (VE), neuromuscular training and, 131
Viral infections
age related response and, 251
bloodborne viral pathogens, 326-328
herpes zoster and, 404-405
herpesviruses, 328-337
multiple sclerosis etiology and, 1426
viral respiratory infections, 337-339
warts (*verrucae*) and, 406
Viral load
HIV treatment and, 268
RNA particles and, 259, 261
Viral respiratory infections
implications for the therapist, 339
influenza, 337-338
respiratory syncytial virus (RSV), 338-339
Viremia
HIV viral replication and, 260f
VZV and, 332
Virion, virus particle of, 260
Virtual reality, Parkinson's disease physical therapy and, 1446
Virulence, pathogen potency and, 305
Virus
latent herpes, Bell's palsy and, 1609
varicella-zoster (VZV), 1626
Viruses
cancer and, 353
cell death and, 199, 199f
definition of, 302
Viscera, systemic sclerosis manifestation of, 429
Visceral fat, adipose tissue and, 486-487
Viscoelastic creep, static lumbar flexion and, 141
Viscosupplementation, osteoarthritis treatment and, 1255
Vision, diabetic retinopathy and, 493
Visual analogue scale (VAS), sciatica pain assessment and, 1609
Vital signs
abnormal heart rate and, 1677-1678
anemia monitoring and, 689-690
asthma monitoring and, 774
changes of, 191
COPD monitoring of, 764
electrolyte imbalances and, 165
exercise and monitoring of, 386
fibromyalgia monitoring and, 295
guidelines for monitoring of, 1674-1675
blood pressure and, 1679-1680
abnormal blood pressure rate and, 1680-1681
heart rate, 1676-1677
abnormal heart rate response 1677-1678
heart rhythm and, 1678
respiratory rate and, abnormal respiratory rate and, 1678-1679
temperature and, 1675-1676
heart transplantation monitoring of, 1082
hematologic disorders and, 680-681
Hematopoietic stem cell transplantation monitoring of, 1066
lung transplantation and, 1093
peptic ulcer disease monitoring of, 845
ventricular assistive device and, 1086
Vitamin B deficiency
anemia and, 686-687
insulin therapy complications and, 503-504, 504t
Vitamin B12
red blood cell and, 1649
therapy, anemia and, 689
Vitamin B12 deficiency
aging GI system and, 833
antacids and, 835
Vitamin C (ascorbic acid)
cell injury and, 200
collagen production and, 213
lung cancer prevention and, 813
osteoarthritis prevention and, 1253
Vitamin D
breast cancer prevention and, 1022
osteoarthritis prevention and, 1253
osteomalacia and, 1174
osteoporosis treatment and, 1167, 1169
sarcoidosis of, 808
Vitamin D receptor (VDR), mammary epithelial cells and, 1022
Vitamin E
CNS damage control and, 1348
lung cancer prevention and, 813
traumatic brain injury and, 1491
Vitamin K, intracerebral hemorrhage treatment and, 1467
Vitamins, cystic fibrosis treatment and, 793
Vitiligo
hypopigmentation and, 451, 451f
VO₂
posttransplant exercise and, 1057
pulmonary capacity and, 748
sickle cell disease and, 738
Vocal fremitus, COPD monitoring and, 764
Volume
decreased stroke, 1676
statis lung, values of, 1664-1665
Volume transmission, cellular dysfunction and, 1320
Volvulus, bowel obstruction and, 863, 864f, 870
Vomiting projectile, hypertrophic pyloric stenosis and, 848
Vomiting, gastrointestinal disease symptoms and, 829
von Hippel-Lindau disease
gliomas etiology and risk factors and, 1372
renal cell carcinoma and, 932
von Hippel-Lindau tumor suppressor gene (VHL), gene abnormalities and, 932
von Recklinghausen's disease
gliomas etiology and, 1372
neurofibromas and, 1223
von Willebrand's disease (vWD)
coagulation factors and, 1653
definition and overview of, 716
medical management of, 717-718
VOR. *See* Reflex, vestibulo-ocular (VOR)
vpr gene, lymphocyte apoptosis and, 261
Vulcanization, latex and, 147
Vulnerable plaque, myocardial infarction and, 560
Vulvar vestibulitis, pelvic floor dysfunction and, 1012
Vulvodynia, pelvic floor dysfunction and, 1012
vWF, glycoproteins and, 716
VZV, HHV-3 and. *See* varicella zoster virus

W

WAGR syndrome, Wilms' tumor and, 934
Waist circumference
adipose tissue and, 487
diagnosis of obesity and, 36-37
Walker-Warburg syndrome (WWS), muscular dystrophy and, 1134
Wallerian degeneration
aging peripheral nervous system and, 1597
peripheral nerve repair and, 230
spinal cord injury demyelination and, 1500

Warfarin
deep venous thrombosis
management and, 628, 629
ischemic stroke prophylaxis and,
1462
Warfarin (Coumadin)
pulmonary embolism treatment
and, 817
Warfin, anticoagulant therapy and,
590
Warts (verrucae), medical
management of, 406, 404, 405
Waste accumulation theory, aging
and, 24
Waste, hazards of, 127
Wasting syndrome (HIV)
body cell mass and, 264
nutritional counseling and, 272
Water pollution, 125
Ways of Coping tool, 48
Weakness
multiple sclerosis manifestations
and, 1428
parkinsonism clinical
manifestations and, 1442
Wear and tear theory, aging and, 24,
197
Weber syndrome, posterior cerebral
artery syndrome and, 1457
Weight bearing
fracture rehabilitation and, 1309
multiple myeloma guidelines for
and, 713
rheumatoid arthritis exercise and,
1275
Weight control, breast cancer
prevention and, 1021-1022
Weight cycling, 34
Weight gain, medication-induced,
34
Weight loss
amyotrophic lateral sclerosis and,
1407
cholelithiasis risk and, 919
disk degeneration and, 1259,
1260
obesity and, 36-37
osteoarthritis treatment and,
1254-1255
rheumatoid arthritis prevention
and, 1269
Wells clinical decision rule for deep
venous thrombosis (CDR), 627,
627t
Werdnig-Hoffmann disease, type 1
spinal muscular atrophy and,
1141, 1142t
Wernicke's aphasia, middle cerebral
artery syndrome and,
1455-1456
West Nile virus
clinical manifestations of, 1358,
1358b, 1359f

West Nile virus (*Continued*)
encephalitis and, 1356f,
1356-1357, 1357t
medical management of,
1359-1361, 1360f
parkinsonisms and, 1447
Western blot testing, prion disease
diagnosis and, 1363
Whipple procedure
(pancreaticoduodenectomy)
biliary tumor removal and, 925
resectable pancreatic cancer and,
917
White blood cells (WBC)
appendicitis and, 877
chemotherapy and, 177
leukocyte accumulation and,
219-221, 220f
White coat hypertension, heart
disease risk and, 554
White fat
adipose tissue and, 485
inflammation and, 487
White visceral tissue, adipose tissue
and, 485
White-tailed deer, Lyme disease and,
340
Whitmore-Jewett staging system,
prostate cancer staging and,
974
WHO (World Health Organization)
bone mineral density classification
and, 1167t
CNS neoplasm classification
system and, 1365, 1366t
definition of health and, 1
definition of obesity and, 32
diet and, 1
pulmonary hypertension
classification and, 818
risk factors and, 26
structure of ICF and, 4f, 4-5, 53
tuberculosis incidence and,
1198
Whole arm palsy, brachial plexus
palsy types and, 1147, 1148
Whole Brain Atlas website, 1342
Wilms' tumor, 934-935
childhood cancers and, 390
Wilson's disease
hepatolenticular degeneration and,
517
implications for therapist, 518
parkinsonian characteristics and,
1447
primary hepatocellular carcinoma
and, 909
Winningham precautions,
chemotherapy aerobic exercise
and, 387
Withdrawal
alcohol and, 85
substance abuse and, 76
transplantation medication and,
1048
WMSD. *See* Work-related
musculoskeletal disorder
WOB (work of breathing). *See* Work
of breathing
Women
alcohol and, 80
alcohol-related liver disease and,
904
breast cancer incidence and,
1017
celiac disease and, 848
cholecystitis and, 923
constipation and, 829
CTS and, 140
eating disorders and, 87, 88
hemophilia manifestations and,
719
HIV and, 263, 266
liver adenomas and, 909
lung cancer and, 356, 809
migraine headache and, 1551
mitral stenosis and, 594
musculoskeletal injury and, 1100
postmenopausal, stroke risk factor
and, 1452
seasonal affective disorder (SAD)
and, 111
stress response and, 44, 46
systemic lupus erythematosus and,
180, 284
systemic sclerosis and, 427
thrombolytic agent bleeding and,
525, 541t-542t
tobacco and, 84
urinary incontinence and, 957
urinary tract infection and, 928
von Willebrand's disease and,
718
Women who have sex with women
(WSW), cervical cancer
prevention and, 1001
Women's Health and Aging Study
(WHAS), surgical menopause
study and, 991
Women's Health Initiative (WHI),
hormone replacement use and,
988
Women's Health Network, HPV
vaccination and, 1002
Work of breathing (WOB)
age-related alterations and, 747
aging and, 747-748
COPD rehabilitation and, 762
dyspnea sensations and, 743
emphysema and, 766
Work-related disease
asthma (WRA) and, 144
common disorders of, 141b
musculoskeletal disease and, 140
Work-related musculoskeletal
disorder (WMSD), physical
therapists and, 143
World Federation of Neurology El
Escorial, ALS diagnosis criteria
and, 1406, 1406b

World Health Organization (WHO).
See WHO
Wound
chronic, 229
gun shot
Brown-Séquard syndrome and,
1502
spinal cord injury and, 1496
Wound healing
aging and, 397
burn management and, 439
closure and, 229b
delay of, 213b, 214, 511
transplantation and, 1056
Wound matrix, fibrin and fibronectin
of, 227
Writer's cramp, 1419
dystonia manifestation and, 1420
Wry neck. *See* Torticollis
WT1 suppressor gene, Wilms' tumor
and, 935
WWS. *See* Walker-Warburg syndrome
(WWS)

X

X-rays, osteoporosis testing of, 1167,
1167f
Xanthelasma, primary biliary
cirrhosis and, 906f
Xanthomatous neuropathy, primary
biliary cirrhosis and, 908
Xenobiotics, 130
Xenogeneic (heterograft), different
species transplantation and,
1037, 1038b
Xenografts (heterografts), temporary
burn grafts and, 439
Xenotransplantation, 1045-1046
Xeroderma, skin disease and, 393
Xerosis, atopic dermatitis and, 398

Y

Young adult, cystic fibrosis transition
care and, 798-799
Youth Risk Behavior Surveillance
System (YRBSS), 31
Yttrium aluminum garnet (YAG),
metastatic bone disease and,
372

Z

Z-score, standard deviation of BDM
and, 1166
Zickel nail, metastatic tumor
treatment and, 1232f
Zinc
collegen and, 213
nutritional deficits of, 251-252
Zone of hypoxic injury, myocardial
infarction and, 561
Zone of infarction, myocardial
infarction and, 206f, 209f, 561,
562f
Zone of ischemia, zone of infarction
and, 562